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 Under current United States (U.S.) regulations, a dairy cow is eligible for slaughter 13 
days following the last of 2 doses of ceftiofur crystalline-free acid (CCFA) for the treatment of 
metritis. A matched-pair longitudinal study was employed to monitor levels of antimicrobial 
resistance among fecal Escherichia coli and Salmonella across 3 dairy farms in the U.S. High 
Plains to evaluate microbial safety pertaining to antimicrobial resistance on the first-eligible 
slaughter date. Environmental samples were collected from multiple areas throughout the farm 
prior to beginning the animal trial. Cows diagnosed with post-parturient metritis via veterinary 
protocol were pair-matched based on lactation number and calving date. A baseline fecal sample 
(day 0) was taken prior to the first administered dose of CCFA with a second CCFA dose 
administered 72 hours later. Additional fecal samples were taken on study days 6, 16, 28, and 56. 
Samples were processed for E. coli and Salmonella for both the general and third-generation 
cephalosporin (3GC) resistant populations. Isolates from 3GC-selective plates underwent 
phenotypic antimicrobial susceptibility testing and whole genome sequencing (WGS). Full-
factorial multi-level mixed linear regression showed a significant difference (P ≤ 0.05) in 
quantitative resistance levels among E. coli populations when comparing treated (metritis) and 
untreated (control) cattle on days 6 and 16. These resistance levels became similar on days 28 
and 56. Overall, levels of Salmonella shedding were higher in both groups on day 0 decreasing 
further in treated cows on days 6 and 16 and with resistance being infrequent. Resistance 
differences were observed primarily by dairy farm based on phenotypic antimicrobial 
susceptibility testing. Resistance genes and Salmonella serotypes were identified from WGS. 
Based on the results of this study, it is recommended to extend voluntary slaughter withholding 
period to 28 days following the first administration of CCFA. This is to allow populations of 
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resistant E. coli to decrease to levels equivalent to that of their untreated counterparts. Such an 
extended slaughter withholding will allow for a reduction of the risk of slaughter fecal 
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*An antibiotic is an organic molecule produced by a variety of microorganisms that inhibit the growth of other 
microbes. The term antimicrobial includes these antibiotics, as well as other inorganic and organic compounds 
exhibiting inhibitory effects on microbes. The two terms will be used interchangeably throughout this document.   
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1.1 DEVELOPMENT AND EXPANSION OF ANTIMICROBIAL RESISTANCE  
Not long after the discovery of penicillin by Alexander Fleming in 1928, antimicrobial 
resistance (AMR) was first reported. In 1940, before penicillin was made available for clinical 
use, the AmpC β-lactamase gene encoding for penicillin resistance within Escherichia coli (E. 
coli) was discovered (Abraham and Chain, 1940). It has been estimated that millions of metric 
tons of antibiotics have been released into the biosphere in the past 50 years, leading to selection 
pressures for resistant bacteria (Davies and Davies, 2010; Ozawa et al., 2012). In addition to 
environmental pollutants, other drivers of AMR include the use, overuse, and misuse of 
antimicrobials in human medicine and animal agriculture (McEwen and Collignon, 2018).  
The repeated introduction of novel antimicrobials* over the decades has led to multidrug-
resistant pathogens, such as Staphylococcus aureus, Enterococcus spp., and the 
Enterobacteriaceae family (Davies and Davies, 2010; Centers for Disease Control and 
Prevention, 2013). The spread of resistance genes via vertical and horizontal gene transfer 
(Daniels et al., 2009) facilitates the development of what are sometimes termed “superbugs” 
(Bennett, 2008; Davies and Davies, 2010). Forms of gene transfer, including the horizontal 
methods of transformation, transduction, and transconjugation (or, simply: conjugation), allow 
for the transfer of genetic material among bacteria (Bennett, 2008). Resistant bacteria utilize a 
variety of mechanisms to avoid succumbing to antimicrobial compounds, including preventing 
drug uptake, enzyme production, efflux pumps, or modifying the drug target (Holmes et al., 
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2016). The development of resistance mechanisms can vary based on the drug and species of 
bacteria, in addition to dosing, route of administration, and length of administration (McEwen, 
2006). Resistance mechanisms can be the result of genetic mutations in the chromosomal DNA 
or else through plasmid transfer. Bacterial resistance to antimicrobials can be spread from the  
local to international scale through human travel, animal movement (including migration of wild 
birds), trade in food products and via environmental factors, such as water, soil and feed 
(McEwen, 2006). 
The use of β-lactam antibiotics is the major selector for β-lactamase producing coliform 
bacteria (Livermore, 1995). Plasmid-mediated β-lactamases have become increasingly more 
common in gram-negative bacterial populations over the past few decades, including the most 
common plasmid-medicated AmpC gene, blaCMY-2 (Livermore, 1995; Jacoby, 2009; Schmid et 
al., 2013). The increase in plasmid-mediated beta-lactam resistance has been assisted by the 
emergence and expansion of the blaCTX-M extended-spectrum β-lactamase (ESBL) gene family. 
Overall, since their emergence in the 1980s, blaCTX-M variants have surpassed those of blaTEM and 
blaSHV as the dominant beta-lactamase gene family in Europe and throughout the world (Bonnet, 
2004; Livermore, 2007; Schmid et al., 2013). While E. coli containing blaCTX-M were isolated from 
gram-negative bacteria in agriculture in other areas of the globe as early as 2000 (Shiraki et al., 
2004), this resistance gene was not reported among E. coli in agricultural settings in the United 






1.2 POLICY CHANGES TO COMBAT AMR 
  Due to continuing bacterial adaptations against antibiotics and the resulting medical and 
economic pressures, and in search of understanding and mitigating the threats allowing for such 
expansions, there have been research and policy efforts focused on the systems and practices 
aiding AMR development. The Joint Committee on the use of Antibiotics in Animal Husbandry 
and Veterinary Medicine report made recommendations in 1969 to regulate feed and therapeutic 
antibiotics separately (Swann, 1969). These recommendations became accepted throughout 
Europe, beginning with Sweden in the early 1980s (McEwen and Collignon, 2018), and removed 
the over-the-counter availability of several antibiotic classes used in growth promotion 
(Kirchhelle, 2016). The European Union, as a whole, finally ended growth promotion uses of 
antibiotics in 2006 (McEwen and Collignon, 2018).  
 In 1997, the United States began to shift its policies regarding antibiotic usage when 
extra-label uses of fluoroquinolones and glycopeptides became prohibited by the Food and Drug 
Administration (FDA) (Doyle et al., 2013). A broader ban in 2001 on fluoroquinolone use in 
poultry was supported by a risk assessment evaluating the human health impact of 
fluoroquinolone-resistant Campylobacter due to chicken consumption (FDA, 2001). While 
antimicrobial usage in animal agriculture tends to be unregulated (and likely underestimated) in 
many countries around the globe, there has been a push to greatly reduce antimicrobial usage 
across these settings (Scott, Midgley, and Loneragan, 2015). Avoiding selection pressures for 
resistance to certain forms of treatment has proven difficult due to the potential for co-selection 
by other antimicrobials (McEwen, 2006; Scott, Midgley, and Loneragan, 2015). This co-
selection can occur via resistance genes found on the same plasmid, transposon, or integron; in 
other words, by using 1 antibiotic, resistance to another antibiotic may be unintentionally 
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selected. However, non-antibiotic options exist for disease prevention including biosecurity, 
vaccination, and herd management, among other approaches (McEwen, 2006). 
 
1.3 CEPHALOSPORINS IN ANIMAL AGRICULTURE 
Having provided historical context to the issues faced with regards to antimicrobial 
resistance, our focus shifts to the use of cephalosporins in animal agriculture, primarily in dairy 
production settings. When first approved for therapeutic use in U.S. dairy cattle in 1988 
(Donaldson et al., 2006), third-generation cephalosporins, such as ceftiofur as sodium or 
hydrochloride and later as crystalline-free acid (CCFA) were not prohibited from extra-label 
usage, although prescriptions from licensed veterinarians were required (Tragesser et al., 2006). 
However, in 2012, the FDA banned many extra label uses of cephalosporins in animal 
agriculture (Food and Drug Administration, 2012). Third-generation cephalosporins (including 
CCFA), along with penicillin, ampicillin, and oxytetracycline have each been used as treatment 
for acute metritis in dairy cows (Drillich et al, 2001; Liebana et al., 2004; Haimerl and 
Heuwieser, 2014; Reppert, 2015). While fourth-generation cephalosporins are available for use 
in food and companion animal medicine in Europe (Liebana et al., 2004), ceftiofur is currently 
the only third- or higher-generation cephalosporin licensed for the treatment of food animals in 
U.S. agriculture (Food and Drug Administration, 2017). Among ceftiofur formulations, a two-
dose labeled treatment of CCFA for metritis is now (since April 2012) required due to the rate at 
which concentrations of drug decrease within uterine tissues. The previously approved one-dose 
treatment regimen did not maintain drug concentrations elevated enough to achieve sufficient 
efficacy according to the manufacturer, who applied for a revised product label (Zoetis, 2012). A 
popular medication used in dairy production medicine, CCFA does not produce detectable levels 
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of antibiotic residues in milk and therefore does not require a milk withholding period (Zwald, 
2004; Tragesser et al., 2006; Heider et al., 2009). While milk is not withheld, under section 
522.313a of the Code of Federal Regulations Title 21, Chapter 1, an animal having received a 
two-dose treatment of CCFA is not eligible to go to slaughter until a 13-day withdrawal period 
has elapsed since the last dosing; specifically, to avoid antibiotic residues in meat products (21 
C.F.R. § 522.313a; 2017). 
 
1.4 AmpC VERSUS ESBL RESISTANCE PATTERNS 
AmpC and ESBL forms of cephalosporin resistance have each continued to expand with 
the continued usage of cephalosporins (Tragesser et al., 2006; Lowrance et al., 2007; Dolejska et 
al., 2011; Snow et al., 2012). This is particularly concerning, as the World Health Organization 
(2019) considers third and higher generation cephalosporins to be of highest priority among the 
critically important antimicrobials for human medicine. Bacteria harboring and exhibiting AmpC 
forms of resistance (e.g., the blaCMY family of genes) are unaffected by penicillins and 
aminopenicillins, first-generation cephalosporins, cephamycins (second-generation 
cephalosporins) and third-generation cephalosporins (Tragesser, 2006; Jacoby, 2009; Pfeifer, 
Cullik, and Witte, 2010; Schmid et al., 2013) as well as these classes of antibiotics paired with a 
beta-lactamase inhibitor such as clavulanic acid, sulbactam, or tazobactam. Their ESBL 
counterparts (i.e., those with blaCTX-M genes, among others) are resistant to penicillins, 
aminopenicillins, and first-, third-, and fourth-generation cephalosporins (Bonnet, 2004; Drieux 
et al., 2008); however, their susceptibility to these classes of antibiotics is recovered once a beta-
lactamase inhibitor is added. Thus, ESBL resistance mechanisms are rendered inactive with the 
addition of clavulanic acid, sulbactam, or tazobactam (Matsuura et al., 1980; Cormican, 
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Marshall, and Jones, 1996; Bonnet, 2004; Drieux et al., 2008; Schmid et al., 2013; Rossi et al., 
2016). As a comparison, while AmpC and ESBL types both are resistant to third-generation 
cephalosporins, AmpCs are inhibited by fourth-generation cephalosporins, and unaffected by 
clavulanic acid (Akova, Yang, and Livermore, 1990) while ESBLs are inhibited by second-
generation cephalosporins and the addition of clavulanic acid to aminopenicillins and 3rd 
generation cephalosporins (Thomson, 2001; Bonnet, 2004; Drieux et al., 2008). Thus, the use of 
an appropriately chosen array of broth or agar media, each containing these distinguishing 
antibiotics, provides a mechanism to phenotypically quantify and distinguish the presence or 
absence of the different genotypes in a genotypically mixed population. 
 
1.5 CMY AND CTX-M BETA-LACTAMASE ENCODING GENES 
These 2 broad forms of resistance, AmpC and ESBL, can further be broken down into 2 
major gene groupings: 1) the cephamycinases with the blaCMY (AmpC) genes and, 2) the 
cefotaximases utilizing the blaCTX-M (ESBL) gene. Within these 2 classifications, numeric 
groupings are used for differentiation among variations of the 2 gene families. The blaCMY genes 
can be located chromosomally or else on a plasmid (Liebana et al., 2004), including the most 
common plasmid-mediated AmpC, blaCMY-2 gene (Jacoby, 2009). Through treatment with higher-
order potentiated aminopenicillins and cephalosporins, bacteria possessing the blaCMY-2 gene have 
the ability to change the gut flora via amplification (Daniels et al., 2009). While blaCMY-2 is the 
widest spread AmpC gene, the ESBL blaCTX-M gene has surpassed extended-spectrum beta-
lactamase TEM and SHV variants in many European countries as the leading beta-lactamase 
gene (Livermore et al., 2007; Schmid et al., 2013). This gene can be found on many mobilized 
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genetic elements, but is mainly found on plasmids encoding for multiple resistance (Livermore et 
al., 2007). 
 
1.6 ORGANISM DESCRIPTIONS 
 Escherichia coli is a motile, facultatively anaerobic, gram-negative bacterium. When 
grown on MacConkey agar, E. coli presents as pink, lactose-fermenting colonies of circular 
morphology. The organism is a rod-shaped, indole-positive bacterium, meaning it actively 
creates indole and pyruvate from tryptophan. E. coli can be either commensal or pathogenic 
depending on the type and location of bacteria (Kaper, Nataro, and Mobley, 2004). As such, it is 
highly prevalent and in large quantities in the feces of domestic mammals and birds; thus, it 
serves as a useful indicator organism for other less common coliforms such as Salmonella, 
Enterobacter, and Citrobacter. The pathogenic forms of E. coli can be categorized as 
enteropathogenic, enterohaemorrhagic, enterotoxigenic, enteroaggregative, enteroinvasive and 
diffusely adherent E. coli, all of which are typed and grouped via their O and H antigenic 
formulae (Kaper, Nataro, and Mobley, 2004). 
 Much like E. coli, Salmonella are facultatively anaerobic, gram-negative, motile, rod-
shaped bacterium in the Enterobacteriaceae family. From a human health perspective, 
Salmonella tend to be grouped as Typhi and non-Typhi to differentiate based on human-host 
specificity. When grown on brilliant green agar (BGA), Salmonella appear red to a white-pink in 
coloration. O-antigen tests can be utilized to further identify an isolate as Salmonella. The ability 
to cause disease depends on the location of bacterial infection and host species susceptibility; 
most often, Salmonella cause illness in the gastrointestinal system due to the consumption of 
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contaminated food or water. However, infections with Salmonella can also be found in other 
extra-intestinal locations including the blood, thereafter leading to sepsis.  
 
1.7 CLINICAL SIGNIFICANCE 
Enteropathogenic E. coli was the first pathogenic form of E. coli to be described after 
causing large outbreaks in the United Kingdom in 1945 (Kaper, Nataro, and Mobley, 2004). 
Typically associated with diarrhea, pathogenic forms of E. coli can also result in urinary tract 
infections, meningitis, sepsis, and hemolytic-uremic syndrome (HUS) (Kaper, Nataro, and 
Mobley, 2004). While our study did explore nor type the E. coli found as pathogenic or 
commensal, E. coli serves as a useful indicator species for other enteric pathogens, such as 
Salmonella (Lowrance et al., 2007; Cummings, Aprea, & Altier, 2014). It has been well-
established that there are inherent risks of pathogen contamination in food products (Todd, 1997; 
Cassin et al., 1998; Zhao et al., 2001; Schroeder et al., 2003; Johnson et al., 2005; Vogt and 
Dippold, 2005; World Health Organization, 2017[a]) with a particular risk of E. coli 
contaminants being introduced onto meat products due to fecal contamination at slaughter or 
through the handling of animal tissue (Jackson et al., 2001).  
A 2011 publication estimated that 9.4 million laboratory-confirmed cases of foodborne 
illnesses, resulting in 55,961 hospitalizations and 1,351 deaths, occur in the United States 
annually (Scallan et al., 2011). Non-typhoidal Salmonella accounted for the second highest 
number of foodborne disease cases and the most hospitalizations and deaths. That equates to 
1,034,000 (11%) cases, 19,587 (35%) hospitalizations, and 379 (28%) deaths from foodborne 
non-typhoidal Salmonella. These data are likely to be an under-estimation of true incidence due 
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to under-diagnosis and under-reporting resulting from patients not seeking treatment, no 
causative organism being isolated, and the illness not being reported to public health agencies 
(Scallan et al., 2011). Therefore, these laboratory-confirmed cases may not be a representation of 
all salmonellosis cases. Furthermore, estimates are based on the 2006 population of the United 
States at 299 million people. According to the most recent United States population estimate on 
July 1, 2017 (United States Census Bureau, 2017), there are over 325.7 million people in the 
country; meaning, foodborne disease cases, hospitalizations, and deaths have all likely increased 
in absolute quantity. A better understanding of the population dynamics leading to an increased 
risk of slaughter contamination with AMR bacterial populations can be achieved by studying 
AMR E. coli and Salmonella populations in animals in their pre-slaughter environment. 
Understanding these dynamics allows for interventions to be designed to mitigate against any 
such risks that might be increased following a two-dose CCFA treatment for metritis.  
 
1.8 STUDY SIGNIFICANCE 
 Our hypotheses were motivated by a risk assessment framework suggested by the late H. 
Scott Hurd (2004, 2006) in which he and colleagues explored the risk of AMR bacteria and their 
determinants escaping the farm at levels higher than ‘baseline’ levels and causing disease 
consequences (such as treatment failure due to microbial resistance) in humans. By temporally 
evaluating the effects of CCFA on AMR enteric bacterial populations, such as E. coli and 
Salmonella in dairy cattle, we directly address a current knowledge gap concerning animal 
slaughter withholding periods following two-dose CCFA treatment; further, we will 
quantitatively assess the potential, if any, for increased levels of AMR bacteria at the time of first 
slaughter eligibility. McEwen (2006) notes there has historically been much more policy focus 
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regarding antibiotic residues in food products than antibiotic resistant bacterial populations. The 
impacts of CCFA on E. coli populations may then be used to model the less prevalent 
Salmonella due to similarities in serovar behaviors, genetic materials encoding resistance (e.g., 
genes, integrons, plasmids, and genetic dispersion (Lowrance et al., 2007; Cummings, Aprea, 
and Altier, 2014), thereby reducing sample size requirements (Lowrance et al., 2007). Results 
from this study will allow dairy producers to make better informed decisions regarding animal 
slaughter withholding times and potential risks posed to consumers, provide a better 
understanding of AMR in the dairy production system, and to improve voluntary antimicrobial 
stewardship strategies. By understanding how levels of AMR Escherichia coli and Salmonella 
fluctuate in the feces of dairy cattle following two-dose CCFA treatment for metritis, steps can 




 Our study evaluates the temporal dynamics of 3GC resistance within fecal E. coli and 
Salmonella populations of Holstein-Friesian dairy cattle over 56 days following a two-dose 
treatment of CCFA for metritis. Our study facilitates the evaluation of the effectiveness of the 
current withholding period of 13 days in allowing levels of 3GC resistant E. coli to return to 
pretreatment (baseline) levels prior to slaughter. We hypothesized that the two-dose CCFA 
treatment initially drives down total E. coli counts, while increasing the levels of 3GC resistant 
E. coli. This rebounds over time, but the proportion of resistance in the total E. coli populations 
could remain elevated above baseline at the first eligible slaughter date. Phenotypic evaluation of 
suspected ESBL E. coli resistance profiles to 14 antibiotics via microbroth dilution allows for 
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exploring the hypothesis that, following treatment administration, there is an increase in the 
number of antimicrobials and classes of antimicrobials to which isolates are resistant due to co-
selection.  
 Examining the shedding of Salmonella throughout the first 3 sampling days allows us to 
explore similar hypotheses that the two-dose CCFA treatment drives down Salmonella shedding 
initially before the populations begin to rebound. Sequencing these isolates provides information 
regarding the background resistance profiles of the population. The application of micro and 
molecular biological techniques provides a more complete picture of Enterobacteriaceae 
population dynamics, 3GC resistance mechanism fluctuations, and the disruption of gut 













CRITICAL REVIEW OF THE LITERATURE 
2.1 ECONOMIC IMPACTS OF AMR 
 Not only acting as a threat to the treatment of infectious diseases, AMR also impacts the 
economy. The scope of this burden depends on the perspective through which it is viewed. These 
focus of these impacts could be broad, such as patient, hospital, or societal perspectives 
(Eliopoulos, Cosgrove and Carmeli, 2003) or more specific, like physicians, patients, healthcare 
businesses, pharmaceuticals, and public perspectives (McGowan Jr., 2001). An argument can be 
made to include surveillance and prevention activities in these estimates, in addition to how 
resistance impacts those who receive prophylactic antibiotics for surgeries, cancer treatment, and 
those patients who are immunocompromised (Smith and Coast, 2013). Differing perspectives, 
the inability to accurately judge costs, and a need to include a variety of industry experts, along 
with frequent differences in study design and estimate generation, make creating accurate 
estimates difficult (McGowan Jr., 2001; Eliopoulos, Cosgrove and Carmeli, 2003; Smith and 
Coast, 2013). Because costs have not been placed on the burden of AMR, progress has been slow 
in the way of health policy (Smith and Coast, 2013). While agreeing with McGowan Jr. (2001), 
Eliopoulos, Cosgrove and Carmeli (2003), and Smith and Coast (2013) that economic impact is 
important in proposing new legislation, to place a large degree of blame on health economists is 
unfair given the scale and multidisciplinary aspects of developing an accurate estimation. 
 These papers (McGowan Jr., 2001; Eliopoulos, Cosgrove and Carmeli, 2003; Smith and 
Coast, 2013) failed to consider the perspectives of animal agriculture and veterinary medicine. 
Within these 2 groups lie many differing viewpoints, including how to use antibiotics 
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(therapeutic, metaphylactic, prophylactic or growth promotion), how to administer antibiotics 
(parenteral, in water, in feed), and public health, moral (animal welfare), and economic 
obligations (Scott, Midgley, and Loneragan, 2015). While science is playing a larger role in 
decision-making, debate still rages regarding less empirical standards, such as the “Precautionary 
Principle” (Scott, Midgley, and Loneragan, 2015).  
 To better understand these moral obligations, the team of Jan et al. (2010) performed a 
cross-sectional study using the Theory of Planned Behavior to determine what moral obligation 
feedlot veterinarians felt toward certain interest groups. These interest groups were divided into 5 
categories consisting of veterinarians and nutritionists in the feedlot industry; feedlot 
owners/managers; beef packers, retailers, and consumers; professional organizations, the FDA 
(and other federal regulators), and licensing boards; and pharmaceutical companies. The team 
sent out 325 18-page surveys to feedlot veterinarians receiving a response rate similar to industry 
average at 32% or 103 completed surveys. The four categories of interest for antibiotic usage 
were for acutely sick, chronically ill, at-risk, or high-risk cattle. For each situation mentioned, it 
was asked if antibiotics would improve cattle health, increase profitability, or improve cattle 
well-being, among a host of other questions based on a theoretical framework from social 
psychology.  
The team found subjective norms and moral obligations did play a role in veterinarian 
decision making regarding antimicrobial usage in each of these 5 groups (Jan et al., 2010). 
However, these pressures varied in usage by category. For instance, pressures from colleagues 
led veterinarians to favor antibiotic use in chronically ill cattle, while organizational pressure led 
to a favorable view of antibiotic usage in acutely ill and high-risk cattle. A decrease was noticed 
when pharmaceutical company pressures were applied to use antibiotics in acutely ill cattle. 
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Moral obligations to clients created a positive view of antibiotic use for veterinarians in 3 of the 
four categories, the exception being usage in high-risk cattle. Subjective norms from colleagues 
provided positive indications of veterinarians using antibiotics in all categories, except at-risk 
cattle (those without evidence of disease). Interestingly, pressure from the groups that establish 
these norms led to decreased frequency in antibiotic uses in acutely ill or high-risk cattle. 
Antibiotic usage in at-risk cattle proved to be the only category in which client pressures 
increased usage; that is, preventive uses and uses of sub-therapeutic antibiotics (legal at the time 
of the survey) were highly impacted by client expectations.  
This study provides insight into the external factors veterinarians consider when 
administering antimicrobials; however, some of the information conflicts. Organizational 
pressures were found to increase antibiotic usage favorability in acutely ill cattle, but pressures 
from the pharmaceutical industry caused a decrease in antibiotic usage in this same group. An 
interesting next step would be to see which view is valued or, in the case of negative effects, not 
valued the most. Do the negative views of pharmaceutical company pressures suppress the 
positive views of organizational encouragement? Is this view ultimately impacted by each 
individual case and the severity of such case? Better understanding these interactions could 
provide further insight and also aid in tailoring antimicrobial stewardship programs to better 
represent all involved.  
In order to adequately access potential costs associated with AMR, all of the above 
components need to be included. These standards are broad and not well defined, as antibiotic 
usage varies within each field of medical practice and with each practitioner. It depends on how 
the use of antibiotics is defined. Is the focus treating infection, preventing infection, or another 
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purpose? To what extent is resistance being considered? Through which lens is the threat of 
resistance viewed among those listed above?  
Even with such difficulties in estimating the burden of AMR, there are groups that have 
attempted to address such issues. High-level AMR models from the World Bank project the 
global gross domestic product (GDP) of low-income countries will decrease by 5.6%, while 
decreasing the GDP of the world by 3.8% on average by 2050 (World Bank Group, 2017). In 
low-level AMR situations, the average GDP is projected to decrease by 1.1% by the same year 
(World Bank Group, 2017). Moreover, world trade and livestock production are projected to 
drop by four and ten percent, respectively (World Bank Group, 2017). Due to decreased trade 
and livestock production, as well as increased cost of medical care, 6.3 to 26.2 million people in 
low-income countries are expected to fall into extreme poverty. On the other hand, 0.6 to 2.1 
million people throughout the rest of the world will become extremely impoverished because of 
antimicrobial resistance (World Bank Group, 2017). It is important to keep economics and 
drivers of prescriptions in mind when designing and generating buy-in for stewardship and 
intervention programs. Ultimately, animal agriculture is a business and it is vital to appeal to 
economic, along with idealistic, concerns. 
2.2 POLICY AND REGULATORY CHANGES TO COMBAT AMR   
A 2002 review of animal antimicrobial use and resistance helped provide a now historical 
viewpoint of policies that were in place and provides a way to measure changes over the decades 
(McEwen and Fedorka-Cray, 2002). The review mentions the 1988 mandate of the FDA to make 
new antimicrobials accessible only by prescription, during a time when extra-label uses could be 
prescribed by a veterinarian and there was continued discussion of banning antimicrobial usage 
as growth promoters. The review alluded to other areas of AMR mobilization among animals, 
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such as husbandry protocols, animal movement, number of animals treated, the environment, and 
more. Pathogen testing at slaughter facilities included in the Hazard Analysis Critical Control 
Point has aided in preventing meat products with pathogens from entering the food supply, but 
regulatory activities based on surveillance programs are difficult to enforce for a variety of 
reasons. The establishment of the National Antimicrobial Resistance Monitoring System by the 
Food and Drug Administration, the U.S. Department of Agriculture, and the Centers for Disease 
Control and Prevention in 1996 has made strides in evaluating trends in resistance profiles 
starting with Salmonella and since adding more bacterial targets. The program looks to provide 
descriptive data, identify changes in resistance level and profile, provide information to medical 
personnel, extend antimicrobial time of effectiveness, and identify areas of further research and 
understanding.  
A literature review by McEwen (2006) proposed recommendations for future policy 
developments. Future policies regarding antimicrobial uses in animal agriculture should apply 
research in a One Health approach that has outcomes valuable not only for humans and the 
environment, but the animals afflicted by disease (McEwen, 2006). Additionally, an 
understanding that the efficacy of these medications is not unlimited and there needs to be 
movement toward reaching an appropriate balance between risk and reward, while maintaining 
effectiveness and consumer confidence. McEwen (2006) suggested establishing veterinary 
relationships, nutritional programs, and treatment directed solely for the target organism, along 
with developing effective and practical guidelines specific to region by engaging veterinarians 
and stakeholders. Another suggestion involved shifting from a focus on antibiotic residues in 
meat products to resistant bacterial load that can then transfer resistance genes on mobile genetic 
elements to other enteric bacteria within the consumer. McEwen’s (2006) approach was largely 
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on pace with the overarching goals of this current PhD project, as various stakeholders from 
multiple sectors, including feedlots and dairy farms, public health regulators, veterinarians, and 
consumer advocates, have been engaged as a way to begin conceptualizing and building 
voluntary stewardship programs that aim to be beneficial and practical for all involved. 
Additionally, the project includes microbiological and molecular techniques to evaluate resistant 
bacterial populations instead of antibiotic residues. Along with animals, the environment is taken 
into account with endpoints of human interest in ensuring animals are not being sent to slaughter 
with levels of antimicrobial resistance increased above baseline. 
Another stewardship study conducted in the state of Washington used a two-survey 
method considering calving management, disease control, AMR, biosecurity, and descriptive 
dairy data (Raymond et al., 2006). The first survey was sent to 589 dairy farms in 2003, with 
follow-up materials sent regarding a variety of dairy production practices. Dairy producers who 
completed the first survey received an additional survey in February of 2005. Both the 2003 and 
2005 surveys had five-dollar completion incentives. Of the 589 original surveys, 381 or 65% 
were returned. Unfortunately, some dairy farms had removed the identification label and some 
had gone out of business by the time of the second survey. This left 360 dairy farms, of which 
292 completed the second survey. With regards specifically to antibiotics and infectious disease, 
23% of responders reported using antibiotics in prohibited or unapproved ways. Additionally, 
81% of farmers reported not testing animals new to the herd for infectious diseases and 33% 
utilized calving and sick pens for multiple other uses. 
Overall, producers seemed to be concerned with antimicrobial resistance, as 59% or 
greater agreed a resistant infection in one cow threatens the herd, antibiotics lose effectiveness 
when frequently used, and antibiotic uses in food animal production could negatively impact 
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human health. The additional materials sent between survey distributions appeared effective, as 
dairymen reported decreased antibiotic usage, increased biosecurity, and changes in vaccination 
protocols in between surveys. The team noted changes were not significant before versus after 
intervention, although changes were reported during the second survey, citing the Hawthorne 
Effect where behavior changes based on observation (Landsberger, 1958). Education is an 
important way to provide individuals with the necessary tools to make decisions; that is, one 
cannot simply expect a person to stop a negative behavior if they do not perceive it as such. 
However, as this study showed, education was not the only thing needed and many factors 
played a role in decision making. Another problem with a study using survey methodology, the 
individuals responding could be the ones most concerned about AMR and thus inflate the 
concern represented on Washington dairy farms. Perhaps non-respondents did not care about or 
not see the threat of AMR and, therefore, failed to respond. As cited by the authors, the 
Hawthorne Effect could play a role, although these dairy farms were not being directly 
monitored. The Hawthorne Effect suggests these individuals were actually changing behavior 
due to being observed. However, the authors did not know for certain the dairy producers were 
changing their behaviors; they were simply taking the producers at their word. Producers could 
have been reporting a change due to the distributed material and the perception they were 
expected to change. This would indicate social desirability bias (Edwards, 1953). 
In 2012, the Society for Healthcare Epidemiology of America, Infectious Diseases 
Society of America, and Pediatric Infectious Diseases Society developed a variety of 




 “…coordinated interventions designed to improve and measure the appropriate use of 
antimicrobial agents by promoting the selection of the optimal antimicrobial drug regimen 
including dosing, duration of therapy and route of admission… to achieve best clinical outcomes 
related to antimicrobial use while minimizing toxicity and other adverse events, thereby limiting 
the selective pressure on bacterial populations that drives the emergence of antimicrobial-
resistant strains. (Fishman, 2012)” 
Among these recommendations were an optimization of antimicrobial usage in ambulatory 
settings, further research on the mechanisms of antimicrobial resistance, and improved 
monitoring of antimicrobial usage. The organizations determined a standardization of the ways 
in which antimicrobials should and should not be used, patient-centered outcomes for clinical 
effectiveness and economic sensibility, and improved knowledge of generic and branded 
antimicrobial usage would be beneficial. Additional recommendations included improved 
diagnostic testing to avoid using antibiotics to treat individuals with viral infections.  
Some of these recommendations are overdue in part due to the complexity associated 
with clinical medicine in that no 2 patients are exactly the same, nor do 2 treatment regimens 
work the exact same way each time. These issues put standardization at risk and the ability to 
place a monetary cost to AMR expansion. Clinical effectiveness should be a constant focus of 
the medical and veterinary fields. The goal should always be to improve the overall health and 
well-being of the patient. Having patient-centered outcomes and improved diagnostic testing 
would not only reduce selection pressures for AMR bacteria, but improve patient response to 
treatment. Much like the studies included in the economics section, the focus of these 
organizations is human patients, but antimicrobials are not only used in human medicine, nor 
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should they be. To make impactful improvements in antimicrobial usage and AMR prevention, 
veterinary medicine and animal agriculture must be included in the discussion. 
From May to August 2015 meetings and workshops were held involving a group in the 
United Kingdom to develop voluntary policies to curb antimicrobial usage, as instigated by 48 
conventional and 25 organic dairy herds (van Dijk et al., 2017). Involving 70 producers and 27 
veterinarians, the discussion revolved around infection control, proper treatment protocol, 
removing the use of antibiotics as a preventative measure, and ensuring proper data collection. 
Discussions took place in small groups prior to larger group discussion. Suggestions were then 
ranked by the complete group on ease of implementation. An overwhelming majority agreed that 
antimicrobial resistance is not a “passing fad” and antibiotics are used too often in United 
Kingdom animal agriculture. An additional majority agreed antimicrobial usage could decrease 
further and still maintain current health and production levels. However, responses regarding the 
estimation of antimicrobials used and AMR organisms on dairy farms varied. Both producers 
and veterinarians viewed veterinarians as being more important than producers in addressing 
these topics. The group developed 5 principles consisting of reducing and eliminating antibiotic 
therapies where possible, using veterinarians to address disease, supervising staff in using 
antimicrobials, reducing antimicrobial usage in prevention protocols, and using data as a 
comparative measure between dairy farms.  
These policy developments hit a snag, as producers struggled to develop a set of common 
terms (Dijk et al., 2017). Producers felt confident in training regular staff on antimicrobial usage, 
but were concerned about temporary workers and a high turnover rate. The United Kingdom 
requires data collection on antimicrobial usage, but in practice collection efforts struggle due to 
limited tools and methodologies. Ultimately, it was determined dairy producers need a better 
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understanding of antimicrobials and their administration, along with developing ways to connect 
dairy and veterinary information. Those goals set the stage for the first year. This study 
highlights the struggles of developing voluntary policy standards. Even when producers agreed 
antimicrobial usage and AMR was an important issue and a broad set of standards were 
established, it became difficult to decide on details and implementation due to a high volume of 
turnover and a lack of tools. Importantly, the combined group identified areas of improvement 
necessary prior to the establishment of a new system. By identifying those areas, producers 
showed a commitment toward developing a better method of practice. These discussions were a 
starting point and it is yet to be seen if measurable improvements stemmed from these meetings 
in the first year. Follow-up studies tracking progress will ultimately determine the level of 
success and commitment of producers and veterinarians. 
 
2.3 CEFTIOFUR EFFECTIVENESS 
 In 2000, a study was conducted across 8 dairy farms in 5 states (California, New York, 
Florida, Michigan, and Texas) to evaluate the efficacy of ceftiofur hydrochloride for the 
treatment of metritis in dairy cows (Chenault et al., 2004). Holstein cattle were enrolled in the 
after passing a variety of exclusion criteria, including not having other treatments or caesarian 
section. The rectal temperatures of cows were checked for 14 days following birth and animals 
were examined for vaginal discharge, dehydration, heart rate, and rumen contractions. Cows 
were blocked in groups to receive saline (0.9% NaCl) at 2 mL per 45.4 kg, ceftiofur 
hydrochloride at 1.1 mg per kg, or ceftiofur hydrochloride at 2.2 mg per kg. Eligible cattle were 
evaluated on study days 6, 10, and 14, and enrolled cattle on days 1, 5 and 9 after treatment. A 
clinical cure was documented based on a rectal temperature below 39.5℃ and absence of a fetid 
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vaginal discharge. Animals that needed additional treatment were removed from the study and 
noted as a failure to cure. In total, 60.6% of the 406 enrolled cows were heifers. Of the 406, 30 
were removed from statistical analysis due to variation from the protocol.  
Cure rates were found to be higher among the group receiving a 2.2 mg per kg ceftiofur 
treatment, but no statistical difference was observed between the 1.1 mg/kg ceftiofur group and 
the saline group (Chenault et al., 2004). No significant difference was observed for any of the 
treatment groups on study days 6 and 10. Through the first 5 days, the rectal temperatures of all 
ceftiofur treated cows decreased at similar rates and were significantly different from those in the 
control group. Upon enrollment, all cows had a vaginal discharge score of 4, but by day 14 an 
almost linear decrease was observed and the average score was 2.5. Based on the cure rates, both 
ceftiofur treatments (2.2 mg/kg and 1.1 mg/kg) had cure rates significantly higher than the 
control group (P=0.004 and P=0.021, respectively). The study enrolled a large number of cows 
across the country and had strict inclusion criteria to accurately attribute success or failure to the 
treatment group in which the cow was enrolled. Furthermore, it addressed metritis from a deeper 
perspective than temperature. Other variables, such as dehydration and heart rate were not 
mentioned outside of the methods section, so it is likely that those variables were only for 
physical examination purposes and not evaluated for the study. 
As with any pharmaceutical approved by the FDA, CCFA has undergone testing to 
ensure its efficacy for its label indications. McLaughlin et al. (2012) performed a randomized 
study on 15 dairy farms across the United States from June through October of 2006 to establish 
the efficacy of a two-dose CCFA suspension (CCFA, 6.6 mg/kg) treatment of metritis in dairy 
cattle. Thirty animals from each location were chosen to comprise each of 2 treatment groups: 
the CCFA group and a group receiving saline as a placebo (1.5 mL/45.4 kg). Eligible cows had 
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to have calved within the past 10 days and have temperatures evaluated as exhibiting a fever to 
determine eligibility. Cattle were excluded if they received any pharmaceutical treatment other 
than a topical antibiotic since calving; they were given an antibiotic other than topical within 14 
days prior to calving; caesarian section, fetotomy or uterine prolapse occurred during calving; or 
retained fetal membranes (RFM) occurred requiring intrauterine or parenteral antibiotic 
administration. A sample of vaginal discharge was collected and scored on a scale of 0 to 4. 
Post-injection measurements, rectal temperature, physical exams, and injection site evaluations 
were all regularly performed. It was found a two-dose treatment with CCFA at the base of the ear 
72 hours apart increased the cure rate of metritis by clinical standards 19% above the saline 
control group. Because this study utilized a large number of dairy farms across the country and 
enrolled a number of cows sufficient to provide statistical power, these results can likely be more 
broadly applied to U.S. dairy cattle populations. Additionally, the team used a variety of metrics 
to evaluate metritis improvement and was careful to avoid any cattle that could confound results 
or leave doubt as to if effective treatment was due to CCFA, a previously administered 
medication, or a combination thereof. Oddly, the previous one-dose CCFA treatment for metritis 
was not included in the treatment protocol for this study. It would have made a useful 
comparison group to see the difference between treatment with a one and two-dose treatment. 
Another study on a large Florida dairy farm tested the efficacy of ampicillin trihydrate 
and ceftiofur hydrochloride for treatment of metritis in dairy cows (Lima et al., 2014). A total of 
528 animals were enrolled in the study, evenly split between heifers and cows. An additional 268 
animals without metritis were enrolled on the twelfth day of the study. Control animals were 
selected based on calving date and parity. Vaginal discharge was scored on a five-point scale and 
temperature was considered elevated when recorded as higher than 39.5℃. Temperature was 
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recorded and documented daily. Cows were blocked in groups of 3 in which 1 received 
ampicillin, 1 ceftiofur, and the other, a control, did not have metritis. Treatments consisted of 
ampicillin at 11 mg/kg and ceftiofur at 2.2 mg/kg daily for 5 days. Metritis diagnosis was 
recorded as study day 1 and animals were assigned body condition scores upon enrollment. Any 
enrollees with difficult or assisted births were noted as having a calving-related disorder. Once 
diagnosed with metritis, animals had temperature data collected from days 1 through 7 and again 
on day 12. Vaginal discharge scores were reassigned on days 5, 7, and 12. Cure was evaluated 
based solely on vaginal discharge, again with vaginal discharge and rectal temperature, and 
whether or not additional treatment was required.  
The average temperature of cows enrolled in the ampicillin group was higher than the 
ceftiofur group, although differences were not observed upon the study end (Lima et al., 2014). 
Metritic cows exhibited a decrease in temperature after the start of antimicrobial treatments. 
Throughout the study, ampicillin performed as well or better than ceftiofur in cure rates. Those 
in the ampicillin treatment group had significantly higher cure rates on day 7 when evaluating 
vaginal discharge alone or in combination with rectal temperature when compared to the 
ceftiofur group. These differences were not observed at the end of the study.  This study provides 
significant data showing treatment with ampicillin can be an effective form of treatment for 
metritis. While ampicillin outperformed ceftiofur in many of the early study day data collection 
metrics, the findings do not indicate ceftiofur was not effective in comparison to the control 
group. Unlike many other metritis studies, this 1 seemed to focus more on vaginal discharge than 
rectal temperature. The only time temperature was evaluated was in combination with vaginal 
discharge, which is interesting. Similar to the criticisms of other publications, this study was 
performed on only 1 dairy in 1 region. For increased confidence in the results, replication of this 
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study in multiple study sites, if not regions/states, is needed to determine if consistent results are 
observed regardless of location. 
A literature review of treatment for puerperal metritis found ceftiofur was the most 
investigated treatment form and, while 7 studies reported clinical improvements, reproductive 
performance was never improved in comparison to control cattle (Haimerl and Heuwieser, 
2014). This review found less than half of the studies used bacteriological exams and 3 or less 
evaluated AMR, antibiotic applications, or antibiotic usage guidelines. Haimerl and Heuwieser 
(2014) searched with the keywords “bovine metritis AND antibiotics” and had strict exclusion 
criteria, including descriptive and in vitro studies, conference proceedings, review articles and 
more.  
However, a literature evaluation by Reppert (2015) of CCFA effectiveness was proven 
difficult due to small sample sizes, lack of control groups, inconsistent dosing and administration 
protocols, and variance among the case definition of metritis. To find studies, the keywords 
“dairy cattle”, “metritis”, and “ceftiofur” were used. Studies had to be controlled, prospective, 
and experimental studies meeting a metritis definition. The definition had to include a 
temperature of 39.5℃, fetid red-brown discharge, and diagnosis occurred within 21 days after 
calving. Additionally, case cows could only be treated with ceftiofur with a variety of measures 
indicating clinical improvement routinely taken. In total, the review included 34 studies, but was 
unable to perform robust analysis due to a lack of consistency among study protocols. The main 
finding of this review was the inability to do a proper review based on available information. 
This review used some additional keywords than the previously mentioned review above, but 
was more selective in the words used and was very selective in papers evaluated. The reasoning 
behind finding limited options is relatable. The most common complaint of studies reviewed in 
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this critical review is a lack of sample size and an inconsistency in dosing and administration in 
the literature as a whole. Some studies utilize multiple administration techniques to determine 
effectiveness, but these techniques are largely variable throughout.  
 
2.4 METRITIS 
In seeking to provide a solution to the variety of metritis definitions, Sheldon et al. (2006) 
published with the intent of describing postpartum uterine diseases. The team defined puerperal 
metritis as consisting of an enlarged uterus with a red-brown discharge, fever greater than 
39.5℃, and signs of systemic illness occurring within 21 days of calving (Sheldon et al., 2006). 
Clinical endometritis was described as having purulent or mucopurulent discharge in the vagina 
21 and 26 days after calving, respectively (Sheldon et al., 2006). These definitions have proven 
useful for other publications (McLaughlin et al., 2012; Reppert, 2015), but have not completely 
solved the problem (Krogh and Enevoldsen, 2014) and helped form the definition used for our 
study. A variety of calving difficulties are risk factors for the development of metritis, including 
dystocia, twins, retained placenta, and stillbirths, in addition to ketosis (Sandals et al., 1979; 
Dohoo and Martin, 1984; Gröhn et al., 1989; Rajala and Gröhn, 1998; Benzaquen et al., 2006; 
Giuliodori et al., 2013).  
The causes of metritis have been the focus of research for decades. Data from 1973 to 
1976 evaluated calving, heat and breeding dates, disease occurrence, and treatment of 293 
Holstein-Friesian cows and 652 calvings in the Guelph area of Ontario (Sandals et al., 1979). For 
the study, retained placenta was defined as an inability for the cow to expel the placenta within 
24 hours of calving. Farmers monitored the cow’s health and were instructed to administer a 
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two-dose treatment of penicillin-streptomycin once the rectal temperature became higher than 
39℃. Case cows were placed in 1 of 3 groups: retained placenta, retained placenta and metritis 
complex, or just metritis complex. Control cows were typically matched within a year of age of 
their case counterparts. Throughout the study, 33 cases fell ill in the first grouping, 40 in the 
second, and 13 in the last. Cows birthing multiple calves were 4.6 times more likely to have a 
retained placenta than their counterparts birthing 1 calf. Most cases happened in the October to 
December calving months, but the authors note this may be due to the increase in calving events 
during those months. While not statistically significant, cows with retained placentas took 
approximately 30 more days to get pregnant than control cows. However, cows with metritis 
took longer to conceive at a statistically significant level (P < 0.05) of approximately 51 days 
longer than control cows. The study continued for an extended period of time and had a robust 
sample size. Their findings are consistent with expectations in that animals suffering from 
complications or infections from the previous calving would require a longer period of time to 
achieve pregnancy again due to an extended recovery period. 
 At the same university, Dohoo and Martin (1984) utilized a case-control study design 
consisting of 1,844 lactations within southern Ontario with disease cases having the disease of 
interest and control cows being disease free. Diseases were wide-ranging, including milk fever, 
ketosis, mastitis, respiratory disease, and others, along with calving difficulties. The team used 
every cow with the disease of interest on a farm as a case. As many control cows as possible 
were enrolled. Control groups were evenly split to match with each case cow. Three models were 
evaluated consisting of 490 lactations from heifers, 751 mature cows with data from the previous 
lactation, and 1,315 lactations, regardless of cow age, while using age as an external factor. The 
team determined the presence of 1 disease increased the likelihood of the cow having another 
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disease. Of the 136 possible disease pairings based on diseases of interest, the team found 32 
different pairs of disease associations in their study. All of these pairs had odds ratios above 1. 
The mature cow model showed age was linked to 6 diseases, while the complete model indicated 
a relationship with 8 of the 19 internal variables. Having the disease in a previous lactation was 
found to be a risk factor for future disease development in 9 of the 17 disease states of interest. 
The only association with metritis was retained placenta. A cross-tabulated model showed more 
significant relationships, but the authors believed it to be due to the cross-tabulation recognizing 
the disease states going from A to B and B to A, statistical changes in sample size and 
distribution when using a four-fold table, and disease intensity for each case. Additionally, the 
study revealed high milk yields did not make a cow more likely to have a certain disease in the 
future. This study provides insight into how disease states in dairy cattle impact the occurrence 
of future disease states, providing farmers with information to better manage herds and reduce 
production loss. The large sample size and multiple groupings of cases and controls, in addition 
to the cross-tabulated and case-control methodologies, make this study very robust and provides 
multiple platforms for evaluation. 
 A research team used retrospective data from the Danish Cattle Database to perform a 
longitudinal study evaluating risk factors for metritis (Bruun, Ersbøll, and Alban, 2002). Of the 
2,391 contacted farmers, 2,148 agreed to be interviewed by students trained to administer 
questionnaires. Cows included in the study calved between July 1, 1993 and June 30, 1994 with 
disease states recorded both 30 days prior to and after calving. Metritic cattle were recorded in 
the Danish Cattle Database as veterinary treatment. Heifers were not included in the study. With 
these criteria, 102,060 cows were included in the study. Dry-cow mastitis, reproductive disease, 
and breed were all variables used in analysis. Confounding was considered a change in test 
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statistic greater than 20% and interactions were evaluated using a variety of variables including: 
RFM, breed, parity, dystocia, grazing, and calving season. In total, 733 cases of metritis were 
included with cumulative lactation incidence ranging from 1 to 21% and 391 herds reporting at 
least 1 case. A variety of variables came back as risk factors. Parity, grazing, calving season, 
dystocia, reproductive disease, ketosis, and an interaction between RFM and breed were all 
implicated as risk factors.  
Upon further breakdown, the team noted a “u-shaped association” between parity and 
metritis suggesting young cows and cows of parity four or higher were more likely to develop 
metritis. Risk of metritis was lower among cows eligible to graze. Calving from November 
through April elevated metritis risk, along with dystocia and reproductive illness due to the 
reduced health of cattle in the winter and traumas of difficult calving or illness. The team noted 
the interaction of breed and RFM was the first of its kind since most studies only enroll 1 breed 
of cow. They did, however, mention a multitude of studies identifying RFM as a metritic risk 
factor. Due to the large number of variables considered, this study shows the breadth of risk 
factors associated with metritis. With that said, there was a very large sample size which could 
lead to some variables testing as more significant than they would otherwise. Additionally, as 
was the case with ketosis, there was some conflict among how results were expressed in the 
paper. Some p-values were displayed in the article, but there was not a breakdown of these p-
values within the category. For instance, parity was listed as significant with a p-value of <0.001. 
Further breakdown would be beneficial in providing a more complete picture of the variables, 
especially as some levels were significant and others are not.  
 A 2007 study evaluated rectal temperature and calving issues in relation to puerperal 
metritis on a 1,000 head dairy herd in northeast Florida from August of 2002 through April of 
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2003 (Benzaquen et al., 2007). Dystocia, twinning, and RFM were noted with RFM being 
defined as membranes not being expelled within 24 hours. RFM was rated on a five-point scale. 
After waiting 60 days, cows began undergoing artificial insemination again and were checked for 
pregnancy by rectal palpation. Cows with cesarean section were not included in the study. Cows 
were monitored 3 to 13 days after giving birth for rectal temperature and attitude. Puerperal 
metritis occurred in 21% of study animals and of those 94 cows, 55 did not have an increased 
rectal temperature. Heifers were more likely to have puerperal metritis in the summer than the 
winter, but cows did not exhibit a seasonal difference. There was a significant interaction 
between day and puerperal metritis. Rectal temperature was significantly higher 3 days prior to 
diagnosis, and maintained as elevated four days after diagnosis. These temperatures began to 
decrease a day after treatment began. Those animals without an increased temperature did not 
see a significant decrease in temperature. The statistical hazard of animals becoming pregnant at 
first conception was impacted by season and parity. The time between last calving and 
conceiving again in 150-day intervals was impacted by season. The team determined calving 
difficulties was a risk factor for puerperal metritis, in addition to calving in the winter for heifers. 
The team also recommended including attitude and uterine examination into the diagnosis of 
puerperal metritis. These findings shed some light on metritis development. While performed on 
a large dairy, it would be beneficial to see if these findings are similar on other dairy farms in 
other climates since rectal temperature still seems to be a large player in metritis diagnosis, even 
though the study shows metritis can still develop without a fever. Like Dohoo and Martin (1984), 
a seasonal difference was found, but Dohoo and Martin (1984) had mentioned more calvings 
occurred in winter, which may impact results. Benzaquen et al. (2007) did not mention an 
increase in calvings in the winter or summer. This information would be useful in determining 
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how much of a role seasonality plays or if it is by happenstance due to a difference in the number 
of calvings occurring in each season. 
 A study to evaluate if cows at risk for metritis could be identified by their pre-calving 
behavior and dry matter consumption began at the University of British Columbia’s Dairy 
Education Research Center in August of 2005 and extended into March of 2006 enrolling 32 
heifers and 69 cows (Huzzey et al., 2007). Feed and water consumption was measured 
electronically using a transponder attached to the animal’s ear tag. As the cow approached the 
feed gate, it opened and the time and bin weight were recorded. Once the cow left the bin, the 
gate closed and time and bin weight were again recorded. The number of times a cow was moved 
away from the feed or water bin due to another cow or vice versa was recorded daily as a 
behavior indicator. Cattle body condition score and weight were monitored both before and after 
the calving. Retained placenta followed the same definition of Sandals et al. (1979), Dohoo and 
Martin (1984), and Benzaquen et al. (2007). Mastitis exams were conducted every 3 days after 
calving for 21 days. Time of calving, feed, and water consumption were observed via video to 
ensure the day 0 feed and water consumption data was measured from the time the calving 
occurred. Study animals were evaluated for vaginal discharge at the same intervals as mastitis 
exams. Vaginal discharge and odor were measured on a scale from 0 to 4. Miscellaneous health 
issues and mastitis removed a combined total of 23 animals from the study.  
Of those with metritis, 7 with severe metritis had a retained placenta and 2 had twins. 
Mild metritis cases consisted of 2 animals with retained placenta. Those animals with mild and 
severe metritis had decreases in milk production by 5.7 and 8.3 kg of milk per day for the first 3 
weeks of production, respectively. An assisted calving, indicating dystocia, was associated with a 
15.8 times higher risk of developing severe metritis. Decreases in dietary consumption and days 
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of gestation were also indicators of severe metritis. The number of calvings or pre-calving body 
weights or conditions were not associated with a risk of developing severe metritis. Animals 
eventually developing severe metritis were found to move other animals from feed or water less 
frequently and also tended to consume less feed and water beginning approximately a week prior 
to calving. The research group concluded these findings were indicators of a heifer or cow 
developing severe metritis; however, it is important to remember correlation does not mean 
causation. Furthermore, lack of energy and appetite is common among most disease states, so 
these metrics might not exclusively indicate metritis, but a more general state of disease. The 
study provides additional insight into potential risk factors of metritis development, but further 
research into the mechanisms for metritis development resulting from decreased aggressive 
behavior, feed intake, and water consumption would provide further support to how closely 
linked these findings are to metritis development.  
 An Argentinian study utilized a 1,600 head Holstein herd to enroll 303 autumn calving 
cows to evaluate risk factors and calving performance associated with metritis (Giuliodori et al., 
2013). The study ran from May through August. The dairy had a 40% cumulative incidence of 
metritis in the 3 years preceding the start of the study. A three-point scale was used for dystocia 
rating and retained placenta utilized the same definition, inability to expel the placenta within 24 
hours, as Sandals et al. (1979), Dohoo and Martin (1984), Benzaquen et al. (2007) and Huzzey et 
al. (2007). Dystocia, retained placenta, and stillbirths were all documented throughout the study. 
Metritis definitions were followed as described by Sheldon et al. (2006). Metritis cows were 
randomly assigned to the treatment or control group of ceftiofur hydrochloride in which treated 
cows received 2.2 mg/kg of body weight for 3 days. 
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Risk factors for metritis, as determined by the study and interpreted by the team, were 
heifers, abnormal calvings, and poor energy levels prior to calving, which provides additional 
support for the findings of Huzzey et al. (2007). Metritis increased the time-to-conception with 
the most impact being with puerperal metritis and both clinical and puerperal metritis decreased 
milk production early in lactation. The team did not find an increased cure rate or milk 
production with the metritis regimen, but did increase the risk of pregnancy with artificial 
insemination and reduced the risk of being culled for reproductive issues. This study’s findings 
remain consistent with others found in the literature regarding decreased milk yield and 
increasing time-to-conception. The authors mention an increased cure rate was not observed with 
ceftiofur and noted most studies only utilized temperature as an indicator of improvement. 
However, both Haimerl and Heuwieser (2014) and Reppert (2015) reported improvements in 
their literature reviews. Chenault et al. (2004) and Lima et al. (2014) each utilized vaginal 
discharge, in addition to temperature, in their investigations into the efficacy of ceftiofur for the 
treatment of metritis and came to the conclusion ceftiofur is an effective form of treatment for 
metritis in cattle, although the data of Lima et al. (2014) suggests ampicillin may be a more 
effective form of treatment. McLaughlin et al. (2012) also utilized routine physical examination 
in their measurements. 
2.5 PRODUCTION COSTS OF METRITIS 
Metritis is a disease associated with large production costs on dairy farms. A literature 
review estimated that the prevention and treatment of metritis costs producers on average of 
$4.70 per dairy cow in inventory annually, although estimates vary by state (Bellows, Ott, and 
Bellows, 2002).  A 1998 publication evaluating the impact of dystocia, retained placenta, and 
34 
metritis on milk production utilized 37,776 Finnish Ayrshire dairy cows from 2,337 herds that 
calved during 1993 (Rajala and Gröhn, 1998). Metritis was broken down by early and late 
metritis, depending on how many days diagnosis followed calving. Milk yields were tested every 
30 days and the lactation period was separated into 17 stages with milk records taken every 10 
days for the first 60 of lactation, every 20 days for lactation days 61-180, and every 30 days from 
lactation days 181-330. Lactations were grouped into categories of 1, 2, 3, and 4 or more 
lactations for curves. Rajala and Gröhn (1998) found early metritis was associated with a 
reduced milk yield, seasonality had significant effects, and cows calving in the winter produced 
more milk than those calving in the summer. For parity 1 cows, retained placenta was significant 
for decreased milk yield and early metritis had an association with decreased milk yield, 
although not statistically significant. Milk production among high producing parity 2 cows with 
early metritis was again associated with a non-significant decrease in milk yield. Dystocia 
dropped milk yields of parity 2 cows significantly and retained placenta negatively affected the 
milk production of high yielding animals. High yielding parity 3 cows had a decrease in milk 
production before diagnosis with early metritis. This decrease was more noticeable when 
dystocia or retained placenta were not included in the model, which would show those variables 
are confounders of early metritis should the difference have a minimum change of 10%. Parity 4 
cows did not indicate a statistically significant decrease in milk yield for any of the 3 conditions 
of interest, but decreases in production were observed. 
When 305-day milk production was evaluated, none of the diseases resulted in a decrease 
in milk production, rather a higher yield (Rajala and Gröhn, 1998). Only late metritis had a 
significant impact on 305-day production. Each disease showed higher levels of impact when 
modeled alone than when involving the other 2 options. This lead the authors to suggest other 
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studies evaluating just 1 option could overestimate the impact of the individual disease or 
condition being evaluating. Some conditions and diseases were associated with higher milk 
yields, which the authors noted could lead to false conclusions if multiple and frequent 
production measurements not been taken. It was also noted that treatments are only administered 
by veterinarians in Finland and retained placenta is rarely treated unless systemic disease is 
beginning to show. Because study animals required a veterinary diagnosis, findings could be 
elevated due to the progressed disease state warranting veterinary examination and treatment. 
This study offers strengths in its sample size and multiple points of measurement. It provides 
good insight into milk production and how various diseases affect milk yield throughout 
lactation. It would be interesting to see the results of a study of similar design in an area where 
farmers could treat animals themselves or animal health is more closely monitored to see if these 
same trends are observed in animals with mild forms of disease. 
A study performed across 5 Israeli commercial dairy herds determined cows and heifers 
impacted by RFM or clinical metritis can result in 300-500 kilograms of reduced milk production 
in comparison to cattle that did not experience clinical metritis or RFM (Goshen and Shpigel, 
2006). Cattle that did receive treatment for clinical metritis observed a 305 day corrected 
lactation of 654 kg more milk than the untreated groups with no statistical difference with 
treatment simply for RFM absent metritis. The study ran from April of 2000 until December of 
2001 and focused on cows that calved in that time period. Collected data included clinical, 
reproduction, production, and management data. Odd numbered cattle with clinical metritis or 
retained fetal membranes were randomly placed into a treatment group receiving 5 grams of 
chlortetracycline twice a week for 2 weeks or no treatment at all. The study contained a total of 
1,416 cows and 804 heifers. Within these populations, 967 cows and 489 heifers did not 
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experience clinical metritis or RFM. Additionally, cows with clinical metritis had a more 
difficult time conceiving than cows without a metritis diagnosis. This impacts milk production 
indirectly, as the cows need to calve to produce milk. Any delay in conception delays milk 
production in the future. This study provides a numerical impact on the issues of metritis. A 
decrease of 300 to 500 kg of milk production per cow with metritis is a large economic impact 
for producers. With different countries potentially employing varying management practices, for 
instance, a two-dose CCFA treatment for metritis in the United States, it would be worth 
performing similar studies in different countries to see if the economic impact is the same. 
Even within the structured protocols and science of dairy production and metritis 
management, there is still a large degree of variation among producers. A 2012 study was 
designed to evaluate dairy interventions, including herd health management programs (HHMP), 
by evaluating data from 121 herds consisting of 76,953 lactations over 15 years in Denmark 
(Krogh and Enevoldsen, 2014). Cattle were routinely examined by veterinarians and vaginal 
discharge rated on a scale of 0 to 9 was employed to determine the degree of metritis. 
Measurement, examination, and treatment varied by veterinarian. Because HHMP is unclear, 
Krogh and Enevoldsen (2014) focused on milk production as a resulting factor of vaginal 
discharge, specifically the relationship between metritis treatment and milk yield. A baseline loss 
of energy-corrected milk (ECM) due to metritis was considered at 192 kg, but became 69 
kilograms after enrollment in an HHMP. Parity 2 cows had a decrease of 91 kg of ECM due to 
metritis disease and treatment if the calf was healthy regardless of HHMP enrollment, although 
the loss was 348 kg if the calf was dead. In cattle with parity greater than 2, a decrease of 247 kg 
in ECM was observed with metritis if the calf was born healthy, regardless of HHMP enrollment, 
but the loss was only 192 kg of ECM with a dead calf. Cows enrolled in HHMP saw 17% less 
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305 day ECM production loss; however, this was based on examination and metritis detection, in 
addition to treatment protocols. Based on study results, HHMPs provided a positive result in 
reducing ECM production loss. A consistent problem remained variation among dairy protocols 
and management practices; perhaps this study showed any HHMP proves beneficial, but a more 
standardized, voluntary version amongst producers utilizing best practices could increase 
production, as not all dairy producers have available capital to make vast improvements at any 
given time. 
Understanding the reasons for CCFA usage instead of other metritis treatments as well as 
the risk factors for and production costs of metritis are critical for our study. Additionally, it is 
important to prevent and treat metritis effectively for the economic well-being of the farmer, and 
the health and welfare of the cows. The lack of a milk withholding period with this treatment 
decreases the economic loss associated with other treatments. Therefore, this is among the most 
commonly used drugs for metritis treatment. Furthermore, this knowledge of metritis highlights 
the scope of the problem caused by the disease. By understanding the risks for metritis and 
mitigating those risks, antibiotic stewardship can be improved by preventing the disease before a 
treatment is necessary. 
2.6 THIRD-GENERATION CEPHALOSPORIN RESISTANCE OF FECAL E. coli IN
DAIRY CATTLE POPULATIONS  
AMR in dairy cattle has been studied from a variety of designs depending on the 
organism, mechanisms of interest, stage of production, and antimicrobial of interest. Zwald et al. 
(2004) evaluated antimicrobial usage and management procedures on conventional (n=32) and 
organic (n=99) dairy farms in 4 states consisting of Michigan, Minnesota, New York, and 
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Wisconsin from May of 2000 through March of 2001. Dairy farms were contacted via letter to 
determine interest in the study and further eligibility. After study dairy farms were selected, a 64-
question survey was sent inquiring about herd size, herd expansion, housing, feed and water 
protocols, calf management, manure management, and antimicrobial usage. Conventional dairy 
farms tended to be larger and produce more milk than organic dairy farms. Differences in 
management practices were largely attributed to differences in herd size, but it was noted organic 
dairy farms were less likely to use feed from off-site and mainly fed soybean-based diets. It was 
discovered ceftiofur was the most commonly used antibiotic on each dairy type, since in the U.S. 
organic dairy farms can use antibiotics in ill cattle so long as milk from the animal is no longer 
sold as organic and the cow leaves the farm after recovering. This is another example of the 
difference between dairy production styles; however, it would have been better to have some 
more empirical measurements, as surveys can be prone to bias. Producers could be answering 
questions as they feel is socially acceptable or could be incorrectly remembering antibiotic 
usage. These biases, while sometimes subconscious or unintentional, can create misleading 
results and incorrect conclusions. A follow-up study that more closely follows these categories of 
interest for a period of time would be beneficial in providing more information toward the 
accuracy of these results. 
In Ohio, a study consisting of 18 dairy farms and 1,266 dairy cows evaluated ceftiofur 
usage and reduced susceptibility to ceftriaxone (Tragesser et al., 2006). Information regarding 
dairy antimicrobial usage protocols and individual cattle antimicrobial usage from the previous 6 
months was obtained. Fecal samples were enriched and plated to antibiotic specific media to 
screen for reduced susceptibility to ceftriaxone before performing PCR to check for the AmpC β-
lactamase gene, blaCMY-2. Prevalence of reduced susceptibility was found to be between 0 and 
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97% with 83% of the reduced susceptibility isolates containing the blaCMY-2 gene. Further 
susceptibility testing was performed on 81 isolates containing the gene. These isolates were 
chosen to represent all herds involved in the study. This additional testing indicated those 
isolates with reduced susceptibility to ceftiofur contained resistance to additional antibiotics. The 
team determined dairy farms using CCFA were 25 times more likely to have E. coli with reduced 
susceptibility to ceftriaxone than their non-CCFA counterparts, which makes sense given both 
medications are third-generation cephalosporins. A linear relationship between reduced 
susceptibility and percentage of treated cows was not observed, leading to their suggestion that 
any interventions should be applied at herd, instead of individual, levels. This recommendation 
was made due to the herd-level association without the individual association; that is, the authors 
believed herd-level interventions may be more impactful in curbing the spread of AMR genes. 
Because the goal was for screening, plates were not colony counted or prepared in a way to allow 
for it. Those counts could have aided in determining if there was a difference among individual 
cows and farms beyond the positive/negative designations given to each sample. Plate counts 
could have allowed for better decision making regarding how individual animals are impacted 
and further supported or, perhaps, provided evidence against a herd – level intervention. 
The effects of ceftiofur on E. coli populations within dairy cattle were further tested on a 
central Pennsylvanian dairy farm (Donaldson et al., 2006). On this dairy farm, 96 calves were 
sampled over 5 months. Ceftiofur was used to treat respiratory infections and scours, but 
documentation was not kept on dosage or number of times administered. The study ran from 
April through August of 2003, but it was noted that the dairy traditionally used a milk-replacer 
medicated with tetracycline and neomycin before switching to non-medicated replacer in May of 
the study period. Calves were weaned after 8 to 9 weeks. Donaldson et al. (2006) found 88.5% of 
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calves in their study were positive for shedding ceftiofur resistant gram-negative enteric bacteria 
and, based on count data, suggested commensal E. coli can be important in spreading multidrug 
resistance on dairy farms, as MDR was found in many of the collected isolates. Caution should 
be used when applying the results of a study using only 1 dairy to a broader population. A 
broader study should be employed in order to comfortably extrapolate the findings to a larger 
population. The team attributes their findings to the use of ceftiofur, but the usage of an 
antibiotic milk-replacer to begin the study complicates whether these findings can be directly 
attributed to the use of ceftiofur or to what extent the tetracycline-neomycin milk-replacer played 
a role in co-selection. Additionally, it would be beneficial to know the dosage or administration 
frequency of ceftiofur to gain a better understanding of the role it may have played. 
In 2007, Lowrance et al. performed a prospective cohort study with 61 steers distributed 
into four cohorts of varying CCFA dosage protocols to evaluate the levels of antimicrobial 
resistance among fecal E. coli populations in feedlot cattle. The cohorts consisted of 10 steers 
with a single dose of CCFA (6.6 mg/kg) on day 0, 10 steers given a single dose of CCFA (4.4 
mg/kg; note, this is an extra-label usage now banned) on day 0, 10 steers given a three-dose 
treatment with CCFA (6.6 mg/kg; note, this is an extra-label usage now banned) administered on 
days 0, 6, and 13, and a final control cohort of 31 steers not given CCFA. The team determined, 
while ceftiofur susceptible isolates tended to be resistant to 1 antimicrobial and ceftiofur-resistant 
E. coli were inclined to contain resistance to 7 antimicrobials, levels of population resistance 
tended to recede to baseline within 2 weeks of final administration. This led to the hypothesis 
that susceptible variants were better equipped for survival in the absence of the ceftiofur 
selection pressure than their ceftiofur-resistant counterparts.  Based on the reduced resistance 
population over a relatively brief period of time, the hypothesis of resistance genes removing a 
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level of fitness under non-selective pressures makes sense. It is interesting this occurred with all 
treatment groups regardless of dosage administered or number of treatments given. These results 
are in agreement with Tragesser et al. (2006) and Donaldson et al. (2006) linking ceftiofur use to 
increased levels of resistance, albeit at the individual animal level. 
A study performed in the Czech Republic aimed to determine ESBL E. coli prevalence 
on a traditional dairy that utilized cephalosporins versus an organic dairy farm without 
cephalosporins (Dolejska et al., 2011). The traditional dairy farm primarily used ceftiofur, 
although other cephalosporins were used (4th generation cephalosporins are approved for use in 
animal agriculture in Europe), with a varying number of administrations. The organic farm used 
a small number of antibiotics (European organic farms are able to treat sick cows), primarily 
tetracycline, but no cephalosporins were used. A total of 309 rectal swabs were taken from the 
traditional dairy farm, with 154 cattle and 46 calves having sample swabs taken from the organic 
dairy. It was found that a dairy farm utilizing third- and fourth-generation cephalosporins was 
more likely to isolate ESBL-producing E. coli, all containing the blaCTX-M-1 gene, as 119 swabs 
tested positive for ESBL E. coli on the traditional dairy farm with only 1 swab from the organic 
dairy testing positive (Dolejska et al., 2011). Each sample testing positive for the blaCTX-M-1 gene 
on the traditional dairy was transferred through conjugation to both E. coli and Salmonella, in 
addition to being associated with the IncN plasmid group. This study is interesting in comparing 
traditional and organic dairy farms to evaluate ESBL resistance prevalence between the 2. The 
small number of locations in these studies makes it difficult to make broad generalizations. 
While commonly used to treat metritis, CCFA can treat other gram-negative bacterial 
infections (Wittum, et al., 1996; Haimerl and Heuwieser, 2014). A matched-pair cohort study 
involving cattle with Leptospira borgpetersenii serovar Hardjo-bovis requiring a treatment of 2.2 
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mg/kg of ceftiofur (no formulation specified), intramuscularly, daily for 5 days was performed 
on a dairy farm milking 150 cows in central Illinois (Singer, Patterson, & Wallace, 2008). All 
cows were housed in a single barn. Five cows were selected as cases and 5 as controls. Lactation 
number was a determining factor in matching. Samples were collected before, during, and after 
treatment. Collected samples were colony counted for E. coli. Selected isolates were tested for 
antimicrobial sensitivity and the blaCMY-2 gene via PCR.  
The team found that usage led to a significant difference in total E. coli load and 
antimicrobial resistance index on study days 4, 5, and 6 with no evidence of blaCMY-2 gene 
transfer (Singer, Patterson, & Wallace, 2008). The blaCMY-2 gene was found in 12 of 203 isolates 
from case cattle, but never found in control group isolates. Similar to Lowrance et al. (2007), 
general E. coli populations decreased upon treatment, but eventually rebounded without an 
expansion of the resistant bacterial population. As stated repeatedly, studies at only 1 location, 
especially with such a small sample size, are hard to generalize from in a broader sense. This 
study has similar results to other studies mentioned throughout the document, but sample size 
and population are important in the establishment and utilization of epidemiology studies. A 
study with only 5 case and 5 control cattle leaves much to be desired in terms of what can be 
learned and applied.  
A cross-sectional study collected cattle fecal samples across 50 Ohio dairy farms from 
the summer of 2004 through the spring of 2006 with herd owners administered surveys regarding 
antimicrobial usage and dairy demographics (Heider et al., 2009). Herds with less than 100 
milking cows had samples collected from every cow, while herds with greater than 100 milking 
cows had up to 100 samples collected totaling 3,840 samples. Of the 50 sample locations, 88% 
used ceftiofur. Based on data collected from MacConkey agar plates made with ceftriaxone 
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regarding bacterial growth, 92%of the herds tested positive for ceftriaxone-resistant E. coli. In 
total, nearly 61% of samples tested positive for ceftriaxone-resistant E. coli.  Alternatively, 44% 
of dairy farms tested positive for Salmonella and nearly 10% of the total samples tested positive. 
All Salmonella isolates had ceftriaxone MICs of less than 8 µg/mL. E. coli with reduced 
susceptibility were found more often on farms positive for Salmonella and increased by 62% 
with every 454 kg increase in average milk production on farm, although an association was not 
found between reduced susceptibility and ceftiofur usage. A subset of E. coli with reduced 
susceptibility to ceftiofur were selected to run PCR for the blaCMY-2 gene and all tested positive. 
The team hypothesized dairy farms with Salmonella were more likely to use ceftiofur, but their 
data did not support this. Therefore, they further hypothesized there were other herd-level factors 
promoting Salmonella growth and E. coli with reduced susceptibility to ceftriaxone.  
 A 2012 cross-sectional study consisting of 25 Ohio dairy farms collected 30 fresh 
samples from the housing floor that appeared to be from only 1 animal with mechanisms in place 
to refrain from sampling the same animal twice (Mollenkopf et al., 2012). Samples were plated 
on MacConkey agar with cefepime and MacConkey agar with cefoxitin in search of blaCTX-M and 
blaCMY-2 E. coli phenotypes. Bacteria susceptibility was determined with a semi-automated broth 
microdilution system and further characterized using PFGE, PCR, and southern blot 
hybridization. The team found 5 herds tested positive for the CTX-M gene with a variance of 1-
30 positive samples per positive herd. Just under 95% of total samples tested positive for the 
CMY-2 gene comprising all study dairy farms. Of the 9.4% of samples containing the CTX-M 
gene, a subset of 30 showed a single strain of E. coli containing both IncI 1 and IncF plasmids. 
The team did not find a link between farmer reported ceftiofur usage and the CTX-M gene, but 
all dairy farms, with the exception of an organic dairy farm, listed ceftiofur as a treatment option. 
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PFGE analysis of isolates containing blaCTX-M showed a predominant E. coli strain throughout 3 
of the dairy farms. Many herds had homogeny among CTX-M isolates, but 1 dairy contained 6 
varied isolates. The study utilized many techniques to determine the diversity of CTX-M isolates 
across a large number of dairy farms, which provides a more complete picture. However, a more 
effective monitoring of ceftiofur usage beyond dairy producer reporting would be beneficial. 
Self-reporting can lead to underreporting, recall bias, and social desirability bias. These biases, 
intended or not, can impact results and any association that could exist between ceftiofur usage 
and CTX-M development. 
A study in northwest England and northern Wales evaluated 65 dairy farms positive for 
blaCTX-M E. coli for risk factors associated with bacteria with this resistance gene to better 
understand the dissemination of the gene (Snow et al., 2012). Dairy farms with links to blaCTX-M 
positive farms served as case farms and controls were selected from a similar geographic 
location, but without a blaCTX-M link. Samples were collected from weaned calves and various 
environmental locations around the dairy. Of the 65 dairy farms, 48 were controls. Farms with a 
blaCTX-M ESBL E. coli link had a prevalence of 58.8%, as 10 of the 17 farms tested positive. The 
prevalence on control farms was 35.4% and 41.5% of the total dairy farms tested positive for 
ESBL E.coli. These differences were not statistically significant. The research group 
hypothesized that due to the large number of control dairy farms testing positive, either the 
blaCTX-M gene was already widely disseminated, some cattle on control farms came from positive 
farms not identified as such, or else the cow was positive for ESBL E. coli independent of farm, 
since individual cattle status at time of movement was not determined. Developed models 
determined dairy farms with closed cattle policies had reduced risks of being ESBL E. coli 
positive. It was found that the usage of third- and fourth-generation cephalosporins made a farm 
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four times as likely to have E. coli possessing the blaCTX-M gene, but amoxicillin/clavulanate usage 
did not increase risk (Snow et al., 2012). This study utilized a much larger number of locations 
making its results more applicable to broader populations. Their results are consistent with those 
of other studies showing third-generation cephalosporin usage increases ESBL E. coli 
prevalence; but interestingly, illustrated that having linkage to an ESBL E. coli positive farm 
does not lead to a statistically significant increase in ESBL prevalence over control farms, even 
with looking for an assorted number of blaCTX-M genes. Of studies explored herein to this point, 
Snow et al. (2012) had the largest number of study sites and evaluated more than 1 blaCTX-M gene. 
Another study performed in the United Kingdom sought to evaluate the epidemiology of 
ESBL E. coli containing the blaCTX-M-15 gene on a dairy farm (Watson et al., 2012). The team 
selected a commercial dairy farm positive for the gene of interest comprised primarily of 
Holstein cattle and observed for two years, all while collecting fresh, fecal pat samples, isolating 
E. coli, and testing them for the blaCTX-M-15 gene via PCR. These 55 samples were collected 
bimonthly from bulling heifers, dry cows, and low- and high-yield lactating cattle. Within the 
study, 24 cattle were selected randomly to sample at pre-calving throughout post-calving to test 
for blaCTX-M. Additionally, calves were randomly tested for 21 days. It was discovered that cows 
and heifers on a farm already positive for E. coli containing the blaCTX-M-15 gene were 8 times 
more likely to test positive for such isolates in the 10 days post-calving than pre-calving. While 
this study involved a wide variety of sampling times and cattle in various stages of life and 
production, some caution should be exercised when applying this study to broader dairy 
populations, as it was performed on only 1 dairy farm. A follow-up study would be advised to 
include more dairy farms in order to see if the results are consistent across study locations. It 
would be beneficial to have comparison dairy farms that had not tested positive for a blaCTX-M 
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gene to see if there were similar trends with other resistance genes or if there were differences in 
the protocol of handling these animals. Perhaps there were differences in levels of CCFA usage, 
differences in the usage of other antibiotics, or other areas of husbandry that allowed for ESBL 
development. 
A retrospective study in the United States analyzed 3,373 samples sent to the Cornell 
University Animal Health Diagnostic Center collected from what was assumed to be primarily 
calves in the northeastern United States from 2004-2011 (Cummings, Aprea, and Altier, 2014). 
Verified E. coli isolates were primarily from fecal samples, although isolates were also collected 
from the gastrointestinal tract and other anatomical locations. Isolates were subjected to 
antimicrobial susceptibility testing with the lowest percentage of resistance being found for 
enrofloxacin at 2.7% and the highest level of resistance found for oxytetracycline at 91.3%. 
Slightly over 70% of isolates tested were resistant to at least 2 antimicrobials on the NARMS 
panel. However, less than 1 percent had resistance to ceftiofur (ceftriaxone was not used in 
susceptibility testing). Over the time span of the study, only enrofloxacin was shown to 
significantly increase in the proportion of resistant isolates.  
Admittedly, the authors mention having background information on the number, type of, 
and frequency of antimicrobial usage in these populations would be beneficial in making better 
conclusions. Additionally, it would be valuable to know if these samples were overwhelmingly 
collected from calves, as the authors assumed, and from what type of cattle they were collected. 
The study just mentions they are bovine, but were they from beef cattle or dairy? Given the large 
number of dairy farms in New York State, 1 could assume they are primarily dairy cattle 
samples, but it is best to not make assumptions when performing scientific work. Having mature 
animals in the study would provide a more well-rounded scope, as it would provide insight into 
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whether or not these patterns extend into adulthood. It could also provide additional insight or 
research questions into how resistance levels change throughout the life cycle of the bovine.  
A similar 2015 study evaluated the prevalence of antimicrobial resistance in Australian 
beef, dairy, and veal cattle (Barlow et al., 2015). Target sample collections were 900, 300, and 
300, respectively, with those samples coming from slaughterhouses that represented 85% of beef 
exports. Fecal samples were randomly collected from rectal end of the intestine during slaughter 
between February and March of 2013 and August and September of the same year. E. coli were 
isolated and micro-broth dilution was used to evaluate phenotypic levels of resistance. In total, 
1,500 fecal samples were collected from 910 beef cattle, 290 dairy cattle, and 300 veal calves. Of 
those samples collected, 92.3% of them tested positive for E. coli. Veal had the highest 
percentage of positive samples followed by dairy and beef cattle. The team discovered E. coli 
resistant to antibiotics, other than tetracycline, remained low at 5 percent or less.  
The results of Barlow et al. (2015) conflict with those of the Cummings, Aprea, and 
Altier (2014) study, suggesting differences in production practices or antimicrobial usage in 
Australia and the northeastern United States; however, there are some key differences in the 
studies. The results of Cummings, Aprea, and Altier (2014) assessed resistance retrospectively 
prior to further changes in American regulations regarding antimicrobial usage, evaluated across 
an 8 year period, and consisted of samples assumed to be primarily from calves of unidentified 
production. Barlow et al. (2015) evaluated 1 year with samples only collected for a quarter of the 
year. The study also consisted of adult beef and dairy cows, in addition to veal calves. While 
these studies have conflicting results, it is important to understand the differences in study 
design, sample population, and methodology before drawing any conclusions between levels of 
AMR in Australia and the northeastern United States.   
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A Pennsylvanian study further surveyed 23 herds from central and south-central 
Pennsylvania for antimicrobial resistant gram-negative enteric bacteria in healthy cattle feces in 
2001 and 2002 (Sawant et al., 2007). Types of antibiotics used and reasoning for administration 
was kept in records, but dosage, frequency of administration, animals treated, and completion of 
treatment were not kept in farm records. Therefore, this information was not available to 
researchers. Ampicillin, florfenicol, spectinomycin, and tetracycline were all used on the farms 
and samples from 213 lactating cows were collected. Study cows were randomly selected while 
exiting the milking parlor. Samples were plated to MacConkey agar and 1 of 5 additional 
MacConkey agars each containing a different antibiotic (ampicillin, tetracycline, spectinomycin, 
enrofloxacin, or florfenicol) at 2 times the MIC breakpoint values for resistance. Of the samples 
processed, 258 isolates (223 of which were E. coli and the others general gram-negative 
Enterobacteriaceae) were selected from MacConkey agar to represent the 23 farms and 213 
sampled cattle. Isolates were then subjected to microbroth dilution to determine levels of 
resistance. PCR, pulsed-field gel electrophoresis (PFGE), and southern blot hybridization assays 
were used to explore isolates for tetracycline resistance genes. The highest prevalence of 
resistance in samples and per farm was tetracycline followed by ampicillin, florfenicol, 
spectinomycin, and enrofloxacin. Multidrug resistance was found in 90 of the isolates and 8 
percent of isolates were resistant to all screened antimicrobials. The isolates contained 21 
different resistance profiles. Of those isolates resistant to tetracycline, 105 possessed the tet(B) 
gene and 8 the tet(A) gene. The group found the most common bacteria present in samples were 
E. coli and postulated lactating cattle were a reservoir for tetracycline and ampicillin resistance 
since those held the highest prevalence. Ceftiofur resistance was found at very low levels in 
2001, similar to that reported in NARMS reports at that time.  
49 
 
This study could have been made more complete by having the missing antimicrobial 
usage data. The team determined lactating cattle were reservoirs of tetracycline and ampicillin 
resistance, but it would have been nice to know how extensive the selection pressure was for 
these bacteria to obtain and maintain these resistances. Were these resistance levels naturally 
found in the intestines of lactating cattle or were these the 2 drugs of choice on study farms for 
lactating cattle, thus promoting a resistance profile found among a majority of these cows on the 
farms? It is uncertain why the team used antibiotics in their agar plates at double the MIC. By 
using this method, they were likely to be missing clinically relevant and resistant isolates. Since 
ceftiofur was not listed as being used on study farms, it is not a surprise these levels of resistance 
remained low.. Furthermore, the results of this study are consistent with those of Cummings, 
Aprea, and Altier (2014) and Barlow et al. (2015) in that tetracycline was the antibiotic to which 
most E. coli were resistant. The team also used multiple antibiotic plates to determine resistance. 
These prevalence-based studies have the ability to provide a great perspective of the 
distribution of a disease or disease-causing organism. It is beneficial to understand how resistant 
populations and Salmonella in general are distributed in a geographic area to then understand the 
risk to public health and ways to mitigate spread. However, the team seemed to make a wrong 
turn by suggesting farms testing positive for reduced susceptibility E. coli correlated with 
Salmonella positive farms due to increased ceftiofur usage when they did not find a correlation 
between reduced susceptibility E. coli and ceftiofur usage. Other studies included in this critical 
analysis have found connections between ceftiofur usage and 3GC resistant E. coli (Tragesser et 
al., 2006; Lowrance et al., 2007; Dolejska et al., 2011; Snow et al., 2012). As mentioned 
throughout this review, there is inherent skepticism with using survey data. The fact that these 
survey data do not show an association between ceftiofur usage and reduced susceptibility E. 
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coli, while others that monitored ceftiofur usage did, furthers such skepticism. Furthermore, the 
team did not produce bacterial counts. While there might not have been an association between 
ceftiofur usage and the presence of E. coli with reduced susceptibility to ceftriaxone, there could 
be a measurable effect between ceftiofur and the number of colonies exhibiting reduced 
susceptibility. 
Our study design will allow us to evaluate 3GC resistance among E. coli from animals 
with known CCFA treatment status, along with known historical CCFA usage on each farm. This 
will allow us to fill in gaps remaining from previous studies. Furthermore, the use of various 
techniques to evaluate ESBL E. coli prevalence will be helpful in phenotypically and 
genotypically determining the extent of ESBL E. coli prevalence across time and by dairy farm, 
and also the gene variants at play. Additionally, by using count data across time, we will be able 
to evaluate previous hypotheses regarding the time at which 3GC resistance decreases in the E. 
coli population. Lastly, many of the studies analyzed were from Europe or the Midwest or 
Northeast United States. With study sites in the panhandle of Texas and northeastern New 
Mexico, our study provides information regarding very large dairy farms from a different 
geographic locations and climates. 
 
2.7 FECAL SALMONELLA SHEDDING AND THIRD-GENERATION 
CEPHALOSPORIN RESISTANCE IN DAIRY CATTLE POPULATIONS 
 Conducted in 20 states comprising 83% of United States dairy cows, the National Animal 
Health Monitoring System enrolled 3,700 dairy producers to evaluate fecal Salmonella shedding 
among dairy cattle on farm and at slaughter from 1994 to 1996 (Wells et al., 2001). A total of 
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100 dairy farms were selected, including 50 small (less than 100 animals) and 50 large (greater 
than 100 animals) dairy farms, proportional to the number of each herd type per state. Small 
dairy farms were visited once and large dairy farms were visited 3 times while collecting fecal 
samples via rectal palpation. The same number of markets as dairy farms were visited with 
samples collected in a similar manner. There was 10% fecal shedding across all samples, but 
18.1% for animals to be culled in the next week. Furthermore, the team determined larger dairy 
farms had more samples with Salmonella shedding. Prevalence was elevated in May, June, and 
July. Some markets required the collection of floor samples. Those samples had a higher 
prevalence of Salmonella, but only accounted for 16% of the total samples taken. Milking cows 
in the South had the highest herd-level shedding at 45%, although the authors noted caution due 
to the varying seasons of sample collection. However, market prevalences were higher in the 
South and Midwest at 76% and 79%, respectively. Dairy farm samples tested positive for 
multiple serotypes at 12.1% and 40% of market samples tested positive for multiple serotypes. 
Levels of antimicrobial resistance remained low throughout the isolates. In total, 91 herds and 97 
markets were included across 19 states. The authors note the sample size and geographic 
diversity, in addition to healthy populations, as strengths of this study. Sample size and 
geography are strengths of the study given the large percentage of milk production for which 
those states account. However, these populations were not necessarily healthy. Animals get sick 
on dairy farms every day, animals tend to mask symptoms, and animals do not have to be 
completely healthy to go to slaughter. Even so, as stated by the authors, many studies are 
performed using ill populations. This study used what one would imagine as a mostly healthy 




 A unique study conducted on a southwestern dairy farm with 3,000 Holstein cows 
collected samples from 60 lactating and 60 non-lactating cows at 7 o’clock in the morning and 5 
o’clock in the evening with a replicate trial conducted 2 weeks later (Fitzgerald et al., 2003). 
These samples were then processed for isolation of E. coli O157:H7 and Salmonella to evaluate 
the effects of heat stress on the fecal shedding of these organisms. Fecal shedding was similar at 
both times (between 30% and 35%), but the percentage of cows shedding E. coli O157:H7 
decreased by 5 percent and Salmonella increased by 3 percent between the morning and evening 
sampling times. The difference in E. coli shedding was statistically significant for non-lactating 
cows, but not those lactating. Salmonella shedding was significant for both groups, but in 
different directions. Lactating cows shed more Salmonella in the morning, while non-lactating 
cows shed more in the evening. Through antibiotic susceptibility testing, the team found 79% of 
Salmonella was resistant to at least 1 antimicrobial, while neither Salmonella nor E. coli showed 
resistance to ceftiofur at an MIC of 8 µg/mL. The group noted temperatures were 
uncharacteristically consistent throughout the sampling days.  
Only 120 cows were enrolled from a 3,000 head herd, which seems low for the dairy size 
(Fitzgerald et al., 2003). The prevalence portion provided some interesting results, as the peak 
Salmonella shedding times seems to be opposite for lactating and non-lactating cattle and the 
peak shedding times for E. coli and Salmonella tend to be opposite too. These results were only 
evaluated as positive/negative and not for counts, but counts would have been beneficial in 
determining if cows also shed more E. coli or Salmonella during their peak times or if there were 
simply more cows shedding those organisms. While sampling lactating and non-lactating cows, 
one might imagine the team had healthy and ill cattle at the proportion at which they occurred on 
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the farm. It would be beneficial to know how many sampled animals, if any, were ill and how 
that impacted fecal shedding and antimicrobial resistance profiles.  
 From October of 1998 until February of 2000, 65 dairy farms in New York having 
recently tested positive for Salmonella enterica subgroup enterica serogroup B by Cornell 
University were enrolled in a study in which fecal samples were collected to evaluate how 
antimicrobial treatments impacted Salmonella shedding in feces (Warnick et al., 2003). Priority 
was given to animals recently diagnosed with salmonellosis, sick calves and cows, and recently 
calved cows. The median percentage of samples testing positive for Salmonella per herd was 
2.5% and the median herd size was 240 cows, which was larger than the median dairy herd in 
New York at the time. In total, there were 2,726 samples collected from 2,381 cows. Nearly 10 
percent of those samples tested positive for Salmonella, but 60% of herds tested positive. Among 
the antimicrobials administered to enrolled cows, ceftiofur was administered to the highest 
number of animals at 9 percent. Positive samples were found to be increased based on 
antimicrobial treatment, with a significant interaction of antimicrobial treatment and age group. 
Calves not receiving antimicrobials were found to be Salmonella positive more than animals at 
other stages of life not receiving antimicrobials. The team hypothesized antimicrobial treatment 
led to more Salmonella-positive samples due to lengthening the infection duration, increasing 
clinical Salmonella infection incidence, or an interaction of treatment with disease severity. At 
first, these hypotheses seem to be counter-intuitive. However, it is important to remember the 
sample population did not only included animals with recent salmonellosis, merely dairy farms 
that had a recent case. Therefore, the additionally enrolled ill cattle could be colonized by 
Salmonella due to the removal or reduction of species previously inhabiting the gut. When 
interpreting the results, it is important to remember the Salmonella status of these dairy farms 
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and the results of this study might not be generalized to all dairy farms or differing climates. 
With greater resources and collaboration, enrolling dairy farms of varying statuses and climates 
could have provided a more complete picture of how antimicrobial treatments increased or 
decreased the number of samples positive for the shedding of Salmonella. 
Using isolates from Warnick et al. (2003), Alcaine et al. (2005) looked into antimicrobial 
resistance profiles and utilized PCR, sequencing, and multi-locus sequence typing to determine 
how ceftiofur-resistant Salmonella isolates acquired their resistance genes. The team determined 
the blaCMY-2 gene was commonly acquired because all isolates carried the gene on a similar allele. 
However, differences in multi-locus sequence types indicated the acquisition of genes was based 
on geographic location. Furthermore, they were able to determine the relationship between the 
blaCMY-2 gene and third-generation cephalosporin resistance, along with the geographic spread of 
the gene in New York. Based on other studies cited throughout this review (Tragesser, 2006; 
Heider et al, 2009; Jacoby, 2009; Pfeifer, Cullik, and Witte, 2010; Schmid et al., 2013), the 
linkages between the blaCMY-2 gene and third-generation cephalosporin resistance is readily 
understood and the gene is found around the globe, although this study was among the first to 
uncover these findings. It also stands to reason the allelic basis of the gene in 1 part of New York 
would differentiate from those in other areas of the state, country, or globe; that is, unless the 
sale of animals brings a cow carrying resistance from 1 area of the state to another region. 
 Using the same dairy farms as Zwald et al. (2004), Ray et al. (2006) collected fecal and 
environmental samples every 2 months from August of 2000 through October of 2001 to 
determine the differences in antimicrobial susceptibility among conventional and organic dairy 
farms. Samples were collected from healthy cows at various stages of production, cows to be 
culled, and sick cows to test susceptibility via microdilution. Samples from 120 farms tested 
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positive for Salmonella; however, 11 conventional dairy farms were excluded from analysis, due 
to being much larger than their organic counterparts, leaving the total samples with isolated 
Salmonella at 1,246. Conventional dairy farms were associated with Salmonella resistant to 5 or 
more antimicrobials, although management style was only associated with higher levels of 
resistance to streptomycin and sulfamethoxazole. None of the farms testing positive for 
Salmonella exhibited resistance to ceftriaxone at the, then, breakpoint of 64 µg/mL, but 13.0% 
would be considered resistant by the current breakpoint of 4 µg/mL. It is interesting that 
conventional dairy farms were more likely to have resistance to 5 or more antimicrobials, but 
management style only accounted for increased levels of resistance to streptomycin and 
sulfamethoxazole. For conventional dairy farms to have resistances to that many antimicrobials, 
but significance only with 2 antimicrobials, there has to be a variation of what comprises those 5 
or more antimicrobial groups for each isolate. A breakdown of those results by state or region 
within state could show regional variability for the differing resistance profiles. Instead of 
broadly reporting the data, a more in-depth analysis could help explain some of these findings. 
 The same team published a very similar paper a year later with the same or very similar 
data that seemed to focus more on state-level variances than differences in organic and 
conventional dairy practices (Ray et al., 2007). Wisconsin dairy herds were positive for 
Salmonella resistant to at least 1 antibiotic at a prevalence of 96.8%. Michigan had the second 
highest prevalence at 89.7% with Minnesota and New York both having a prevalence of 83.3%. 
The group reported 81.2% of all Salmonella tested as pan-susceptible, but some of the more 
common resistance patterns involved resistance to 5, 9, and 10 antimicrobials. Of those isolates 
testing as resistant to 5 or more antimicrobials, 25.3% were from calves, 13.3% were from ill 
cows, and 4.2% from healthy cows, showing calves were at higher risk for harboring multi-drug 
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resistance than their ill or healthy adult counterparts. Sixty-four percent of the isolates were 
resistant to 9 or more antimicrobial agents on 1 Wisconsin dairy farm. This follow-up paper 
touches on some of the remaining questions mentioned in the above analysis, as there was more 
focus on the state from which the isolate came and not the type of dairy farm. Wisconsin had the 
highest prevalence of isolates resistant to 1 antimicrobial while 1 particular Wisconsin dairy herd 
contained over half of the isolates resistant to 9 or more antimicrobials. One might then wonder 
how many of the remaining isolates with such levels of resistance were found in Wisconsin or 
the distribution of isolates with resistance to 5 or more antimicrobials spread across the states. 
These results are consistent with Barlow et al. (2015) in which calves tended to test positive for 
AMR bacteria, or those with higher levels of resistance, pointing to an area in which intervention 
could have very beneficial results. 
 A study conducted by Frye and Fedorka-Cray (2007) utilized NARMS Salmonella 
enterica (S. enterica) collected from various sources of production and clinical evaluation, along 
with resistance profiles and molecular techniques, from 1999 – 2003 for characterization. 
Salmonella serovars Kentucky, Heidelberg, and Typhimurium were among the most reported 
serovars of the study with serovar Newport (n = 1928) comprising the greatest percentage 
(36.2%) of samples containing resistance genes. Of the 34,411 isolates evaluated, almost 11% 
had resistance to ceftiofur. However, by year, this percentage increased annually from 4.0% in 
1999 to 18.8% in 2003. Interestingly, ceftriaxone resistance was below 1 percent across all years, 
although the breakpoint has since shifted from 64 µg/mL to 4 µg/mL. All ceftiofur resistant 
isolates were from animal agriculture with general cattle isolates having ceftiofur resistance at 
levels of 17.6% and dairy cattle having the highest level at 28.3%. When only evaluating clinical 
samples, ceftiofur resistance jumped to 18.5% and isolates from dairy cattle were 11% higher 
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than beef cattle at 35.8%. PCR was performed on 125 isolates. The blaCMY-2 gene was found in 
102 isolates with southern blot showing location on a large plasmid. ESBL genes were also 
found on select isolates. It is not any surprise that ceftiofur resistance grew over the four year 
period with the highest percentage of resistance found in dairy cattle, as AMR was and is an 
increasing threat to public health and ceftiofur is frequently utilized in dairy production. Now, 
further removed from 2003, another similar study would show if the rate of resistance is still 
increasing or if some of the stewardship programs and regulations now in place are being 
effective. Given ceftiofur and ceftriaxone are the same generation of cephalosporin, it is 
surprising that as ceftiofur resistance grew by year, ceftriaxone resistance remained low. One 
would expect these resistant rates to be very similar.  
These studies, both within the United States and internationally, have shown links 
between CCFA usage and increased levels or prevalence of ceftiofur and ceftriaxone-resistant 
enteric bacteria. These results were shown even when comparing conventional and organic dairy 
farms. While the results were consistent throughout, sample sizes and locations tended to be 
small and documentation regarding antimicrobial types, dosage and administration were often 
non-existent or from unreliable sources. More controlled studies are required to truly strengthen 
the understanding and knowledge of how these levels of resistance develop and fluctuate within 
dairy cattle populations. Our study will fill the gaps regarding antimicrobial dosage, and 
administration impact on Salmonella shedding. Further, it will provide a current evaluation of 
these impacts and a look into the resistance mechanisms and Salmonella serotypes found on 





2.8 BACTERIAL CONTAMINATION OF RETAIL MEATS 
 Common pathogens of food are Campylobacter spp. (Zhao et al., 2001), Salmonella 
serovars (Zhao et al., 2001; White et al, 2001; Chen et al., 2004; Zhao et al., 2009; Glenn et al., 
2013), and E. coli (Todd, 1997; Cassin et al., 1998; Zhao et al., 2001; Schroeder et al., 2002; 
Johnson et al., 2005; Vogt and Dippold, 2005). Contamination can be found in vegetables (Todd, 
1997) and meat products, including poultry (Zhao et al., 2001; Schroeder et al., 2003; Johnson et 
al., 2005), pork (Zhao et al., 2001; Schroeder et al., 2002; Johnson et al., 2005), and beef (Zhao 
et al., 2001; Schroeder et al., 2002; Johnson et al., 2005; Vogt and Dippold, 2005). 
A study performed at Iowa State University’s Veterinary Diagnostic Microbiology 
Laboratory evaluated 377 bovine and porcine E. coli isolates collected between November of 
1998 and December of 1999 with an additional 1,017 E. coli isolates from humans collected 
between November 1998 and March of 2000 to determine the transfer of plasmids containing the 
blaCMY-2 gene from food animals and humans (Winokur et al., 2001[a]). All samples were 
collected around the state of Iowa. Of the collected isolates, 59 food animal isolates were 
cephalosporin resistant and 6 human isolates were resistant to cephamycins, monobactams, and 
extended-spectrum cephalosporins. Isolates were all subjected to PFGE as well as molecular, 
plasmid, and integron analysis. The team identified homology between blaCMY-2 genes in animals 
and humans with plasmid similarity to determine a transmission of resistance from food animals 
to people. Of the over 1,000 human isolates, only 6 were of benefit in this study. In order to 
make broader generalizations, having more isolates would be necessary. Even so, this earlier 
study demonstrated how important it is to send animals to slaughter with as few AMR organisms 
as possible. The current study will aid in better understanding the temporal dynamics of AMR 
enteric bacterial populations in dairy cattle. An additional study with a more extensive 
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environmental focus would also be beneficial in determining how readily these resistance genes 
can be transferred to humans.  
 Microbial contaminants in retail meats are not restricted to E. coli, as over a million cases 
of foodborne Salmonellosis occur in the United States annually. A survey of 2 hundred meat 
samples consisting of an equal number of chicken, beef, turkey, and pork was collected from 3 
markets in Washington D. C. between June and September of 1998 (White et al., 2001). Samples 
were processed to isolate Salmonella. Antimicrobial susceptibility testing was done for each 
Salmonella isolate. Isolates with resistance to ceftiofur and ceftriaxone were tested for the blaCMY-
2 gene (the only gene encoding 3GC resistance in the U.S. at that time). Chicken samples had the 
highest prevalence of Salmonella followed by turkey, pork, and beef samples. In total, 20% of 
samples tested positive for Salmonella. Of those isolates, 84% were resistant to 1 antibiotic and 
53% were resistant to 3 or more antibiotics. Isolates with ceftiofur resistance were found in all 
meat sources except pork. With meat samples coming from 3 different supermarkets, it was 
evident the issue of contamination lies within the meat itself and not the grocery. The study 
design was relatively basic, but provided further support for the risks of retail meat containing 
pathogenic or potentially pathogenic bacteria and the ability of those bacteria to spread from 
animal to human populations via food sources.  
A 2001 study evaluated 825 retail meat samples across four supermarket chains (59 total 
stores) in the Greater Washington D.C. area for the presence of E. coli and Salmonella (Zhao et 
al., 2001). Meat samples consisted of chicken carcasses, turkey breasts, beef steaks, and pork 
chops. Samples were collected on alternating Mondays from June of 1999 to July of 2000.  Of 
the meats included in the study, chicken was found to contain more E. coli than beef, pork, or 
turkey products (Zhao et al., 2001). Additionally, only 3 of 179 PCRs tested E. coli isolates were 
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positive for toxin production: 1 for heat-labile enterotoxin, 2 for heat-stable enterotoxins, and 
none for Shiga toxins. This led the team to determine most contaminants were due to commensal 
E. coli flora. An effect due to seasonality was not observed. In those same samples, Salmonella 
spp. were found in 3.0% of total samples. The study provided a good evaluation of the 
prevalence of microbial contamination among retail meats in the Greater Washington D.C. area 
by sampling from a variety of groceries, a variety of meat sources, and a large sample size. The 
PCR approach provided important insight into the pathogenicity of contaminating E. coli 
populations, although looking for virulence factor genes, other than toxins, and AMR genes 
could have provided further insight. These populations can still be harmful if containing AMR 
genes by spreading them to the enteric bacterial populations of the consumer in the case of 
underprepared meats or by bacterial uptake of those in the gut from those bacteria succumbing to 
high temperatures during cooking.  
Schroeder et al. (2003) performed a study in the same laboratory and Greater Washington 
D.C. area as Zhao et al. (2001). The same 825 retail meats consisting of the same samples and 
collection times were used from the Zhao et al. (2001) study; however, 200 ground meat samples 
collected from June and September 1998 consisting of beef, chicken, pork, and turkey also were 
included. Antimicrobial susceptibility was determined by broth micro dilution. The team found 
the prevalence of E. coli in contaminated meats was higher in ground meats than whole meat 
cuts and isolates tended to be resistant to tetracycline, streptomycin, sulfamethoxazole, 
cephalothin, and ampicillin (in that order) with other resistance forms existing at lower levels. 
This study helped to address the AMR portion left unevaluated by the Zhao et al. (2001) and 
provided some additional perspective on the risk of AMR E. coli in retail meats. Furthermore, 
the distinction between ground and whole meats is important and, unsurprisingly, ground meats 
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tended to be more contaminated. This might be due to the additional processing and grinding 
presenting a greater opportunity for contamination with enteric bacteria.  In addition, the 
grinding of a whole cut of meat increases the surface area. Finally, ground meat often includes 
trim from less desirable cuts of meats located in regions of the carcass more likely to be 
contaminated during slaughter such as the flank and umbilicus. These findings are important in 
the current dissertation project because a majority of culled dairy cattle become ground beef. 
This form of ground meat has the tendency to be more contaminated and, therefore, increases the 
risk of transmitting AMR E. coli to the consumer should levels of resistance not recede to 
baseline levels prior to culling after treatment with CCFA. 
Further support for this risk pathway was a publication from Chen et al. (2004) testing 
antimicrobial susceptibility of Salmonella found in retail meats from Washington D. C. and the 
People’s Republic of China. The isolate total consisted of 89 collected from Washington D. C. 
from June through September of 1998 (White et al., 2001) and from August of 1999 until August 
of 2000 with 44 isolates collected from the meat products in 10 Chinese provinces from October 
of 1999 until December of 2000. Susceptibility testing and PCR was performed to determine 
resistance profiles and the genetic components leading to such resistance. Isolates from those 
samples collected in Washington D. C. were resistant to at least 1 antimicrobial 82% of the time 
and showed resistance to various classes of antimicrobial, including beta-lactams. Of isolates 
from the People’s Republic of China, 64% of isolates were resistant to at least 1 antimicrobial, 
none of which had beta-lactam resistance. However, isolates from China had greater resistance to 
quinolones and reduced susceptibility to ciprofloxacin was 30 times higher than isolates from 
American products. American isolates were found to contain blaCMY-2 and blaTEM-l genes, whereas 
isolates from the People’s Republic of China were found to only have blaTEM-l genes. The team 
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noted American isolates contained more resistance than those from China and most genes were 
contained on integrons located within a plasmid. However, they noted a larger sample size was 
needed. The only information provided on sample size was with regards to the number of 
isolates, but not the number of food sources tested outside of what was documented in White et 
al. (2001). Such information would be beneficial in knowing exactly what the sample size was 
and to what it might need to be expanded. Additionally, samples were taken from 10 provinces in 
the People’s Republic of China, but only 1 city in America. To adequately compare multiple 
places at the country level, the team should have considered sampling from additional areas 
around the United States. The study did provide insight into how differing policies concerning 
the use of antimicrobials in animal agriculture settings might create varying selection pressures 
for differing resistance profiles; however, further studies should be performed to allow stronger 
conclusions. 
By utilizing a prospective study design involving 10 retail stores and 1,648 food samples 
consisting of meat, fruit, vegetables, and miscellaneous items in the Minneapolis and St. Paul 
area from 2001-2003, Johnson et al. (2005) were able to determine that, among beef and pork 
products, there was a greater risk of E. coli among these products when ground. Pork products 
tended to have higher levels of resistance to ampicillin, tetracycline, and sulfisoxazole. These 
findings are consistent with Schroeder et al. (2003). Antimicrobial-resistant organisms were 
found in poultry, beef, and pork items in addition to pre-cooked meals with the highest resistance 
prevalence being found in meats versus fruits, vegetables, and miscellaneous items (Johnson et 
al., 2005). The research group found many differences in the number of E. coli and levels of 
antimicrobial resistance based on a multitude of factors. The type of meat, storage procedure, 
season, and year all yielded statistically significant differences (Johnson et al., 2005). 
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Furthermore, chicken samples were contaminated with E. coli at a higher rate than any other 
sample type at 92%, which is consistent with Zhao et al. (2001). Given the higher prevalence 
among chicken, it is not a surprise that isolates from chicken samples also tested higher for 
virulence traits. Aspects of the Johnson et al. (2005) study complimented or filled in gaps from 
the Zhao et al. (2001) and Schroeder et al. (2003) studies. However, Johnson et al. (2005) found 
seasonal differences in prevalence whereas Zhao et al. (2001) did not. Additionally, the Zhao 
team determined prevalent E. coli populations were mainly commensal varieties and the Johnson 
team found many virulence factors, though the later team looked beyond Shiga toxins. The team 
noted a small number of markets from which the samples were taken and transmission from 
foods to consumers was not evaluated. The differences noted among these 3 studies could be due 
to geographic location, plant processing procedures, or other elements. To gain a better 
perspective, larger or and more studies from other geographic locations around the United States 
would be invaluable.   
 A study by Zhao et al. (2009) provided an interesting variant on studying antimicrobial 
resistance among Salmonella found in retail meats, by accessing Salmonella isolates known to 
have ampicillin resistance from NARMS. Isolates were from the sample years of 2002 through 
2006. While there was not a large difference in the number of isolates from each year, a majority 
of the 344 isolates were from 2004 and 2005 and 92.9% of the isolates were from poultry or 
turkey. Antimicrobial susceptibility testing revealed 66.9% of isolates were resistant to 5 or more 
antimicrobials and 4.9% were resistant to 10 or more. While all isolates were susceptible to 
cefepime, 55.5% were resistant to amoxicillin with clavulanic acid, 50% were resistant to 
ceftiofur with the same percentage resistant to cefoxitin, and 24.7% were resistant to ceftazidime. 
Multi-drug resistant AmpC phenotypes were observed in 7 percent of the isolates. Ultimately, 19 
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isolates tested positive for blaCMY-2 and 13 were able to transfer the gene to a recipient in 
conjugation experiments. The team noted it was hard to draw conclusions regarding beef and 
pork products due to the low sample size in their study, but none of the beef isolates displayed 
ceftiofur resistance. Salmonella tended to be associated with poultry products at higher rates than 
other products. While ceftiofur resistance was not observed in Salmonella isolates from beef 
samples in this study, it is not implausible to consider Salmonella isolates in beef products from 
dairy cows likely to contain resistance to ceftiofur or other cephalosporins given the rate at 
which ceftiofur is used in dairy production for the treatment of metritis. Creating a study using 
only beef samples could provide greater insight into the forms of resistant Salmonella these food 
products harbor; that said, differentiating retail beef from fed beef versus dairy cows is difficult, 
especially for ground product.  
 Another study used Salmonella enterica isolates selected from various agencies to 
provide a sample population of Salmonella from animals, humans, and retail meat products from 
the United States and Canada (Glenn et al., 2013). Isolates with resistance to the greatest number 
of antimicrobials were selected for use in the study. Of the 56 isolates in the study, 32 contained 
the blaTEM gene and 30 had the blaCMY-2 gene. Other resistance genes also were found within the 
isolates. Two plasmid replicon groups dominated the Salmonella isolates, as 27 isolates fit into 
group A with 52-180 IncA/C plasmid genes with 5-12 core regions and 27 isolates fit into group 
B with 52 or less IncA/C genes and 1 or fewer core regions. Interestingly, 14 of the 17 human 
isolates and all of the cattle isolates were contained in group A, while isolates from retail meats 
and other animal sources were mainly found in group B. The team noted that the small sample 
size limited the application of findings and, due to total DNA being utilized, it remains unknown 
as to whether the genes were contained on the plasmid or chromosome. The authors were correct 
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in their small sample size statements. The total number of isolates used was small, and became 
even smaller when broken down into groupings of human, animal, and retail meat categories or 
when doing analysis on resistance comparing countries. However, the results from the cluster 
analysis are intriguing and performing a larger study could be beneficial. With human and cattle 
isolates falling within the same group at larger sample populations, one could begin looking at 
similarities in pathogenesis compared to group B and begin determining if isolates from cattle 
pose an increased risk to human health over isolates from pork and turkey products.  
As these studies sought to evaluate risks and a prevalence of E. coli and Salmonella in 
retail meats, a proper risk assessment involves evaluating the processing and grinding, storage, 
cooking, consumption, and dose-response (Cassin et al., 1998). While those are broad categories, 
subheadings were used to provide a more detailed outline of variables taken into account. 
Additional variables playing a role in the transition from 1 section into another, such as when 
prevalence in ground beef, probability of exposure, and ingested dose were included. Outbreaks 
of foodborne pathogens are not unique to the United States. This model could better identify any 
risks based on the original region from which the animal came, animal shipping, and 
contamination from the hide. AMR elements could be added, too, in order to evaluate the 
probability of becoming ill with a resistant pathogen. These outbreaks occur around the globe 
affecting every continent, with exception of uninhabited Antarctica, and show the need for better 
and updated surveillance systems (Todd, 1997). 
 Many elements of our project are highlighted throughout this critical analysis. There are 
many factors at play when establishing the economic burden of and regulatory/policy options to 
combat AMR. Due to the number of factors, stakeholders, and areas of professional expertise 
needed to address such topics, progress has been slow in collective, collaborative steps to address 
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this public health threat. Even within animal agriculture, there are differing antimicrobial 
regulations by country due to a variety of factors including, production systems, main animal of 
production, and size of production. Within dairy production, metritis is an important disease 
affecting the health and production of farm animals, but is difficult to prevent due to the number 
of host-related risk factors associated with the disease. To reduce production costs, CCFA is a 
popular medication to treat metritis resulting, at least partially, from a lack of need to discard 
milk after treatment. However, because CCFA is in the same class of drug as ceftriaxone, 
utilization of this drug provides a selection pressure for resistance to critically important and 
highest priority antimicrobials used in human medicine (WHO, 2019). Furthermore, multiple 
studies have illustrated the contamination of retail meats with E. coli and Salmonella bacteria, 
many of which carry antimicrobial resistance genes. Exploring these topics is important for a 











CHAPTER III  
MATERIALS AND METHODS 
3.1 STUDY POPULATION 
A pair-matched longitudinal study was conducted. We enrolled 3 dairy farms in west 
Texas and eastern New Mexico (Figure 1). Dairy cows with postpartum metritis were diagnosed 
by a licensed veterinarian or else the dairy herdsman using a veterinarian established protocol 
and thereafter prescribed a two-dose treatment with CCFA (Excede®, Zoetis Animal Health, 
Florham Park, NJ). The first treatment was given subcutaneously at the base of 1 ear upon 
diagnosis and the second was given 72 hours later in the opposite ear. Doses were administered 
per label at 6.6 mg per kg of body weight. Treated cattle were pair-matched with healthy, 
untreated control counterparts on the day of diagnosis. Control cattle were of a similar lactation 
number (i.e., production age) and calving date when compared to the treated, metritis-diagnosed 
cows, but not diagnosed with metritis and not given CCFA. Additional metrics, such as other 
ailments, calving difficulties, cow age, enrollment period, and time lapse from calving to 
enrollment were recorded. Each dairy farm had 15 pairs of cattle enrolled in a spring season 
replicate (April to June). A second larger replicate was performed in the fall season (September 
to April) with 25 pairs of cattle enrolled per dairy farm. Approval for the animal experiments 
was granted by the Texas A&M University Institutional Animal Care and Use Committee 





Study Geographic Area 
 
Figure 1: The geographic area in which the 3 enrolled dairy farms were selected is depicted 
by the blue circle (map adapted from Southard, 2016). 
 
Through utilization of this study design, we were able to evaluate how the treatment 
protocol impacts third-generation cephalosporin (3GC) resistance among E. coli and Salmonella 
against what was observed among untreated populations. Additionally, by pairing cattle 
comprising the treated and untreated groups, we controlled for 2 potential confounding factors: 
age (as lactation number) and days to diagnosis post-calving. This approach improved 
confidence that any inference regarding differences observed in 3GC resistance result from the 





3.2 ENVIRONMENTAL SAMPLE COLLECTION 
Prior to beginning the trial, environmental samples were collected from each dairy farm 
to test for the quantity of E. coli (total and 3GC-resistant) and determine the AMR phenotypic 
and genotypic profiles of 3GC-resistant isolates. The data resulting from these samples aided in 
understanding background levels of resistance within each dairy farm environment. Having such 
data assisted in our ability to assess each farm and consider ways through which antimicrobial 
stewardship can be improved. Furthermore, it contributed in explaining patterns observed within 
and among the animals of each farm, such as baseline levels of 3GC resistance, when compared 
to that of the other farms.  
Surface manure samples were collected from milking, hospital, maternity and fresh-cow 
pens, in addition to the compost area. Samples were collected using an obstetric (OB) sleeve to 
pick up and composite approximately 5 g of feces from 12 locations along a transect line in each 
area of interest. Once collected, the OB sleeves were turned inside out and tied off. The dairy 
farm, sample location, and date were noted on the sleeve. Water samples also were collected 
throughout the farm. These samples, consisting of 5 mL each, were collected from 8 water 
locations via sterile, plastic spoons, and placed into a 50 mL conical tube (Falcon®, Corning, 
NY). Using the same procedure, 2.5 mL were removed from each of the same 8 water sources 
and placed into a 50 mL conical tube containing 20 mL of sterile, 50% glycerol (Fisher 
Chemical, Thermo Fisher Scientific, Waltham, MA) and thoroughly mixed. Samples were 
transported in a cooler on ice packs to the Agricultural Science Center (ASC) of New Mexico 
State University (NMSU) located in Clovis, New Mexico.  
Once at the Center, the samples underwent further processing. Sleeves containing the 
manure samples had a hole cut in 1 of the fingers and 40 g of sample was squeezed into a 50 mL 
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conical tube without glycerol and 20 g was placed in a 50 mL conical tube containing 20 mL of 
sterile, 50% glycerol. Sample tubes were labeled the same as the OB sleeves, zip lock bags, and 
water tubes with a “G” written on the tube to denote those containing glycerol. All tubes 
containing manure and water samples were stored at 4°C before being transported on coolers 
with ice packs to Eastern New Mexico University (ENMU) in Portales, New Mexico and stored 
at -80°C. The samples were later shipped overnight on dry ice to the laboratory of Dr. H. M. 
Scott at Texas A&M University (TAMU) in College Station, Texas.  
 
3.3 CATTLE FECAL SAMPLE COLLECTION 
The samples from individual animals provided data for evaluation of the temporal 
dynamics of fecal shedding of total and 3GC resistant Enterobacteriaceae; specifically, E. coli 
and Salmonella enterica subspecies enterica. The first 3 sampling days (0, 6, and 16) are 
particularly important in showing population dynamics relating to disease and treatment. The day 
0 sample served as the baseline, as the sample was taken prior to the administration of CCFA. 
The day 6 sample provided insight into how these populations initially change in the immediate 
aftermath of both doses of CCFA in treated versus control cows. Finally, day 16 represents the 
first eligible slaughter date after the two-dose treatment. Data from this day shed light on 
whether the current slaughter withholding is effective in allowing 3GC resistant 
Enterobacteriaceae to return to baseline levels. Later days provided additional information 
regarding potential return to baseline prevalence. 
Once a cow was diagnosed with metritis, a fecal sample was taken per rectum with a 
shoulder-length OB sleeve prior to first dosing with CCFA. The OB sleeve was not contaminated 
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with soap or other materials prior to sampling. Once a sample was taken, the sleeve was turned 
inside out and tied into a knot. The farm identifier, whether the cow was treated or control, the 
cow ID, sample day and the date was written on the sleeve. On the same day, a control cow was 
selected and a fecal sample taken via the same process. The sleeves were then placed into a 
cooler with ice packs for storage during transportation to the laboratory for further processing. 
These first samples from treated and untreated cows served as the day 0 samples. After the 
collection of the baseline sample, treated cows were given their first dose of CCFA. The second 
dose was administered 72 hours later. Subsequent fecal samples were taken on study days 6, 16, 
28, and 56 for both treated and control cows (Figure 2). These samples were processed in the 
same manner as the environmental samples. Upon arrival in College Station, the environmental 
and per rectum fecal samples were organized by dairy farm identifier and sample collection day. 








Figure 2: Study design is displayed above. The red cow is indicative of metritis diagnosis, pink cows represent the cow 
having been treated with CCFA, and white cows show a non-metritis state. The syringe by the ear of the first 2 cows in 
the treated group represent the administration of CCFA. Gloves with fecal samples represent days at which samples 
were collected. Day 0 samples were collected prior to CCFA administration.
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3.4 E. coli ISOLATION FROM FECAL SAMPLES  
Samples cultured for E. coli were spiral plated onto plain MacConkey agar (MAC) (BD 
Difco™, Franklin Lakes, NJ) and MacConkey agar containing ceftriaxone (Sigma-Aldrich, St. 
Louis, MO) at 4 µg/mL (MACCEF) in addition to CHROMAgar™ Orientation (CHROMagar™, 
France) with Tween 80 (Hardy Diagnostics Santa Maria, CA) and CHROMAgar™ ESBL 
supplement (570 µg/mL) (CHROMagar™, France) (CHROM-ESBL). Growth on MAC displays 
both 3GC susceptible and resistant populations. MACCEF growth displayed only those 
coliforms with 3GC resistance. By counting those plates for E. coli, we were able to determine 
fluctuations within populations and compare the proportion of 3GC resistant to total E. coli 
population over time. Samples with growth on CHROM-ESBL agar display an ESBL resistance 
profile; however, previous experience in our laboratory suggests that AmpC genotypes also are 
isolated using this medium. Since we enrich these samples in a manner to promote the growth of 
bacteria containing an ESBL resistance profile, these plates were noted only for E. coli growth or 
lack thereof. Isolates selected from the CHROM-ESBL plates were subjected to further 
molecular and phenotypic analysis. This allowed for a further understanding of prevalence of 
such resistance profiles and changes temporally. Laboratory work involving E. coli and 
Salmonella was conducted under Texas A&M University Institutional Biosafety Committee 
protocol number 2017-049. 
To begin E. coli microbiological processing, 1 g of each environmental manure or cow 
fecal sample in glycerol was placed into 9 mL of 1x phosphate buffered saline (PBS) (Gibco®, 
Thermo Fisher Scientific, Gaithersburg, MD) in a 15 mL conical tube (Falcon®, Corning, NY) 
yielding a final 1:20 dilution (accounting for glycerol). After vortexing, 1 mL was pipetted into a 
5 mL cup and a 50µL aliquot was spiral plated onto plain MAC and MACCEF using the Eddy 
74 
Jet 2® instrument (Neutec Group Inc., Farmingdale, NY). The 4 µg/mL ceftriaxone concentration 
in MACCEF agar represented the MIC for the human clinical resistance breakpoint for E. coli 
established by the Clinical Laboratory Standards Institute (CLSI, 2019), Additionally, 1 mL from 
the PBS solution was pipetted into 9 mL of MacConkey broth (BD Difco™, Franklin Lakes, NJ) 
with 2 µg/mL of ceftriaxone. At this time, 4 g of each glycerol and non-glycerol sample was 
transferred into a 5 mL polypropylene tube for further storage at -80˚C. Following 18 hours of 
incubation at 37˚C, MAC and MACCEF plates were counted for defined, pink, lactose-
fermenting colonies using the Flash & Go® instrument (Neutec Group Inc., Farmingdale, NY). 
After the MACCEF broth (2 µg/mL of ceftriaxone) was incubated for 18 hrs at 37˚C, the 
tubes were vortexed and 1 mL was pipetted into a spiral plating cup. Using the Eddy Jet 2®, 50 
µL were spiral plated onto CHROM-ESBL. After incubating for 18 hrs at 37˚C, these plates 
were removed from the incubator and checked for pink, lactose fermenting colonies to evaluate 
E. coli growth. Two pink, isolated colonies suspected to be E. coli were selected with a 1 µL 
loop from each CHROM-ESBL agar plate and then streaked onto tryptic soy agar (TSA) 
containing 5% sheep blood (Remel™, Lenexa, KS) and incubated at 37˚C for 18 hrs.  
Following this incubation period, isolates were indole tested using James Reagent 
(bioMérieux, Marcy-l’Étoile, France); in addition, a Matrix Assisted Laser Desorption/Ionization 
– Time of Flight Mass Spectrometry (MALDI-TOF MS) (Bruker, Billerica, MA) plate was
prepared for organism confirmation/identification. One colony selected from the pure culture 
blood agar plate was rubbed onto a filter containing James Reagent. A color of pink on the area 
in which the colony was rubbed indicated an indole-positive colony. MALDI-TOF MS plates 
were prepared by placing Bacterial Test Standard (BTS) (Bruker, Billerica, MA) as a positive 
control in the first 2 wells of a 96 well target plate. A different sample isolate went into each of 
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the remaining 92 wells by being applied to the well with a sterile toothpick. A template was used 
to keep track of which sample was in each well. The last 2 wells contained matrix (Bruker, 
Billerica, MA) as a negative control. Matrix was then applied to all wells and allowed to dry. The 
plate was read using mass spectrometry for organism identification. Those isolates testing indole 
positive and identified as E. coli by MALDI-TOF MS were placed on cryo-beads (Scientific 
Device Laboratory, Des Plaines, IL) for storage at -80˚C. Water samples were processed in the 
same manner as environmental manure and cow fecal samples. 
 
3.5 AmpC AND ESBL DIFFERENTIATION 
A subset of 30 samples across the 5 different spring sample collection days (i.e., 0, 6, 16, 
28, 56), the 3 enrolled dairy farms, and 2 treatment groups (treated and control) that tested 
positive on both MACCEF and ESBL agars were selected to be spiral plated onto MAC and 
MACCEF, along with MacConkey agar infused with cefoxitin (MACFOX) (32 µg/mL; Sigma-
Aldrich, St. Louis, MO), MacConkey agar with cefepime (MACFEP) (16 µg/mL; Sigma-
Aldrich, St. Louis, MO) and MacConkey agar infused with ceftriaxone (4 µg/mL) and clavulanic 
acid  (MACCCA) (4 µg/mL; Sigma-Aldrich, St. Louis, MO). Once the sample was placed into 
1x PBS for a 1:20 dilution, 50 µL was spiral plated onto each of these plates and incubated at 
37˚C for 18 hrs. One mL was extracted from the 1x PBS solution and placed into a 15 mL 
conical tube with 9 mL MACCEF broth (1 µg/mL) for incubation at 37˚C for 18 hrs. Another 
mL was removed from the PBS solution and placed into 9 mL MACCEF broth (2 µg/mL) for 
incubation at 37˚C for 3 hrs. After the broths were incubated for their allotted times, the tubes 
were removed from the incubator, vortexed, and 50 µL each was spiral plated onto MAC, 
MACCEF, MACFOX, MACFEP, and MACCCA plates. After spiral plating, the plates were 
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incubated at 37˚C for 18 hrs. Since the enrichment was applied throughout the plates, a relative 
count could be made, even among the enriched samples. After the incubation period of each of 
the plates, they were removed and colony counted for pink, defined, lactose-fermenting CFUs.  
The goal was to get an overall and relative count of the susceptible and resistant E. coli 
population on each of the MAC plate types (Thomson, 2001). The 30 samples were selected 
based upon samples that tested positive on both MACCEF and ESBL agar plates so we knew 
they have a CFU count for AmpC/ESBL at least as high as the limit of quantification. By doing 
so, we could further evaluate the effectiveness of this highly intensive differentiation method for 
consideration in usage with a larger number of samples. The MACCEF plate gave a combination 
of those bacteria displaying AmpC and ESBL forms of resistance, as those forms both allow for 
resistance to third-generation cephalosporins (Tragesser, 2006; Jacoby, 2009; Pfeifer, Cullik, and 
Witte, 2010; Schmid et al., 2013). Since cefoxitin is a second-generation cephalosporin, the 
MACFOX plate only grew E. coli with AmpC resistance, as ESBL bacteria do not have 
resistance to second-generation cephalosporins (Bonnet, 2004; Drieux et al., 2008). With 
cefepime being a fourth-generation cephalosporin, that plate would only grow ESBL coliforms 
because AmpC resistance profiles do not allow for resistance to fourth-generation cephalosporins 
(Akova, Yang, and Livermore, 1990). The MACCCA plates only grow E. coli with AmpC 
resistance profiles because the addition of clavulanic acid removes the ability of the ESBL 
genotype to remain resistant to third-generation cephalosporins (Matsuura et al., 1980; 
Cormican, Marshall, and Jones, 1996; Bonnet, 2004; Drieux et al., 2008; Schmid et al., 2013; 
Rossi et al., 2016). These counts allowed us to evaluate which proportion of 3GC resistant E. coli 
had an AmpC or ESBL resistance profile, as the MACCEF plates yielded both resistance forms, 
MACFOX and MACCCA yielded bacteria with an AmpC resistance profile, and MACFEP 
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produced bacteria with an ESBL resistance profile. After the plates were counted, 6 MACCEF 
isolates and 3 isolates from each of MACFOX, MACFEP, and MACCCA were streaked to blood 
agar, incubated for 18 hrs at 37°C, indole tested, MALDI-TOF MS tested, and saved to cryo-
beads, if positively identified as E. coli. Should a plate not have the number of colonies 
indicated, all colonies from that plate were saved to cryo-beads. 
3.6 AGAR PREPARATION 
All agars and broth were prepared per manufacturers’ protocols and autoclaved as 
recommended. Antibiotics were added to the agar after first being dissolved in 1 mL of water 
and the media was appropriately cooled and mixed. Once the antibiotic was suspended in water, 
it was added to the MAC agar or broth and allowed to further mix before the agar or broth was 
dispensed. Similar methods were used to prepare brilliant green agar (BGA) (Difco, Becton 
Dickinson, Franklin Lakes, NJ), which is a medium used in isolating Salmonella. Antibiotic 
media was consistently maintained in darkness. CHROMAgar™ Orientation was prepared using 
the manufacturer’s protocol and Tween 80. The media were autoclaved prior to the addition of 
CHROMAgar™ ESBL supplement. The supplement was added in the same manner as described 
previously for MAC and BGA media. 
3.7 BROTH MICRODILUTION 
Broth microdilution is an effective way of quickly assessing phenotypic levels of 
susceptibility or resistance within any bacterial isolate to an array of 14 antimicrobials across 9 
antimicrobial classes. These plates provide many levels of evaluation from the basic level 
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regarding the concentration (minimum inhibitory concentration: MIC) at which isolates fail to 
grow, whether they are susceptible, intermediate, or resistant to an antimicrobial based on 
interpretive criteria, the number of cumulative classes or antimicrobials to which an isolate is 
resistant (intermediate, or susceptible), and analyses to determine the concentration of antibiotic 
at which 50% and 90% of isolates are inhibited by a certain antimicrobial.  Consequently, co-
selection could be observed when combinations of phenotypes are observed to move in concert 
with extrinsic factors such as antibiotic treatments applied to cows. This provided insight into 
potential families of resistance genes within the isolate that would not have been revealed using 
the selective agar plating technique we utilized. These analyses provided an in-depth phenotypic 
evaluation of the selected 3GC isolates.  
 One E. coli isolate from each of the positive CHROM-ESBL agar plates was subjected to 
phenotypic antibiotic susceptibility testing using the broth microdilution Sensititre™ National 
Antimicrobial Resistance Monitoring System (NARMS) Gram Negative CMV3AGNF plate 
(TREK, Thermo Fisher Microbiology, Oakwood Village, OH). Each isolate was recovered from 
cryo-beads in storage at -80°C and streaked onto blood agar. Blood agar plates were incubated 
for 18 hrs at 37°C. One colony from each blood agar plate was selected and placed into 4 mL of 
sterilized water and standardized to a McFarland standard of 0.5. Afterwards, 50 µL of 
suspension was transferred into 11 mL of Mueller-Hinton broth before 50 µL of that suspension 
was added to each well on the NARMS plate via the Sensititre automated delivery system 
(TREK). Additionally, Escherichia coli ATCC 35218, Escherichia coli ATCC 25922, 
Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, and Pseudomonas 
aeruginosa ATCC 27853 (American Type Culture Collection, Manassas, VA) were used as 
control strains whenever a new batch of plates was used. Plates were incubated for 18 hrs at 
79 
 
37°C before being read via Sensititre OptiRead™ (TREK, Thermo Scientific Microbiology). 
Clinical Laboratory Standards Institute (2019) guidelines were used in interpreting isolates as 
susceptible, intermediate, or resistant using SWIN software (TREK, Thermo Scientific) 
(National Antimicrobial Resistance Monitoring System, 2019). Isolates recorded as intermediate 
were reclassified as susceptible for statistical analyses of binary response variables. The 
resistance cutoffs are shown in Table 1. The National Antimicrobial Resistance Monitoring 
System generates human breakpoints when CLSI does not. Unfortunately, the plate does not 
have concentrations high enough to determine resistance to azithromycin or sulfisoxazole.                                                                                                                                                 
 
 
Table 1: Minimum Inhibitory Concentration Breakpoints for Resistance 
Antibiotic Resistance Cut-off Value 
Amoxicillin/Clavulanic Acid Combination ≥32 µg/16 µg/mL 
Ampicillin ≥32 µg/mL 
Azithromycin > 16 µg/mL 
Cefoxitin ≥32 µg/mL 
Ceftiofur ≥8 µg/mL 
Ceftriaxone ≥4 µg/mL 
Chloramphenicol ≥32 µg/mL 
Ciprofloxacin ≥1 µg/mL 
Gentamicin ≥16 µg/mL 
Naladixic Acid ≥32 µg/mL 
Streptomycin ≥32 µg/mL 
Sulfisoxazole > 256 µg/mL 
Tetracycline ≥16 µg/mL 
Trimthoprim-Sulfamethoxazole Combination 4 µg/76 µg/mL 
The MIC for a resistant designation is shown for each antibiotic. Any MIC recorded below 
the given breakpoint was considered susceptible to that antibiotic.  
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3.8 SALMONELLA ISOLATION FROM CATTLE FECAL SAMPLES 
 
The following protocol was utilized in isolating Salmonella from cattle fecal samples. 
Through enriching the samples, we were attempting to get the most accurate results regarding the 
animal-level prevalence of Salmonella fecal shedding from the 2 treatment groups and over time. 
Enrichment supported the growth of Salmonella in the sample, even if found in low numbers. 
The samples were only identified as positive or negative because the enrichment process inflated 
the number of colonies found in the sample. Furthermore, we were able to better understand the 
dynamics of any 3GC resistant Salmonella shedding throughout the study in addition to the 
shedding of total Salmonella.  
Salmonella was cultured from all samples collected on study days 0, 6, and 16 of both 
trials by following the protocols published in Ohta et al. (2017). After thawing on ice, 0.5 g of 
fecal sample was placed into 5 mL of tryptic soy broth (TSB) (Difco, Becton Dickinson, 
Franklin Lakes, NJ) and left to incubate for 2 hrs at room temperature. After such time, the TSB 
tubes were placed in a 42°C incubator for 6 hrs. After the 6 hr incubation period, the tubes were 
placed in a 4°C refrigerator overnight. The tubes were then removed from the refrigerator and 
vortexed before 1 mL of TSB was pipetted into 9 mL of tetrathionate broth (TTB) (Difco, 
Becton Dickinson, Franklin Lakes, NJ) with 200 µL of iodine and then further incubated for 18 
hours at 37°C. After incubation, the tubes were vortexed and 100 µL was pipetted from the TTB 
solution and into 10 mL of Rappaport Vassiliadis R10 broth (RV) (Difco, Becton Dickinson, 
Franklin Lakes, NJ) and incubated for 18 hrs at 42°C. After the incubation period, the tubes were 
vortexed before 50 µL of RV solution was spiral plated onto BGA (Difco, Becton Dickinson, 
Franklin Lakes, NJ) and incubated for 18 hrs at 37°C. The following day, the plates were 
checked and growth, or lack thereof, was noted. Pink colonies were selected as suspected 
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Salmonella. One isolate from the plain BGA plate and 3 isolates from the BGA plate containing 
4 µg/mL of ceftriaxone were tested via MALDI-TOF MS and those identified as Salmonella 
were saved to cryo-beads. Beads were stored at -80℃. The same previously described protocols 
for MALDI-TOF MS and preservation on cyro-beads for E. coli were followed for Salmonella. 
3.9 WHOLE GENOME SEQUENCING 
An E. coli isolate recovered from each MACFEP (16 µg/mL) agar plate and Salmonella 
isolate recovered from BGA and BGACEF (4 µg/mL) agar plates were whole genome 
sequenced. Additionally, 15 E. coli isolates were selected based upon their ciprofloxacin MIC 
values or unique AmpC or ESBL profiles. These isolates were selected, along with the elevated 
ciprofloxacin MICs, to explore the genetic mechanisms behind their unique phenotypes. 
Sequencing these isolates provided information regarding the serogroup, serotype, and sequence 
type, along with resistance genes and plasmids contained in the general population (Salmonella) 
and those with known resistance to 3GCs (Salmonella and E. coli). We evaluated which 
serotypes predominated in the sample pre-treatment and observed changes post-treatment. The 
resistance genes encountered provided insight into what was observed in the general Salmonella 
population and are selected via CCFA treatment. 
Each isolate (1 from each positive BGA and BGACEF sample plate) was placed into a 15 
mL conical tube containing 6 mL of TSB and incubated for 18 hrs at 37°C. After incubation, 
DNA was extracted using the QIAcube HT via the QIAamp 96 DNA QIAcube HT Kit (Qiagen, 
Valencia, CA). To do so, 1 mL of the incubated broth solution was transferred into and 
subsequently centrifuged via Centrifuge 5424 (Eppendorf, Hamburg, Germany) for 15 minutes at 
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4,000 rpm in a 1.2 mL micro-collection tube. The supernatant was removed and ATL buffer 
(Qiagen) and DX reagent was used to resuspend the bacterial pellet. Furthermore, after adding 
small pathogen lysis beads (Qiagen) to the suspension, the Qiagen TissueLyser system (Qiagen) 
was used to agitate the solution for 5 minutes at 25 Hz. Once the tubes were centrifuged, 40 µL 
of Proteinase K was added to each tube. The tubes were then placed into a ThermoMixer 
(Eppendorf, Hauppauge, NY) for 1 hr at a temperature of 56°C while mixing at 900 rpm. A 10 
minute heat shock at 95°C followed. After cooling to room temperature, 4 mL of RNAse A was 
added to each tube and DNA from the samples was extracted using the recommended Qiagen 
protocol on the QIAcube HT.  
The extracted DNA was then evaluated for quality and quantity via fluorescence using 
the Qubit 3 Fluorometer (Invitrogen, CA) and absorbance utilizing the Fluostar Omega Plate 
reader (BMG LABTECH, Cary, NC). Once the DNA is determined to be of acceptable quality 
with a ratio of absorbance at 260 nanometers to 280 nanometers between 1.8-2.0, tagmentation 
steps were followed to tag the DNA with adapter sequences via bead-linked transposome. 
Libraries were prepared using the Illumina Nextera XT kit (Illumina, Inc., San Diego, CA). A 
post-tagmentation cleanup was performed to remove the adapter-tagged DNA before amplifying 
the tagmented DNA. The libraries were then cleaned via double-sided beads to purify the 
libraries. The quality of the prepared libraries was evaluated using the Fragment Analyzer 
(Advanced Analytical Technologies, Inc., Santa Clara, CA) as a final quality control prior to 
pooling and normalizing the libraries and to begin sequencing the isolates via MiSeq (Illumina, 
San Diego, CA). Samples were sequenced using a MiSeq v2 reagent kit with 500 cycles with 
2x250 paired end reads (Illumina, San Diego, CA). Once the sequences were assembled, the 
web-based tool SeqSero (http://www.denglab.info/SeqSero) was used to determine Salmonella 
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serotypes using raw fastq files generated from forward and reverse reads, while making serotype 
decisions based on H1 and H2 antigens, along with O-antigen gene clusters (Zhang et al., 2015). 
E. coli sequence types and resistance genes for all sequenced isolates were evaluated using the 
online platform ResFinder (Zankari et al., 2012) from the Center for Genomic Epidemiology 
(Danish Technical University, Lyngby, Denmark). 
 
3.10 STATISTICAL METHODS 
Broad descriptive statistics were performed to gain a better understanding of data 
distribution. Furthermore, cross tabulations were performed based on replicate, dairy farm, 
animal group, and study day. We generated descriptive statistics regarding mean, standard errors, 
95% confidence interval, and median for our quantitative CFU count data. Colony count data 
will be log10 transformed. Due to the detection limit in our colony counting methodology being 
~2.5 log10 bacterial growth and the low levels of 3GC resistant bacteria that tended to exist in the 
feces, we had a high number of MACCEF agar plates displaying levels of growth below the level 
of detection. While these plates appeared to be negative for E. coli growth, based on herd mate 
status and shared environments, we hypothesized these animals were likely to be shedding the 
bacteria below the level of detection for our methodology. We utilized a multiple imputation 
method to distribute those plates displaying no growth across the levels below detection by 
establishing a lower limit of 0 log10 CFU and an upper limit of 2.5 log10 (STATA
® 15, STATA 
Corp., College Station, TX). This method used the other count data and regression model factors 
to distribute the counts below detection in order to not violate the assumptions of the linear 
regression model. 
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Mixed effect linear regression on log10 transformed CFU count data was performed to 
account for fixed and random effects, while featuring nested of clusters to explore sources of 
variation by using the command “mixed”. Random effects consisted of the season or replicate 
number, dairy farm, and animal. Fixed effects consisted of whether a cow was treated for 
metritis, sample collection day, cow lactation, and the interaction of treatment with sample day. 
Historical CCFA usage levels also were explored as fixed effects in the model. When evaluating 
differences in E. coli dynamics by dairy farm, farm was included in the model as a fixed effect. 
Additionally, ordinal variables indicating historical ceftiofur usage were evaluated as fixed 
effects within the models. Multivariate regression analysis with an interaction between treatment 
and sample day was utilized to evaluate the difference in log10 growth of E. coli across the agar 
plates used in AmpC and ESBL differentiation from total counts. 
Logistic regression was used to explore the phenotypic ESBL E. coli profile based on the 
breakpoint interpretation of isolates selected from CHROM-ESBL agar produced using the 
microbroth dilution method while keeping the interaction of treatment and sample day. Survival 
analysis via Kaplan-Meier plots utilizing the MIC values was performed to evaluate the 
antimicrobial concentration at which 50% and 90% of the isolates experience inhibited growth. 
The role of treatment, dairy farm, and sample day were all independently evaluated for effect on 
MIC regarding each of the antibiotic compounds via the Mantel-Haenszel rate ratio. These 
analyses provided insight into the forms of resistance the isolates forming the 3GC population 
possessed as indicated at each time point and by treatment under the aforementioned selection 
criteria. BGA plates were not colony counted and were only evaluated as positive or negative for 
Salmonella; therefore, mixed-effects logistic regression was utilized to evaluate the data 
85 
 
(STATA® 15, STATA Corp., College Station, TX) using similar modeling approaches as 



















4.1 FECAL E. coli DATA ANALYSES 
4.1.1 Descriptive Statistics 
In total, 9 pen-floor samples were collected from each of fresh cow, hospital, maternity, 
and milking pens, along with the compost area from each dairy farm. Samples were analyzed 
independently and CFU means were calculated from the growth data of each sample; that is, 
environmental samples were not pooled outside of their farm/pen location. Total E. coli CFU 
counts were similar across all 3 dairy farms; however, Dairy Farm 3 had mean quantifiable levels 
of 3GC resistant E. coli approximately 1.5 log10 CFU greater than the other 2 farms (Dairy Farm 
1 95% CI: 0.575-3.116; Dairy Farm 2 95% CI: 0.286-2.939; Dairy Farm 3 95% CI: 1.765-4.575; 
Table 2). This led to differences between total and 3GC growth of approximately 1 log10 CFU 
less than the other 2 dairy farms (Table 2). All water sources sampled across the 3 dairy farms 
tested negative for detectable levels of E. coli. 
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Table 2: Quantitative E. coli Data Descriptive Statistics from Environmental Samples 
Descriptive data concerning the distribution of environmental E. coli growth across each dairy farm. MAC, plain 
MacConkey agar; 3GC, third-generation cephalosporin; MACCEF, MacConkey agar with 4 µg/mL of ceftriaxone. 
Growth Metric 
Log10 Total E. coli (MAC) 
Log10 3GC  
Resistant E. coli (MACCEF) 
Log10 Growth Arithmetic 






















5.220 1.846 0.618 
0.575-
3.116 










5.328 1.613 0.645 
0.286-
2.939 










5.858 3.170 0.683 
1.765-
4.575 






The mean cow lactation number was 1.7 and cows were, on average, 9.8 days in milk at 
the time of enrollment. The average age of cows enrolled in the study was 34.3 months and 60% 
of enrolled cows were primiparous (first-calf heifers). The estimated weight of first lactation 
animals was 545 kg, 615 kg for second lactation, and 665 kg for third and higher lactation 
animals on the dairy farms. Based upon the age and lactation of enrolled animals, along with the 
estimated weights of each lactation number on the farms, it is estimated the average weight of 
animals enrolled in the study was 601 kg. The treatment ratio of cows and heifer lactation days 
freshened in the prior year with any ceftiofur formulation was 9.0% on Dairy Farm 1, 8.4% on 
Dairy Farm 2, and 121.0% on Dairy Farm 3. These numbers were generated by dividing the 
number of ceftiofur dosages by the number of cows at risk. Of those ratios, 0% from Dairy Farm 
1, 23.6% from Dairy Farm 2, and 8.6% from Dairy Farm 3 were intra-mammary formulations 
and not systemic therapy given via injection. This means animals on Dairy Farm 1 averaged 
0.090 treatments per cow-lactation, with 0.084 treatments on Dairy Farm 2, and 1.210 treatments 
per fresh cow or heifer on Dairy Farm 3. Since ceftiofur formulations have been prohibited for 
off-label usage in the United States since April 2012, we have assumed that each dosage of 
CCFA administered was at 6.6 mg per kg of body weight and the other ceftiofur formulations 
also were at labeled dose. 
 Summary statistics (mean, standard error, 95% confidence intervals and the median) by 
treatment group, day, dairy, and season are presented in Table 3. Treated animals had lower 
mean and median values of growth on MAC, but higher values of growth on MACCEF; 
meanwhile, the arithmetic difference between those 2 outcomes decreased substantially among 
treated animals in comparison to the untreated group (Table 3). Similar trends were observed 
regarding these metrics across sample day relating to the time from drug administration. There 
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was a mean decrease in the total E. coli population on the first sampling day following treatment 
with an increase in mean 3GC resistant E. coli population on the same day. Thereafter, the total 
E. coli population increased and 3GC resistant E. coli population decreased as time progressed 
from treatment administration. Descriptive statistics illustrating these phenomena are shown in 
Table 4. Samples from Dairy Farm 3 exhibited higher mean and median E. coli growth on both 
MAC and MACCEF agars, with a smaller arithmetic difference between the 2 when compared to 
Dairy Farms 1 and 2 (Table 3). Values remained steady across plate type and arithmetic 
difference with regards to the metrics of mean, median, and standard error for the factor of 
season. Sample number varied across these metrics, as some animals were culled prior to study 
completion or else samples were missed during the collection period (Table 3). 
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Table 3: Quantitative E. coli Data Descriptive Statistics from Cattle Samples         
                                                                                        
Descriptive data concerning the distribution of E. coli growth within the factors of treatment, day, dairy farm and 
season. Univariate summary statistics are unadjusted for clustering by farm, pen, and animal. MAC, plain MacConkey 
agar; MACCEF, MacConkey agar with 4 µg/mL of ceftriaxone.
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Table 4: Descriptive Data on the Distribution of E. coli Growth across Treatment and 












Sample Size 123 121 118 120 113 
Mean 4.701 3.000 4.388 4.758 4.903 
Standard 
Error 
0.113 0.190 0.145 0.115 0.115 
95% CI 4.481-4.922 2.627-3.374 4.103-4.673 4.533-4.983 4.678-5.128 
Median 4.757 3.681 4.663 4.864 5.105 
Untreated 
Sample Size 123 118 121 117 117 
Mean 4.581 4.876 4.776 4.761 4.775 
Standard 
Error 
0.111 0.108 0.105 0.106 0.098 
95% CI 4.364-4.799 4.665-5.088 4.570-4.982 4.552-4.969 4.583-4.967 






Sample Size 123 121 118 120 113 
Mean 0.635 1.564 1.095 0.554 0.554 
Standard 
Error 
0.121 0.188 0.168 0.117 0.124 
95% CI 0.398-0.873 1.195-1.933 0.766-1.424 0.325-0.784 0.311-0.798 
75th 
Percentile 
0.000 3.556 2.603 0.000 0.000 
Untreated 
Sample Size 123 118 121 117 117 
Mean 0.410 0.567 0.458 0.393 0.404 
Standard 
Error 
0.097 0.121 0.111 0.102 0.107 
95% CI 0.219-0.600 0.331-0.804 0.241-0.675 0.193-0.592 0.194-0.615 
75th 
Percentile 










Sample Size 123 121 118 120 113 
Mean 4.066 1.436 3.292 4.204 4.349 
Standard 
Error 
0.138 0.183 0.188 0.137 0.148 
95% CI 3.795-4.337 1.077-1.796 2.924-3.662 3.934-4.473 4.059-4.639 
Median 4.292 0.176 3.623 4.511 4.5798 
Untreated 
Sample Size 123 118 121 117 117 
Mean 4.172 4.309 4.318 4.368 4.371 
Standard 
Error 
0.133 0.138 0.138 0.116 0.115 
95% CI 3.911-4.432 4.038-4.580 4.047-4.590 4.141-4.595 4.144-4.597 
Median 4.326 4.538 4.722 4.526 4.593 
 
Descriptive data regarding E. coli growth. MAC, plain MacConkey agar; 3GC, third 
generation cephalosporin; MACCEF, MacConkey agar with 4 µg/mL of ceftriaxone 
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The distribution of E. coli CFU counts grown on MAC agar is displayed in Figure 3. 
Samples with quantifiable 3GC resistant E. coli CFU count growth were most prevalent on day 6 
of the study (Table 4).  Dairy Farm 3 had the largest number of samples with 3GC resistant E. 
coli both in total and on each sample day (Table 5). The distribution of CFUs on MACCEF 
reflected a large number (n= 966) of plates with no detectable growth (Figure 4). It is unlikely 
these counts were truly 0. Because of this zero-inflation, modeling the count data using linear 
regression was not ideal due to inappropriate residuals, non-normal error distribution, heightened 
instability, and enlarged coefficients. By utilizing multiple imputed data of 3GC growth below 
the limits of detection, model estimates increased in stability due to the more normalized data 
distribution (Figure 4). Furthermore, the general distribution regarding the difference between 
the total and 3GC resistant E. coli populations is displayed in Figure 5. There were a few data 
points that displayed more 3GC resistant E. coli than total E. coli.  This is an artefact of 
limitations of our counting system and its inherent imprecision and also due to some plates 
displaying small levels of growth. Therefore, a difference of 1 3GC resistant isolate compared to 
no growth on MAC portrays a large difference in the 2 populations. Of the isolates presumed to 
be E. coli and selected for further testing (n=1603), 100% tested as indole positive and 98.6% of 
these were later confirmed via MALDI - TOF MS as E. coli providing confidence in our ability 
to phenotypically identify and include only E. coli in the colony counting procedure. 
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Table 5: Frequency of Samples with Third-Generation Cephalosporin Resistant E. coli 






Dairy Farm 1 
Dairy Number 
Dairy Farm 2 Dairy Farm 3 
Total 
     
Sample Day 0     
Growth 4 9 29 42 
No Growth 78 75 51 204 
Total 82 84 80 246 
     
Sample Day 6     
Growth 18 8 41 67 
No Growth 66 68 38 172 
Total 84 76 79 239 
     
Sample Day 16     
Growth 9 6 35 50 
No Growth 74 71 44 189 
Total 83 77 79 239 
     
Sample Day 28     
Growth 11 6 17 34 
No Growth 71 70 62 203 
Total 82 76 79 237 
     
Sample Day 56     
Growth 10 1 21 32 
No Growth 67 74 57 198 
Total 77 75 78 230 
Ceftriaxone resistance with frequency of samples testing positive shown across dairy farm 
by day. Samples are considered positive if confirmed E. coli colonies were isolated from 






Figure 3: The distribution of total E. coli growth on a log10 scale is displayed with a line 





Figure 4: Left: Distribution of actual ceftriaxone-resistant E. coli growth data on a log10 
scale. Right: Distribution of imputed 0 count ceftriaxone-resistant E. coli growth data on a 
log10 scale. CFU, colony-forming unit. 
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Figure 5: Distribution of difference in total and ceftriaxone-resistant E. coli growth on a 
log10 scale. CFU, colony-forming unit. 
4.1.2 Mixed Model of Total E. coli CFU Counts 
Mixed-effect linear regression was utilized to evaluate E. coli counts on a log10 scale. 
Figure 6 represents modeled marginal mean E. coli log10 CFU estimates with 95% confidence 
intervals on plain MAC agar by treatment group and across study days for all 3 farms. Both 
treated and untreated groups had similar quantities of enteric E. coli pre-treatment at the start of 
the trial (Day 0: P = 0.927; Treated: log10 CFU: 4.723; 95% CI: 4.301-5.145; Untreated: log10
CFU: 4.616; 95% CI: 4.194-5.037). However, following 
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 sequential doses of CCFA, the modeled count of E. coli in the treated group decreased by nearly 
2 log10 CFU below that of the untreated group (P < 0.0001: Treated 95% CI: 2.600-3.445; 
Untreated 95% CI: 4.497-5.345). At day 16, the first eligible date for slaughter after a two-dose 
treatment regimen with CCFA, the E. coli population of the treated group rebounded but 
remained  somewhat different (P = 0.053; Treated 95% CI: 3.999-4.847; Untreated 95% CI: 
4.396-5.242) from the control group. By study days 28 and 56, the E. coli populations of the 
treated group showed levels similar to that of the untreated group. Historical usage of ceftiofur 
formulations did not result in significantly different total E. coli growth counts with Dairy Farm 
2 as referent category (Dairy Farm 1: P = 0.854, 95% CI = -0.685 – 0.828; Dairy Farm 3: P = 
0.144, 95% CI = -0.192 – 1.321). Random effects attributed to dairy farm accounted for 11.4% 
of the variance components in the model with 9.7% attributed to animal. 
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Figure 6: Total E. coli CFU counts grown on MacConkey agar on a log10 scale across study 
day are displayed with marginal means and 95% confidence intervals. Treated cows are 
shown in blue and untreated in red. The vertical green line represents the first-eligible 
slaughter date. CFU, colony-forming unit. 
Figure 7 displays the fluctuation of the total E. coli population by each dairy farm across 
time. The treatment group from Dairy Farm 1 experienced a significant 2.416 log10 decrease in 
the total population (P < 0.0001, 95% CI = -3.190 – (-1.643)), but returns to similar population 
levels as the untreated group at day 16, as the population was 0.653 log10 units lower (P = 0.099, 
95% CI = (-1.429) – 0.123). This was also observed on Dairy Farms 2 and 3. Dairy Farm 2 
observed a drop in total E. coli population in the treated group of 1.482 log10 units on day 6 (P < 
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0.0001, 95% CI = -2.271 – (-0.693), but the population rebounded to levels similar to those of 
the untreated group by day 16 with a lower total population of 0.430 log10 units (P = 0.284, 95% 
CI = -1.216 – 0.357). The total E. coli drop of the treated group on Dairy Farm 3 at day 6 was -
2.158 log10 (P < 0.0001, 95% CI = -2.959 – (-1.357)). This population rebounded on day 16 to 
levels similar to the untreated group, much like that of the other 2 dairy farms, at -0.425 log10
units lower (P = 0.298, 95% CI = 1.226 – 0.376). 
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Figure 7: Total E. coli population growth on MacConkey agar is shown on a log10 with 
individual graphs by dairy farm for better comparison of groups within farm. 95% 
marginal means are displayed with treated animal values displayed in blue and untreated 
in red. The vertical green line represents the first-eligible slaughter data. CFU, colony-
forming unit. 
4.1.3 Mixed Model of 3GC Resistant E. coli CFU Counts 
Figure 8 depicts the quantity of enteric E. coli resistant to ceftriaxone at an MIC  ≥ 4 
µg/mL by treatment and study day modeled with mixed effects linear regression. Following the 
two-dose treatment with CCFA, the 3GC resistant E. coli population of the treated group 
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increased to 1.5 log10 CFU above the untreated group by study day 6 (P < 0.0001; Treated 95% 
CI: 2.383-2.938; Untreated 95% CI: 1.496-2.052). On study day 16, the population of 3GC 
resistant bacteria in the treatment group had been reduced by 0.5 log10 CFU, remaining higher, 
though not significantly different, than the untreated group (P=0.134; Treated 95% CI: 2.031-
2.587; Untreated 95% CI: 1.501-2.057). As time progressed to days 28 and 56, the population of 
3GC resistant E. coli further decreased towards pre-treatment levels. Cows with a lactation 
number greater than 3 had higher relative quantities of 3GC resistant E. coli than first lactation 
animals (P = 0.002; 95% CI: log10 CFU difference of 0.114-0.501). Historical ceftiofur usage 
with Dairy Farm 2 as referent did not yield a statistically significant difference regarding 3GC 
resistant E. coli growth when compared to Dairy Farm 1 (P = 0.341, 95% CI: -0.199 – 0.576), 
but was substantively different when compared to Dairy Farm 3 (P < 0.0001, 95% CI: 0.645 – 
1.405). Following imputation and incorporating all fixed and random effects, 7.63% of the 
variance in the model was attributed to the dairy farm with 9.8% attributed to animal. 
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Figure 8: Ceftriaxone-resistant (4µg/ml) E. coli growth on a log10 scale across study day 
with 95% marginal means confidence intervals after 0 count data were imputed across 
levels below detection. The blue line represents animals in the treated group and the red 
represents animals in the untreated group. The vertical green line represents the first-
eligible slaughter date. CFU, colony-forming unit. 
To evaluate the differences in 3GC growth among the 3 dairy farms, an additional mixed 
effect model was run with an interaction between dairy farm, treatment group and sample day. 
Treated and untreated groups had similar marginal means on study days 0, 28 and 56 across all 
dairy farms. On day 6, the treatment groups increased to a greater log10 CFU growth than their 
untreated counterparts: Dairy Farm 1 (Treated marginal means = 2.275, 95% CI = 1.981 – 2.568; 
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Untreated marginal means = 1.616, 95% CI = 1.323 -1.909), Dairy Farm 2 (Treated marginal 
means = 2.368, 95% CI = 2.075 – 2.662; Untreated marginal means = 1.535, 95% CI = 1.242 – 
1.829), and Dairy Farm 3 (Treated marginal means = 3.344, 95% CI = 3.043 – 3.644; Untreated 
marginal means = 2.131, 95% CI = 1.830 – 2.432). The treated group of Dairy Farm 3 had the 
highest marginal means on day 6 than all other group. The untreated population at the same 
location had marginal means at levels similar to that of the treated groups on Dairy Farms 1 and 
2 on the same day. On day 16, only Dairy Farm 3 had marginal means in the treatment group 
elevated above those of the untreated group (Treated marginal means = 2.846, 95% CI = 2.565 – 
3.147; Untreated marginal mean = 2.036, 95% CI = 1.735 – 2.336). 
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Figure 9: Ceftriaxone-resistant E. coli population growth on MacConkey agar containing 
ceftriaxone (4µg/ml) after 0 count data were imputed across levels below detection is shown 
on a log10 scale. Individual dairy farm graphs are displayed for better comparison of 
treatment groups within dairy farm. 95% marginal means are displayed with treated 
animal values displayed in blue and untreated in red. The vertical green line represents the 
first-eligible slaughter date. CFU, colony-forming unit. 
4.1.4 Mixed Model of Difference between Total and 3GC Resistant E. coli CFU Counts 
The outcome modeled as the arithmetic difference between the total enteric E. coli 
(MAC) CFU count and the 3GC resistant enteric E. coli (MACCEF) CFU count by treatment 
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across study days using mixed effects linear regression is displayed in Figure 10. This analysis 
utilized the original MACCEF data, not imputed values. The rationale for this analysis was that 
as the baseline levels of total coliforms changes, the observed changes in quantity of resistance 
resulted from shifts in either the numerator, denominator, or else both. The difference in the 
relative quantities across sampling days for the untreated group remained constant over time (day 
0 95% CI: 3.847-4.520; day 6 95% CI: 3.990-4.673; day 16 95% CI: 4.002-4.679; day 28 95% 
CI: 4.050-4.735; day 56 95% CI: 4.044-4.729). At baseline day 0, the arithmetic difference in the 
relative quantities was at similar levels for both treated and untreated groups (P = 0.775; Treated: 
log10 CFU: 4.080; 95% CI: 3.740-4.420; Untreated: log10 CFU: 4.185; 95% CI: 3.846-4.525). 
However, following treatment with CCFA, the log10 arithmetic difference between total E. coli 
and 3GC resistant E. coli CFU was reduced to 1.5 log10; meaning, of bacteria remaining after 
treatment, approximately 1 in 32 total colony-forming units were resistant to ceftriaxone. Of 
note, this differed significantly from the untreated group (P < 0.0001; Treated 95% CI: 1.111-
1.788; Untreated 95% CI: 3.990-4.673). This difference was also observed on the first-eligible 
slaughter date (day 16) (P = 0.001; Treated arithmetic differences in log10 CFU 95% CI: 2.970-
3.653; Untreated 95% CI: 4.002-4.680). On study day 16, approximately 1 in 1,250 E. coli CFU 
were 3GC resistant. By study days 28 and 56, the differences in total and resistant E. coli 
populations in the treatment group were not significantly different (P > 0.05) from levels from 
the untreated group (Day 28: P = 0.808; Treated 95% CI: 3.877-4.556; Untreated 95% CI: 4.050-
4.735; Day 56: P = 0.775; Treated 95% CI: 4.029-4.722; Untreated 95% CI: 4.044-4.729). 
Similar to 3GC resistant E. coli models, historical ceftiofur usage with Dairy Farm 2 as referent 
did not yield significantly different values from Dairy Farm 1 (P = 0.135, 95% CI: -0.638 – 
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0.086), but did differ statistically from Dairy Farm 3 (P = 0.009, 95% CI: -0.848 – -0.122). In 




Figure 10: The graph displays the difference in growth between total and ceftriaxone-
resistant (4µg/ml) E. coli populations across study day. Decreases in growth difference are 
indicative of higher proportions of ceftriaxone-resistant E. coli. 95% confidence intervals 
are displayed with marginal means. Treated animals are represented by the blue line and 
the untreated group is represented by the red. The vertical green line indicated the first-





 Due to the variability resulting from dairy farm, mixed effect linear regression with three-
way interaction of farm, treatment, and sample day was performed on the arithmetic difference in 
E. coli growth on MAC and MACCEF agars. Figure 11 shows the breakdown of the difference 
of total and resistant E. coli populations by dairy farm. The difference in counts for untreated 
groups remained constant throughout. However, on both study days 6 and 16, the Dairy Farm 3 
treatment group exhibited the smallest difference between total and resistant E. coli populations, 
followed by Dairy Farm 1 and Dairy Farm 2. Figure 11 shows the starting log10 CFU arithmetic 
differences between total and 3GC resistant populations are a single log10 CFU lower on Dairy 
Farm 3 than those same paired differences on Dairy Farms 1 and 2; meaning, dairy 3 has a 
higher proportional level of resistant E. coli than the other 2 locations. The ratio of 3GC resistant 
to total E. coli increases significantly in the treated group compared to the untreated group on 
day 6 on all 3 farms: Dairy Farm 1 (P < 0.0001; Treated 95% CI: 0.912-1.846; Untreated 95% 
CI: 3.851-4.785), Dairy Farm 2 (P < 0.0001; Treated 95% CI: 1.976-2.945; Untreated 95% CI: 
3.859-4.853), and Dairy Farm 3 (P < 0.0001; Treated 95% CI: 0.034-0.991; Untreated 95% CI: 
3.785-4.753). These differences begin to decrease as time progresses. However, the level of 
significance concerning these differences on day 16 (slaughter eligibility) varies greatly by farm. 
The differences observed on day 16 for the treated groups are significantly different from the 
untreated group on Dairy Farm 1 (P = 0.027; Treated 95% CI: 2.728-3.673 Untreated 95% CI: 
3.807-4.740) and 3 (P = 0.008; Treated 95% CI: 2.352-3.321; Untreated 95% CI: 3.892-4.848), 
but are non-significantly different on Dairy Farm 2 (P= 0.081; Treated 95% CI: 3.385-4.366; 
Untreated 95% CI: 3.844-4.812). Because Dairy Farm was included in this model as a fixed 
effect, unlike overall models where it was included as a random effect, historical ceftiofur usage 




Figure 11: The difference in growth between total and ceftriaxone-resistant (4µg/ml) E. coli 
across study day with 95% marginal means is displayed with individual graphs by dairy 
farm. Decreases in difference show increases in the proportion of colony-forming units 
resistant to ceftriaxone. Animals in the treated group are represented by the blue line and 
the untreated group is represented by red. The vertical green line indicates the first-eligible 
slaughter date. CFU, colony-forming unit. 
 
 
4.2 AmpC AND ESBL E. coli DIFFERENTIATION 
 Histograms, resulting from attempts to determine what proportion of 3GC resistant E. 
coli growth possessed AmpC or ESBL resistance, shown in Figure 12 provide a visual depiction 
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of the frequency of different plate types with varying levels of growth. Due to the large number 
of samples that either did not display growth or else displayed colonies in a manner that was too 
numerous to count, the x-axes are displayed as no growth, countable, or overgrown rather than as 
a log10 scale, as with the quantifiable E. coli CFU count data of the previous chapter. The first set 
of histograms displays growth on the 5 agar types without sample enrichment (Figure 12). The 
samples that did display detectable levels of growth all displayed countable amounts. 
Unfortunately, the MACFEP agar did not display any detectable levels of growth for any of the 










Figure 12: The figures above display the quantity of samples (n = 30) with varying amounts 
of growth across the 5 agar plate types when the samples are spiral plated without an 
enrichment step in processing. MAC, plain MacConkey agar; CEF, ceftriaxone (4 µg/mL); 




The extended enrichment period of an 18 hr incubation at 37℃ in MacConkey broth with 
1 µg/mL of ceftriaxone created a large number of agar plates with colony growth too numerous 
to count. This was the case with a majority of samples on every agar type, but MACFEP (Figure 
13). However, the lengthened enrichment produced 6 samples displaying countable levels of 
growth on MACFEP. A shorter enrichment period (3 hrs) with a higher concentration of 
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ceftriaxone in the MacConkey broth (2 µg/mL) yielded similar results to the agar plates without 
sample enrichment (Figure 14). All plates with detectable levels of growth provided countable 
quantities. Unfortunately, even with the increased levels of ceftriaxone in the MacConkey broth 
to reduce selection pressure, the shortened enrichment period did not yield detectable levels of 












Figure 13: The above figures display the frequency of samples ( n = 30) with differing 
amounts of growth when spiral plated to 5 different agars after undergoing an 18 hr 
enrichment in MAC broth with 1µg/mL of ceftriaxone. MAC, plain MacConkey agar; 
CEF, ceftriaxone (4 µg/mL); FOX, cefoxitin (32 µg/mL); FEP, cefepime (16 µg/mL); CCA, 






Figure 14: The figure, broken down by agar type, display the number of samples (n = 30) 
displaying differing levels of growth when spiral plated after a 3 hr incubation in MAC 
broth with 2 µg/mL. MAC, plain MacConkey agar; CEF, ceftriaxone (4 µg/mL); FOX, 




4.3 AmpC/ESBL FECAL E. coli SHEDDING 
  
4.3.1 Descriptive Statistics 
 All collected samples (n = 1197) were spiral plated to CHROM-ESBL agar with 25.98% 
testing positive (n = 311) and 74.02% tested negative. Of the isolates that grew on ESBL agar, 
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310 out of 311 isolates shown to be E. coli via indole testing and MALDI-TOF were tested for 
their phenotypic MIC for 14 antibiotics via microbroth dilution (1 isolate was misplaced and not 
tested). Microbroth dilution showed that 74.52% of isolates had a phenotypic ESBL resistance 
profile, while 25.48% had an AmpC resistance profile. Of the phenotypic ESBL E. coli isolates, 
58.9% were found in the treated group; however, this was not dependent on treatment when 
tested by the Pearson Chi-Square Test (P = 0.923) (Table 6). The number of samples testing 
positive for a phenotypic ESBL resistance profile was maintained consistently across study days 
while decreasing slightly on day 56, but was still dependent upon sampling day with a significant 
Pearson’s Chi-Squared test (P = 0.019) (Table 7). The number of AmpC resistance profiles 
peaked on day 6 and decreased to its lowest level on day 56, similar to the quantitative 3GC E. 
coli counts (Figure 8). The number of isolates exhibiting an ESBL phenotype varied significantly 
(Pearson’s Chi-Squared P = 0.001) by farm with Dairy Farm 3 having the largest number of 

















ESBL 136 95 231 
AmpC 47 32 79 
Total 183 127 310 









0 6 16 28 56 
ESBL 46 49 48 52 36 231 
AmpC 16 28 20 9 6 79 
Total 62 77 68 61 42 310 
The distribution of antimicrobial resistance profile of E. coli isolates grown on CHROM-





Table 8: Frequency of E. coli Isolates Displaying ESBL or AmpC Resistance Profile by 
Dairy Farm 
Phenotype 
Dairy Farm Number 
Total 
1 2 3 
ESBL 74 38 119 231 
AmpC 11 9 59 79 
Total 85 47 178 310 




4.3.2 AmpC/ESBL E. coli Prevalence 
 The prevalence of AmpC/ESBL fecal E. coli shedding over time was modeled (Figure 
16). Because CHROM-ESBL agar was used with enrichment, the selection criteria was biased 
toward the ESBL phenotype. Animals from Dairy Farm 2 had a decreased odds of shedding 
AmpC/ESBL resistant E. coli than Dairy Farm 1 (Odds ratio: 0.508, P = 0.001, 95% CI: 0.343 – 
0.752), but Dairy Farm 3 had an elevated odds of nearly 3.4 times as likely that an animal tested 
positive for shedding E. coli with an AmpC/ESBL phenotype than the referent Dairy Farm 1 
(Odds ratio: 3.35, P < 0.0001, 95% CI: 2.438 – 4.608). Although not significant at all levels, the 
odds of testing positive for an AmpC/ESBL E. coli decreased by sampling day after the first 
treatment sample was taken. The odds on day 6 increased to 1.79 (P = 0.046, 95% CI: 1.010 - 
3.191) among the treatment group compared to the control group, decreasing slightly to 1.316 (P 
= 0.358, 95% CI: 0.0.733 – 2.362) on day 16, decreasing back to even with the referent day 0 on 
day 28 at 0.995 (P = 0.988, 95% CI: 0.549 – 1.807), and improving to better than the referent 
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day 0 on day 56 with an odds of 0.760 (P = 0.387, 95% CI: 0.408 – 1.416). Similar trends were 
observed regarding the prevalence of animals testing positive for shedding an E. coli with an 
AmpC or ESBL form of resistance (Figure 16), while also noting treated animals tended to have 
a higher prevalence (day 0: 28.7% (95% CI: 21.2% – 36.2%), day 6: 40.1% (95% CI: 32.0% – 
48.2%), day 16: 33.9% (95% CI: 25.9% – 41.8%), day 28: 28.6% (95% CI: 21.1% – 36.2%), day 
56: 24.0% (95% CI: 16.6% – 31.5%)) than their control counterparts (day 0: 22.2% (95% CI: 
15.2% – 29.1%), day 6: 23.1% (95% CI: 16.1% – 30.2%), day 16: 23.9% (95% CI: 16.8% – 








Figure 15: The change of prevalence of cows shedding fecal E. coli with an AmpC or ESBL 
resistance phenotype by sample day is shown with the blue line representing the treatment 
group and red showing the control group. The vertical green line represents the first-
eligible slaughter date.  
 
 
 By adding an interaction of treatment, sample day, and dairy farm, the odds of an animal 
shedding an AmpC/ESBL-producing E. coli increased insignificantly to 1.819 (P = 0.297, 95% 
CI: 0.591 – 5.598) on Dairy Farm 2 and the odds of having an animal shedding an E. coli isolate 
with an AmpC or ESBL resistance profile based on the CHROM-ESBL agar selection bias 
increased significantly to 5.346 (P = 0.002; 95% CI: 1.833 – 15.590) on Dairy Farm 3 in 
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comparison to Dairy Farm 1. The odds varied by sampling day after peaking on day 6. The 
greatest odds of an animal testing positive for shedding an E. coli isolate with an AmpC or ESBL 
phenotypic resistance based upon the CHROM-ESBL agar selection criteria was an odds ratio of 
3.291 (P = 0.030, 95% CI: 1.122 – 9.654) on day 6, before steadily decreasing to an odds ratio of 
2.733 (P = 0.071, 95% CI: 0.917 – 8.146) on day 16 and 2.153 (P = 0.177, 95% CI: 0.708 – 
6.548) on day 28 with a slight increase to 2.594 on day 56 (P = 0.096, 95% CI: 0.843 – 7.984). 
The starting prevalence of treated and control cow groups were the same on Dairy Farms 1 
(Treated: Prevalence = 14.7%, 95% CI: 3.9% - 25.4%; Control: Prevalence = 9.8%, 95% CI: 
0.7% – 18.8%) and 2 (Treated: Prevalence = 23.7%, 95% CI: 10.9% – 36.5%; Control: 
Prevalence = 16.6%, 95% CI: 5.4% – 27.8%), while the prevalence of AmpC/ESBL E. coli was 
slightly higher among the treated group than the control on day 0 on Dairy Farm 3 (Treated: 
Prevalence = 47.4%, 95% CI: 32.1% – 62.8%; Control: Prevalence = 39.9%, 95% CI: 24.9% – 
55.0%) (Figure 17). The prevalence increased in both groups on Dairy Farms 1 (Treated: 
Prevalence = 35.8%, 95% CI: 21.4% – 50.3%; Control: Prevalence = 21.5%, 95% CI: 9.1% – 
33.9%) and 3 (Treated: Prevalence = 63.9%, 95% CI: 48.9% – 78.9%; Control: Prevalence = 
39.9%, 95% CI: 24.9% – 55.0%) on day 6, but were maintained the same or decreased on Dairy 
Farm 2 (Treated: Prevalence = 20.4%, 95% CI: 7.8% – 33.0%; Control: Prevalence = 7.7%, 95% 
CI: -0.6% – 16.1%). Advancing to day 16, the prevalence of animals testing positive for 
AmpC/ESBL E. coli began to decrease among both groups from Dairy Farms 1 (Treated: 
Prevalence = 31.7%, 95% CI: 17.6% – 45.9%; Control: Prevalence = 7.2%, 95% CI: -0.6% – 
15.0%) and 2 (Treated: Prevalence = 7.8%, 95% CI: -0.7% – 16.3%; Control: Prevalence = 
10.2%, 95% CI: 0.7% – 19.6%), while remaining stable in the treatment (Prevalence = 61.6%, 
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95% CI: 46.5% – 76.8%) group and increasing in the control (Prevalence = 54.9%, 95% CI: 




Figure 16: The change of prevalence regarding phenotypic AmpC/ESBL-producing 
resistant E. coli by sample day is shown with the blue line representing the treatment group 
and red showing the control. The vertical green line represents the first-eligible slaughter 





4.3.3 Antibiotic Class Resistance  
 The percentage of isolates with resistance to the antibiotics and antibiotic classes on the 
NARMS gram-negative Sensititre™ plate is shown with a breakdown by treatment group (Table 
13). Due to the selection criteria and process, there was no difference in the percentage of 
isolates with resistance to a certain antibiotic or class among treated or untreated animal groups. 
All isolates showed resistance to ampicillin and ceftriaxone with nearly 100% having phenotypic 
resistance to ceftiofur (due to AmpC and ESBL isolates specifically being selected on CHROM-
ESBL media). Furthermore, nearly 27% of all isolates had phenotypic resistance to 
amoxicillin/clavulanic acid and cefoxitin, consistent with an AmpC form of resistance. Of further 
concern were the levels of resistance or decreased susceptibility observed to ciprofloxacin and 
azithromycin, as both quinolones and macrolides are listed among the antibiotics that are 
critically important and of highest priority to human medicine as determined by the WHO 
(2019). While roughly 11% of the isolates selected tested as having phenotypic resistance to 
ciprofloxacin, approximately 25% also had reduced susceptibility with MICs in the range of 0.25 
– 0.50 µg/mL. Furthermore, nearly 11% had reduced susceptibility to azithromycin with 
macrolides not readily used in adult cow dairy production settings. It is important to remember 
these isolates were selected for an ESBL resistance profile and were not selected from the 
general population, so the isolation approach was biased. 
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Table 9: Resistance Distribution by Breakpoint and MIC values 
 
The MIC distribution of isolates and resistance to each antibiotic and antibiotic class are broken down by treatment group. 
The vertical black line represents the Clinical Laboratory Standards Institute or NARMS consensus breakpoint for resistance. 
Numbers in red represent the percentage of resistant isolates at each MIC. Red numbers displayed on a grey background 
indicate the percentage of isolates with a minimum inhibitory concentration greater than that of the plate (right-censored)
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4.3.4 Survival Analysis 
 In Figure 17, the minimum inhibitory concentration for 50% of the isolates (MIC 50) had 
an MIC less than or equal to 8/4 µg/mL of amoxicillin/clavulanic acid, while 90% of isolates fell 
less than or equal to the upper limit of  32/16 µg/mL These trends remained the same regardless 
of treatment, while isolates from the treated group maintained a slightly higher proportion of E. 
coli with higher MIC levels, as the Mantel-Haenszel rate ratio increased slightly to 1.031 (P = 
0.8130, 95% CI: 0.802 – 1.325) in the control group (Figure 18). Both groups had the same MIC 
50 (8 µg/4 µg/mL) and MIC 90 (> 32 µg/16 µg/mL). Dairy Farm 1 had isolates exhibiting a 
greater proportion of lower MICs indicated by a rate ratio of 0.794 (P = 0.0023, 95% CI: 0.685 – 
0.921) above Dairy Farm 2. Dairy Farm 3 had the lowest rate of isolates reaching their MIC and 
a greater proportion of isolates with higher-level MICs than the other 2 dairy farms (Figure 19). 
However, the isolates from each farm still maintained the same MIC 50 (8 µg/4 µg/mL) and 
MIC 90 (> 32 µg/16 µg/mL). Unsurprisingly, there was an increase in the rate at which isolates 
reached their MIC by day at a rate of 1.012 (P = 0.0021, 95% CI: 1.004 – 1.019). It was observed 
that day 6 had a greater proportion of isolates with an increased MIC than days 0 and 16 or day 
28 and 56, which had the lowest proportion of isolates with an MIC of 8 µg/4 µg/mL or greater 
(Figure 20). Isolates from day 6 had an increased MIC 50 over isolates from the other days (16 
µg/8 µg/mL versus 8 µg/4 µg/mL). Isolates from days 28 and 56 had MIC 90s of 32 µg/16 





Figure 17: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to an amoxicillin and 





Figure 18: The Kaplan-Meier survival estimate is shown for all isolates based on treatment regarding the phenotypic MIC to 
an amoxicillin and clavulanic acid combination. The treatment group is represented by the blue line and the untreated red. 





Figure 19: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to an 
amoxicillin and clavulanic acid combination. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy 





Figure 20: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to an 
amoxicillin and clavulanic acid combination. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 
a gray line. The MIC 50 is shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line.
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 Regarding azithromycin, the greatest proportion of isolates in general were inhibited at a 
concentration of 4 µg/mL, which also happens to be the MIC 50 (Figure 21). Meanwhile, the 
MIC 90 was 16 µg/mL. It can be observed from Figure 22 the rate at which isolates from the 
treated and untreated groups reached their MIC was consistent, as indicated by a rate ratio of 
0.983 (P = 0.8864, 95% CI: 0.773 – 1.250) and their MIC 50 and 90 was the same as the isolates 
in general. Yet again, the rate at which isolates were inhibited decreased from Dairy Farm 1 to 
Dairy Farm 2 and Dairy Farm 3, although not at levels of significance (Rate ratio = 0.873, P = 
0.0639, 95% CI: 0.756 – 1.008). The MIC 50 of isolates from Dairy Farm 1 (4 µg/mL) was 
lower than that of isolates from Dairy Farms 2 and 3 (8 µg/mL) (Figure 23). While the MIC 90 
of isolates from Dairy Farm 1 and 3 was 16 µg/mL, the MIC 90 of isolates from Dairy Farm 2 
was greater than the 16 µg/mL limiting concentration of the plate. Dairy Farm 2 also maintained 
the highest proportion of isolates with MICs at or above 4 µg/mL. The rate ratio for isolates 
reaching their MIC with increases in day remained consistent at 1.004 (P = 0.2359, 95% CI: 
0.997 – 1.011). However, the MIC 50 for isolates from day 6 was elevated to 8 µg/mL, while 




Figure 21: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to azithromycin. The 





Figure 22: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
azithromycin. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 





Figure 23: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
azithromycin. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 





Figure 24: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
azithromycin. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 The MIC 50 of all isolates to cefoxitin is 8 µg/mL with an MIC 90 of greater than 32 
µg/mL (Figure 25). While the MIC 50 for both the treatment and control groups were the same at 
8 µg/mL and the MIC90 was greater than 32 µg/mL, there was a greater proportion of isolates in 
the treated group with MICs above 8 µg/mL than the control group (Figure 26). The rate ratio 
increases slightly to 1.164 in the control group (P = 0.2554, 95% CI: 0.896 – 1.513). Similar to 
treatment, the MIC 50 and 90 maintained the same at 8 µg/mL and greater than 32 µg/mL; 
however, the proportion of isolates from Dairy Farm 3 was consistently greater than those of 
Dairy Farm 1 and 2 (Figure 27). This was evidenced by a decrease in the rate ratio of 0.767 
between Dairy Farms 1 and 2 and Dairy Farms 2 and 3 (P = 0.0007, 95% CI: 0.658 – 0.894). 
Much like what was observed in the amoxicillin/clavulanic acid combination, the rate ratio 
slightly increased by sample day at 1.015 (P = 0.0003, 95% CI: 1.007 – 1.023). Results from 
days 28 and 56 mirrored each other as do those of day 0 and 16 with a greater proportion of 
isolates from day 6 having an MIC greater than 4 µg/mL in comparison to the other 4 sampling 
days (Figure 28). The MIC 50 for days 28 and 56 was 4 µg/mL, while the MIC 50 for the other 




Figure 25: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to cefoxitin. The MIC 





Figure 26: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
cefoxitin. The treatment group is represented by the blue line and the control red. The MIC 50 is shown by a dashed, grey line 





Figure 27: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
cefoxitin. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 50 is 





Figure 28: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
cefoxitin. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is shown 
by a dashed, grey line and the MIC 90 is represented by a dashed, black line.
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 In general, 50 and 90% of the isolates had a ceftiofur MIC greater than 8 µg/mL (Figure 
29), which was consistent regardless of treatment, farm, or day (Figure 29 - 37).  While treatment 
was associated with an increased Mantel-Haenszel rate ratio by 1.166 in the control group (P = 
0.6910, 95% CI: 0.546 – 2.492), a rate ratio decrease of 0.786 (P = 0.2753, 95% CI: 0.510 – 
1.212) between Dairy Farms 1 and 2 and Dairy Farms 2 and 3, and a slightly decreased rate ratio 
of 0.993 (P = 0.5315, 95% CI: 0.973 – 1.014) with an increase in sampling day, none of those 




Figure 29: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to ceftiofur. The MIC 





Figure 30: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
ceftiofur. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, grey 





Figure 31: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
ceftiofur. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 50 is 





Figure 32: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
ceftiofur. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is shown 
by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 The MIC 50 for isolates regardless of treatment, dairy farm, or day was 64 µg/mL for 
ceftriaxone with an MIC 90 greater than the 64 µg/mL limitation of the plate (Figure 33).   The 
Mantel-Haenszel rate ratio increased by 1.139 (P = 0.833, 95% CI: 0.833 – 1.557) in the control 
group, but the greatest differences among the groups was observed prior to the MIC of 32 µg/mL 
(Figure 34). The MIC 50 and 90 remained the same for the treated and control group as is the 
general isolates regardless of grouping. The rate ratio decreased between Dairy Farms 1, 2, and 3 
by 0.736 (P = 0.0011, 95% CI: 0.613 – 0.885). The MIC 50 of isolates from Dairy Farms 1 and 3 
was 64 µg/mL with an MIC 90 greater than 64 µg/mL, whereas both the MIC 50 and 90 were 
greater than 64 µg/mL among Dairy Farm 2 isolates (Figure 35). Dairy Farm 2 maintained a 
higher proportion of isolates with an MIC greater than 16 µg/mL in comparison to the other 
dairy farms. The rate ratio relating to day maintained consistent as day increased (Rate ratio = 
1.001, P = 0.8620, 95% CI: 0.992 – 1.009) (Figure 36). Interestingly, isolates from days 6 and 28 




Figure 33: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to ceftriaxone. The 





Figure 34: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
ceftriaxone. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 





Figure 35: The Kaplan-Meier survival estimate is shown for isolates based on farm regarding the phenotypic MIC to 
ceftriaxone. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 50 






Figure 36: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
ceftriaxone. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is shown 
by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 The MIC 50 of isolates to chloramphenicol was 16 µg/mL with an MIC 90 of 32 µg/mL 
(Figure 37). The rate ratio remained the same (Rate ratio = 1.000, P = 0.9981, 95% CI: 0.773 – 
1.366) regardless of treatment or control group with MIC 50 and 90 the same as the isolates in 
general (Figure 38). The Mantel-Haenszel rate ratio decreased by 0.827 (P = 0.0435, 95% CI: 
0.688 – 0.994) between the 3 dairies. Chloramphenicol is the first antibiotic which had a 
different MIC 50 for each of their isolate groups. The MIC 50 for isolates to Dairy Farm 1 was 8 
µg/mL, 16 µg/mL for Dairy Farm 3, and greater than 32 µg/mL for Dairy Farm 2 (Figure 39). 
The MIC 90 for isolates was greater than 32 µg/mL for all farm groups. Increases in sample day 
did not lead to any variance in the rate ratio (Rate ratio = 1.000, P = 0.733, 95% CI: 0.733 – 
1.366). The MIC 50 tended to vary by day while the MIC 90 was greater than 32 µg/mL (Figure 
40). The MIC 50 for isolates from day 0 and 16 was 8 µg/mL, 16 µg/mL for day 6, greater than 




Figure 37: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to chloraphenicol. The 




Figure 38: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
chloramphenicol. The treatment group is represented by the blue line and the control red. The MIC 50 is shown by a dashed, 





Figure 39: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
chloramphenicol. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The 





Figure 40: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
chloramphenicol. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 The MIC 50 for ciprofloxacin among all isolates from the CHROM-ESBL agar was 
0.015 µg/mL with an MIC 90 of 1 µg/mL (Figure 41). The Mantel-Haenszel rate ratio decreased 
insignificantly by 0.801 (P = 0.632, 95% CI: 0.632 -1.015) in the control group, but the main 
difference was observed in the MIC 90. The MIC 50 was 0.015 µg/mL for isolates regardless of 
group, whereas the MIC 90 for isolates in the treated group was 1 µg/mL and greater than 4 
µg/mL in the untreated group (Figure 42). The rate ratio decreased by 0.410 (P = 0.0000, 95% 
CI: 0.347 – 0.486) from Dairy Farm 1 to 2 to 3, but was impacted largely by Dairy Farm 3. The 
MIC 50 for isolates from both Dairy Farm 1 and 3 was 0.015 µg/mL and 0.5 µg/mL for Dairy 
Farm 2; however, this was also the MIC 90 for Dairy 2, whereas the MIC 90 for isolates from 
Dairy Farm 1 was 1 µg/mL and greater than 4 on Dairy Farm 3 (Figure 43). The rate ratio 
slightly decreased by 0.980 (P = 0.0000, 95% CI: 0.974 – 0.986) as day increased. This 
observation was most noticeable among the proportion of isolates with an MIC of 1 µg/mL or 
greater (Figure 44). At these MICs, day 56 had the highest proportion of isolates followed by day 




Figure 41: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to ciprofloxacin. The 





Figure 42: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
ciprofloxacin. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 





Figure 43: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
ciprofloxacin. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 





Figure 44: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
ciprofloxacin. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 For isolates in general, the MIC 50 to gentamycin was 1 µg/mL and the MIC 90 is 2 
µg/mL (Figure 45).  The rate at which isolates from the control group reached their MIC was 
1.543 (P = 0.0002, 95% CI: 1.226 – 1.943) times greater than the treatment group. The MIC 50 
was 1 µg/mL in both treated and control groups, but the MIC 90 was 1 µg/mL for isolates from 
the control group and 2 µg/mL in the treated group (Figure 46). The rate ratio decreased by 0.939 
(P = 0.3339, 95% CI: 0.827 – 1.067) between the 3 dairies. The MIC 50 was the same among 
isolates from all dairy farms at 1 µg/mL (Figure 47). The MIC 90 varied by farm, as Dairy Farm 
2 had an MIC 90 of 1 µg/mL, 2 µg/mL on Dairy Farm 3, and 4 µg/mL on Dairy Farm 1.  The 




Figure 45: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to gentamicin. The 




Figure 46: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
gentamicin. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 




Figure 47: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
gentamicin. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 50 




Figure 48: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
gentamicin. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is shown 
by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 The MIC 50 for nalidixic acid was 4 µg/mL with an MIC 90 greater than 32 µg/mL 
among the isolates in general (Figure 49). The rate ratio was 0.963 (P = 0.7624, 95% CI: 0.755 – 
1.229) for the control group, but isolates from both groups maintain the MIC 50 and 90 of the 
isolates not broken down into categories (Figure 50). Similar to previous antibiotics, the rate 
ratio decreased by 0.715 (P = 0.0000, 95% CI: 0.616 – 0.829) among isolates from Dairy Farms 
1, 2, and 3. This yielded variability in the MIC 50 and 90 of the isolate groupings. The MIC 50 
among isolates from Dairy Farm 1 was 2 µg/mL, followed by Dairy Farm 3 at 4 µg/mL, and 
Dairy Farm 2 at 8 µg/mL (Figure 51).  The MIC 90 for isolates from Dairy Farms 1 and 2 was 16 
µg/mL, but greater than 32 µg/mL on Dairy Farm 3. The MIC 50 among isolates from day 28 
was 2 µg/mL and 4 µg/mL for all other days (Figure 52). Similar to ciprofloxacin, the MIC 90 
for isolates from day 0 and 6 (16 µg/mL) was less than that of isolates from days 16, 28, and 56 
(> 32 µg/mL). This was consistent with the rate ratio decreasing by 0.991 as day increased (P = 




Figure 49: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to nalidixic acid. The 





Figure 50: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
nalidixic acid. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 





Figure 51: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
nalidixic acid. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 





Figure 52: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
nalidixic acid. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 Isolates, regardless of grouping, showed an MIC 50 of 16 µg/mL and MIC 90 of 64 
µg/mL to streptomycin (Figure 53). The rate ratio of the control group did not differ significantly 
from the treatment group (Rate ratio = 0.976, P = 0.8312, 95% CI: 0.778 – 1.224). The MIC 50 
and 90s were both the same as isolates without a breakdown by group (Figure 54). The rate ratio 
decreased by 0.902 (P = 0.1394, 95% CI: 0.787 – 1.034) regarding isolates from Dairy Farm 1 to 
2 and 2 to 3. The MIC 50 for isolates from Dairy Farm 1 was 8 µg/mL, 16 µg/mL on Dairy Farm 
3, and 64 µg/mL on Dairy Farm 2 (Figure 55). This pattern was observed from the concentration 
of 8 µg/mL with isolates from Dairy Farm 2 reaching their MIC at lower rates and higher 
concentrations followed by Dairy Farm 3 and Dairy Farm 1. The rate ratio maintained the same 
as day increased (Rate ratio = 1.005, P = 0.1259, 95% CI:  0.998 – 1.012) due in part to the 
offsetting nature of isolates from days 28 and 56 (Figure 56). The MIC 50 among the groups was 
variable with isolates from day 56 having the lowest MIC 50 at 8 µg/mL, day 28 with the highest 




Figure 53: The Kaplan-Meier survival estimate is shown for isolates regarding the phenotypic MIC to streptomycin. The MIC 





Figure 54: The Kaplan-Meier survival estimate is shown for all isolates based on treatment regarding the phenotypic MIC to 
streptomycin. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 





Figure 55: The Kaplan-Meier survival estimate is shown for isolates based on dairy farm regarding the phenotypic MIC to 
streptomycin. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 





Figure 56: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
streptomycin. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 When tested with sulfisoxazole, both the MIC 50 and MIC 90 of isolates, regardless of 
grouping, was greater than the 256 µg/mL plate limit (Figure 57). The rate ratio slightly 
increased by 1.107 for isolates from the control group, but at a non-significant level (P = 0.5460, 
95% CI: 0.796 – 1.541). The MIC 50 remained greater than 256 µg/mL among both groups 
(Figure 58). Following a similar pattern to other antibiotics to which susceptibility was tested, 
the rate ratio dropped 0.731 (P = 0.0019, 95% CI: 0.599 – 0.890) between Dairy Farms 1 and 2 
and 2 and 3. While the pattern of MIC followed a similar trend among Dairy Farms 2 and 3 with 
MIC 50s greater than 256 µg/mL, Dairy Farm 1 had an MIC 50 of 16 µg/mL (Figure 59).There 
was, again, not a difference among the rate ratio regarding day (Rate ratio = 1.001, P = 0.7870, 
95% CI:  0.992 – 1.001) most likely offset by isolates from day 56. The MIC 50 of isolates from 
days 0 and 56 were 32 µg/mL, while isolates from all other days had an MIC 50 greater than the 
256 µg/mL plate maximum concentration (Figure 60). Isolates from day 28 tended to have the 




Figure 57: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to sulfisoxazole. The 




Figure 58: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
sulfisoxizole. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 




Figure 59: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
sulfisoxizole. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 




Figure 60: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
sulfisoxizole. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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 All isolates from the CHROM-ESBL agar exhibited MICs 50 and 90 greater than the 32 
µg/mL maximum plate concentration for tetracycline (Figure 61). While having a slightly 
reduced rate ratio not of statistical significance in the control group (Rate ratio = 0.923, P = 
0.6860, 95% CI: 0.627 – 1.359), the MIC 50 of isolates from both treated and control animals 
maintained a concentration above 32 µg/mL (Figure 62). However, the rate ratio increased by 
1.406 (P = 0.0017, 95% CI: 1.136 – 1.741) between isolates from Dairy Farm 1 to 2 and 2 to 3, 
which was the first instance of such a pattern among the antibiotics tested. While all isolate 
groups had MIC 50s greater than a concentration of 32 µg/mL, isolates from Dairy Farm 1 had 
the highest MIC concentrations followed by Dairy Farms 2 and 3 (Figure 63). Furthermore, the 
rate ratio was similar among sampling days (Rate ratio = 0.991, P = 0.0853, 95% CI: 0.980 – 





Figure 61: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to tetracycline. The 





Figure 62: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
tetracycline. The treatment group is represented by the blue line and the untreated red. The MIC 50 is shown by a dashed, 





Figure 63: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to 
tetracycline. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and Dairy Farm 3 the green line. The MIC 50 





Figure 64: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to 
tetracycline. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and day 56 a gray line. The MIC 50 is 
shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line.
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 The MIC 50 of isolates to a trimethoprim/sulfamethoxazole combination was 0.12 
µg/2.38 µg/mL with an MIC 90 greater than a concentration of 4 µg/76 µg/mL (Figure 65). With 
a rate ratio consistent among groups (Rate ratio = 0.997, P = 0.9838, 95% CI: 0.779 – 1.278), the 
MIC levels remained the same as the isolates without a breakdown by treatment group (Figure 
66). The greatest discrepancy among the isolates was grouping by dairy farm. This variable was 
associated with a rate ratio of 0.232 (P = 0.0000, 95% CI: 0.190 – 0.284) between Dairy Farms 
1, 2, and 3.  This was reflected in the MIC 50 and 90 metrics, as well. The MIC 50 of isolates 
from Dairy Farms 1 and 2 was 0.12 µg/2.38 µg/mL and 0.25 µg/4.75 µg/mL on Dairy Farm 3 
(Figure 67). A bigger impact was observed among the MIC 90, as isolates from Dairy Farm 1 
had an MIC 90 of 0.25 µg/4.75 µg/mL, 2 µg/38 µg/mL for Dairy Farm 2, and greater than 4 
µg/76 µg/mL among Dairy Farm 3 isolates. The MIC 50 for all sampling days, but day 28 (0.25 
µg/ 4.75 µg/mL), was 0.12 µg/2.38 µg/mL (Figure 68).  The MIC 90 for day 0 was 0.5 µg /9.5 
µg/mL, but was elevated above the 4 µg /76 µg/mL trimethoprim/sulfamethoxazole combination 
for all other sampling days. Day 16 had the greatest proportion of isolates with elevated MICs 
followed by sampling days 28, 56, 6, and 0.  The rate ratio decreased by 0.990 as day increased 




Figure 65: The Kaplan-Meier survival estimate is shown for all isolates regarding the phenotypic MIC to a 
trimethoprim/sulfamethoxazole combination. The MIC 50 is shown by a dashed, grey line and the MIC 90 is represented by a 





Figure 66: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to a 
trimethoprim and sulfamethoxazole combination. The treatment group is represented by the blue line and the untreated red. 





Figure 67: The Kaplan-Meier survival estimate is shown for isolates based on treatment regarding the phenotypic MIC to a 
trimethoprim and sulfamethoxazole combination. Dairy Farm 1 is represented by the blue line, Dairy Farm 2 the red, and 





Figure 68: The Kaplan-Meier survival estimate is shown for isolates based on sample day regarding the phenotypic MIC to a 
trimethoprim and sulfamethoxazole combination. Day 0 is represented by blue, day 6 red, day 16 green, day 28 orange, and 
day 56 a gray line. The MIC 50 is shown by a dashed, grey line and the MIC 90 is represented by a dashed, black line. 
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4.4 E. coli WHOLE GENOME SEQUENCING 
 Select ESBL E. coli isolates were chosen for whole genome sequencing to explore the 
genotypic mechanisms for interesting resistance profiles and to gain insight into mechanisms of 
fluoroquinolone resistance. Of the 15 E. coli isolates, four were from Dairy Farm 1, 5 from Dairy 
Farm 2, and 6 from Dairy Farm 3. Isolates from treated animals accounted for 9 of the 15 
isolates. Isolates were distributed by day with 3 from day 0, four from day 6, 3 from day 16, four 
from day 28, and 1 from day 56. Of selected isolates, 10 had an MIC of 0.5 µg/mL, three had an 
MIC of 1 µg/mL, and 2 had an MIC of 4 µg/mL to ciprofloxacin. Furthermore, 8 had an ESBL 
resistance profile, 1 had an AmpC resistance profile, 1 had an intermediate MIC to cefoxitin, 2 
had an intermediate MIC to amoxicillin/clavulanic acid, had an intermediate MIC to both 
cefoxitin and amoxicillin/clavulanic acid, and 1 had resistance to cefoxitin but was susceptible to 
the amoxicillin/clavulanic acid. Isolates with intermediate susceptibility to cefoxitin or 
amoxicillin/clavulanic acid or with resistance to cefoxitin and susceptibility to clavulanic acid do 
not follow the typical AmpC or ESBL resistance profiles.  
 Resistance genes were determined via ResFinder (Zankari et al., 2012). These sequences 
had a mean contig length of 829 with a median of 185 and a range of 54 – 12,999. Additionally, 
the average N50 of sequenced E. coli isolates was 182,574 ranging from 991 – 507,721 and a 
median of 154,346. The mean genome size was 4,862,414 bp with a range of 4,627,288 bp – 
5,354,275 bp with a median of 4,777,550 bp. One sequence was removed from analysis due to a 
genome size of 8,966,986 and suspected contamination. Of the isolates selected from MACFEP 
agar, four were from Dairy Farm 1 and 2 were from Dairy Farm 3. The blaCTX-M-1 and blaCTX-M-32 
genes were found among isolates from Dairy Farm 1 with 3 isolates also containing the qnrB19 
gene encoding for reduced susceptibility to fluoroquinolones (Table 10). Suspected ESBL E. coli 
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isolates selected for sequencing based upon their ciprofloxacin MIC values displayed a wide 
range of blaCTX-M genes. E. coli isolates from Dairy Farm 1 contained blaCTX-M-1 and -32 within 
cluster 3 of the CTX-M gene family; isolates from Dairy Farm 2 contained blaCTX-M-1, -15, and -65 
among clusters 3 and 14 of the CTX-M gene family; and isolates from Dairy Farm 3 contained 
blaCTX-M-1, -14, -15, -27,-32, -55, and -65 from clusters 3 and 14 of the CTX-M gene family (Zhao & Hu, 
2013). One E. coli isolate from Dairy Farm 3 had both blaCTX-M-14 and blaCTX-M-32, along with 
blaTEM-1A (the sequence from this isolate is thought to contain two bacteria due to an enlarged 
genome size noted above). In total, 2 blaCTX-M gene types were found in isolates from Dairy Farm 
1, 3 from Dairy Farm 2, and 7 from Dairy Farm 3 among only 8, 5, and 8 E. coli isolates with a 
phenotypic ESBL resistance profile sequenced at each location.  
 Of the 6 isolates with a blaCTX-M-1 gene, 5 of them also had a blaTEM-1A gene. Among 
isolates with blaCTX-M-14 or higher (n = 14), 5 also contained blaTEM-1B with 1 containing blaOXA-10.  
Uniquely, an isolate from Dairy Farm 1 with phenotypic cefoxitin resistance and 
ampicillin/clavulanic acid susceptibility contained a blaCTX-M-32 gene, which does not fit the 
typical ESBL resistance profile. The only other resistance gene found in this isolate was tet(A). 
Each dairy farm had E. coli isolates with the fluoroquinolone reduced susceptibility gene qnrB19 
with Dairy Farms 2 and 3 also having isolates with qnrS1. Furthermore, each farm had E. coli 
isolates with the mph(A) gene encoding for macrolide resistance (or, reduced susceptibility given 
the construct of the NARMS panel). Of the 8 isolates containing the mph(A) gene, 7 of them also 
contained the qnrB19 gene, and due to the selection criteria for the isolates, all had a blaCTX-M 
gene. Resistance genes for aminoglycosides, macrolides, phenicols, sulphonamides, rifampicin, 
tetracycline, and trimethoprim were also noted among the isolates. 
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 In total, 13 different E. coli multi-locus sequence types were found among the sequenced 
isolates. Sequence types 10, 56, 301, 2325, and 5727 were found on Dairy Farm 1 with 10, 398, 
683, 7588 on Dairy Farm 2, and 58, 69, 515, 2073, 2325, 5727, 7588, and an unknown sequence 
type on Dairy Farm 3. There were no dominant sequence types among the limited number of E. 
coli sequenced from the farms. However, sequence types 10, 2325, 5727, and 7588 were found 










Table 10: Resistance Genes of Interest among Sequenced E. coli Isolates. 
 
Genes for 3GC and macrolide resistance and reduced susceptibility to fluoroquinolones are shown along with E. coli ST 




4.5 SALMONELLA SHEDDING 
 
4.5.1 Salmonella Descriptive Statistics 
 
 The largest number of Salmonella positive samples were from the first sampling day 
(Table 11). Dairy Farm 3 had the lowest number of Salmonella positive samples with Dairy 
Farms 1 and 2 having nearly the same number of positive samples (Table 11). The number of 
Salmonella positive samples decreased in the subsequent days following day 0 (Table 11). At 
some point during the 3 sampling days, 50% of cattle from Dairy Farm 1, 47.6% of cattle from 
Dairy Farm 2, and 13.8% of cattle from Dairy Farm 3 tested positive for Salmonella shedding. 
Salmonella positive samples were found at similar levels among treated (17.1%) and untreated 
(18.7%) treatment groups (Figure 69). A higher percentage of samples were Salmonella positive 












Table 11: Frequency of Salmonella Growth by Dairy Farm and Sample Day 
Salmonella 
Growth 
Dairy Farm 1 
Dairy Farm 
Number 
Dairy Farm 2 Dairy Farm 3 
Total 
     
Sample Day 0     
Growth 34 32 7 73 
No Growth 48 52 73 173 
Total 82 84 80 246 
     
Sample Day 6     
Growth 12 7 4 23 
No Growth 72 69 75 216 
Total 84 76 79 239 
     
Sample Day 16     
Growth 7 12 4 23 
No Growth 76 65 75 214 
Total 83 77 79 239 








Figure 69: The percentage of samples testing positive and negative across the treated and 
untreated groups are shown above. 
 
 There were four samples positive for phenotypic 3GC resistant Salmonella. Dairy Farm 1 
produced 1 3GC resistant Salmonella positive sample on day 0. Dairy Farm 2 did not test 
positive for any 3GC resistant Salmonella samples. Dairy Farm 3 tested positive for 1 3GC 
resistant Salmonella sample on day 0 and 2 on day 6. A positive sample from day 6 was from the 
same animal producing the 3GC resistant Salmonella on day 0. All 3GC resistant Salmonella 
positive samples were collected from treated animals; however, this was not significant based 




4.5.2 Prevalence of Salmonella Shedding 
Salmonella prevalence via growth on BGA did not yield statistically significant 
differences between the treated and untreated groups across time (Figure 70). The treated group 
(cows with metritis) had a greater probability of being Salmonella positive than the untreated 
group on day 0 (P = 0.058, 95% CI = -0.037 – 2.140). The prevalence of Salmonella in the 
treated group decreased on day 6, but was not different from the untreated group. (P = 0.463, 
95% CI = -1.812 – 0.824) and remained at similar levels on day 16, which was omitted for 
collinearity. These differences were not statistically significantly different from the treatment 
group for any of the 3 days due, in part, to robust marginal mean confidence intervals. A large 








Figure 70: The probability of Salmonella growth across sampling day is shown above with 
the treated group represented by the blue line and the untreated group represented by the 
red line accompanied by 95% confidence intervals with marginal means. 
 
 
Dairy Farms 1 and 2 had higher probability of samples from both treated and untreated 
groups testing Salmonella positive than those from Dairy Farm 3 (Figure 71). Both dairy farms 
displayed decreases in the probability of being Salmonella positive as time progressed; however, 
differences were not observed between treated and untreated groups. The prevalence observed in 
the treated group of Dairy Farm 1 started at 48.3% (95% CI = 32.7% – 63.8%) before decreasing 
to 9.4% (95% CI = 0.6% – 18.2%) on day 6 and 4.9% (95% CI = -1.7% – 11.4%) on day 16. The 
untreated group had a starting prevalence of 35.4% (95% CI = 20.7% – 50.0%) before decreasing 
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to 18.7% (95% CI = 6.9% – 30.5%), and 11.5% (95% CI = 2.0% – 20.9%). These numbers are 
similar to what was observed on Dairy Farm 2 where the treated group started with a prevalence 
of 49.6% (95% CI = 34.0% – 65.3%) prior to decreasing to 4.4% (95% CI = -1.6% – 10.5%) and 
increasing slightly to 14.5% (95% CI = 3.5% – 25.5%) on day 16.  The untreated group on the 
same farm began with a prevalence of 28.9% (95% CI = 15.2% – 42.6%), then decreased to 
12.9% (95% CI = 2.4% – 23.3%) on day 6 and was at 15.7% (95% CI = 04.2% – 27.2%) on day 
16. The treated group of Dairy Farm 3 began with the lowest prevalence of the 3 groups at 6.5% 
(95% CI = -2.2% – 15.3%) prior to dropping to 3.3% (95% CI = -3.0% – 9.6%) and remaining at 
that level at day 16 (95% CI = -3.0% – 09.6%). The prevalence in the untreated group started at 
12.0% (95% CI = 0.4% – 23.6%) before reducing to 6.2% (95% CI = -2.3% – 014.8%) on day 6 






Figure 71: The probability of Salmonella growth is displayed by individual farm with the 
blue line representing treated animals and a red line representing untreated. 95% 
confidence intervals with marginal means are also shown. 
 
 
4.6 SALMONELLA WHOLE GENOME SEQUENCING 
 To further evaluate the Salmonella isolates, all isolates displaying phenotypic 3GC 
resistance (n = 4) were sequenced and all (n = 119) but 1 isolate, selected from the BGA plates 
were sequenced (1 was not located in storage). SeqSero (http://www.denglab.info/SeqSero) was 
used to determine Salmonella serotypes and resistance genes were determined via ResFinder 
(Zankari et al., 2012). The average contig length was 230 base pairs (bp) with a median of 100 
and range between 58 and 5154 base pairs. The average N50 of the sequences was 358,667 bp 
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with a median of 372,009 and a range of 3205 – 703,778 bp. The mean genome size was 
4,809,808 with a range of 4,560,150 – 7,348,638 bp and a median of 4,760,431. 
 Each dairy farm contained multiple Salmonella serotypes, but different serotypes 
dominated within the general population (Table 12). Dairy Farm 1 had four serotypes and 1 
unidentified, but serotypes Anatum and Montevideo accounted for 82.14% of the Salmonella 
sequenced on this farm. Dairy Farm 2 had many more serovars, as eleven were present with 4 
samples having serotypes that were undetermined. Serovars Cerro, Meleagridis, and Muenster 
were found at a higher frequency. These serotypes accounted for 67.35% of the isolates 
sequenced from Dairy Farm 2. Only 12 serotypes were found within the general Salmonella 
population on Dairy Farm 3, although a third serovar was found upon evaluation of an isolate 
displaying phenotypic 3GC resistance. The dominant serovar on this dairy farm was Meleagridis, 
which accounted for 92.86% of the serovars within the general population.  
 Serovar dominance varied based upon the sampling season. Montevideo accounted for 
85.0% of the 20 isolates in the spring, but only 44.4% of the four serovars isolated from fall 
samples on Dairy Farm 1. Similarly, serovar Cerro accounted for 85.71% of the 12 Salmonella 
serovars isolated from spring samples, while serovar Cerro only accounted for 22.9% of the 11 
serovars isolated from fall samples followed by Meleagridis (20.0%) and Muenster (17.1%) on 
Dairy Farm 2. No samples tested positive for Salmonella during the spring on Dairy Farm 3, but 
serovar Meleagridis accounted for 92.9% of the Salmonella serovars isolated from fall and total 
Salmonella serovars on Dairy Farm 3. It is not surprising a greater percentage of total Salmonella 
was isolated from fall samples (Dairy Farm 1: 64.3%, Dairy Farm 2: 71.4%, and Dairy Farm 3: 
100.0%) because more samples were taken in the fall sampling season; also, the literature 
supports a higher prevalence at the end of warmer months in summer. 
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 While samples from Dairy Farm 2 had the highest number of serovars, Dairy Farms 1 and 
2 had the highest number of animals testing positive for multiple serovars across the study days. 
Each of farms 1 and 2 had four and Dairy Farm 3 had 1. Only 1 animal was positive for 3 
serovars and it was located on Dairy Farm 2. It is worth noting there may be more animals 
harboring multiple Salmonella serovars, as only 1 isolate from each positive sample was 
sequenced. Therefore, any animal determined to harbor multiple serotypes was because a 
different serotype was detected in either a sample from another sampling day in the study or 
because a different serotype was detected in an isolate from a plain BGA plate in comparison to 














Table 12: Frequency of Salmonella Serotypes by Dairy Farm 












Anatum 0 (0.00%) 13 (36.11%) 13 (23.21%) 
Cerro 1 (5.00%) 2 (5.56%) 3 (5.36%) 
Meleagridis 2 (10.00%) 4 (11.11%) 6 (10.71%) 
Montevideo 17 (85.00%) 16 (44.44%) 33 (58.93%) 
N/A 0 (0.00%) 1 (2.78%) 1 (1.79%) 
Serovar Total: 4 20 (35.71%) 36 (64.29%) 56 (47.06%) 
Dairy 
Farm 2 
Agoueve 0 (0.00%) 1 (2.86%) 1 (2.04%) 
Cerro 12 (85.71%) 8 (22.86%) 20 (40.82%) 
Derby 0 (0.00%) 1 (2.86%) 1 (2.04%) 
Mbandaka 0 (0.00%) 1 (2.86%) 1 (2.04%) 
Meleagridis 0 (0.00%) 7 (20.00%) 7 (14.29%) 
Montevideo 0 (0.00%) 1 (2.86%) 1 (2.04%) 
Muenster 0 (0.00%) 6 (17.14%) 6 (12.24%) 
N/A 0 (0.00%) 4 (11.43%) 4 (8.16%) 
Oranienburg 0 (0.00%) 1 (2.86%) 1 (2.04%) 
Panama 1 (7.14%) 1 (2.86%) 2 (4.08%) 
Typhimurium 0 (0.00%) 1 (2.86%) 1 (2.04%) 
Virginia 1 (7.14%) 3 (8.57%) 4 (8.16%) 
Serovar Total:11 14 (28.57%) 35 (71.43%) 49 (41.18%) 
Dairy  
Farm 3 
Meleagridis 0 (0.00%) 13 (92.86%) 13 (92.86%) 
Montevideo 0 (0.00%) 1 (7.14%) 1 (7.14%) 
Serovar Total: 2 0 (0.00%) 14 (100.00%) 14 (11.76%) 
 Serovar Total: 13 34 (28.57%) 85 (71.43%) 119 (100%) 
The number of different Salmonella serovars in the general sample population per dairy 
farm are displayed, along with sevovar frequency. 
 
 
 Third-generation cephalosporin resistance was detected in 5 isolates from 5 samples in 
four animals. Isolates from the same sampling day showing beta-lactam resistance on both BGA 
and BGACEF agar are only included once in Table 13 to avoid overinflating the number of 
samples with 3GC resistance. All Salmonella isolates with 3GC resistance contained the blaCMY-2 
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gene. Only one isolate was shown to possess the blaCMY-2 gene in a sample not showing 
phenotypic resistance. This isolate also had genotypic resistance to aminoglycosides, 
sulfonamides, streptomycin, and trimethoprim. It is not surprising that the dairy farm with the 
highest usage of ceftiofur also harbored the highest number of samples with 3GC resistant 
Salmonella, whether phenotypic or genotypic resistance. 
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Anatum 1 100% N/A blaCMY-2 N/A N/A N/A 
Dairy 
Farm 2 
N/A N/A N/A N/A N/A N/A N/A N/A 
Dairy 
Farm 3 
Meleagridis 3 66% 
N/A blaCMY-2 N/A N/A N/A 
N/A blaCMY-2 N/A N/A N/A 
aadA2 blaCMY-2 sul2 strA, strB dfrA12 
Newport 1 100% N/A blaCMY-2 N/A N/A N/A 
Sequenced Salmonella displaying phenotypic or genotypic beta-lactam resistance are displayed, along with serotype, 





5.1 FECAL E. coli  
 The results of this study highlight the impact of a two-dose treatment of CCFA for 
metritis on the dynamics of total and 3GC resistant E. coli populations over time. The data have 
shown that a 13-day withholding period from the final administration of a two-dose treatment of 
CCFA for metritis may be insufficient to ensure that 3GC resistant E. coli populations return to 
baseline levels in all treated cattle and thus mitigate the risk of these organisms “escaping from 
the farm” as illustrated in the risk assessment framework of Hurd et al. (2004, 2006). It has 
previously been reported that at the aggregate level, dairy farms employing ceftiofur are 25 times 
more likely to have detectable E. coli with reduced susceptibility to ceftriaxone (Tragesser et al., 
2006). The fact that all 3 dairy farms in our study harbored 3GC resistant E. coli is consistent 
with earlier work that found 92% of tested herds had ceftriaxone-resistant E. coli and 88% of 
tested herds used ceftiofur (Heider et al., 2009). While the number of samples containing 
resistant E. coli varied, each dairy farm had detectable E. coli with phenotypic resistance to 
ceftriaxone. As expected, based on work by Lowrance et al. (2007), Kanwar et al. (2008) and 
Singer et al. (2014), the total E. coli count in cattle decreased significantly following treatment 
with CCFA, but rebounded over time (Figure 6). The distribution of E. coli growth on MAC agar 
is likely right truncated to do restrictions regarding our colony counting methodologies. 
Furthermore, 3GC resistant E. coli populations were significantly higher in treated groups 
than untreated groups on day 6 (Figure 8). This was observed even with large numbers of 0 
counts and remained after the large 0 counts (Figure 4) were imputed to distribute those values 
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across levels below detection (Figure 4). It seemed implausible that the distribution contained 
true 0 values below the limit of quantification for the assay (i.e., that the 0 values were truly 0), 
given the cows are raised in common shared space. A number of techniques have been deployed 
and evaluated to deal with this problem (Boyer, Hanson, & Singer, 2013). While not significant 
(P<0.05) overall, with robust marginal mean confidence intervals, treated animals harbored 
higher levels of 3GC resistant E. coli than untreated groups on study day 16. While there were a 
few samples with 3GC resistance among control animals (75th percentile = 0), there remained 
elevated levels in treated cows (75th percentile = 2.603 log10 CFU). It has been suggested such 
increases in total 3GC resistant E. coli counts may be due to an increased ability to detect them 
due to the suppression of total growth (Singer, Patterson, & Wallace, 2008); however, at day 16 
total E. coli CFU (MAC) did not differ significantly between groups. The probability of 3GC 
resistant E. coli increased in cows with parities above 3. This may be a result of these animals 
having been repeatedly treated with or had exposure to CCFA throughout their life. 
When evaluating the arithmetic difference in total and 3GC resistant E. coli growth, 
higher proportions of colonies were resistant to 3GCs in the treated groups on days 6 and 16 than 
among untreated groups (Figure 10). However, the level of significance regarding these counts 
varied by dairy farm (Figure 11). This may be a result of increased 3GC resistant E. coli 
populations in environmental manure accumulating based on higher levels of historical ceftiofur 
usage. Due to the significance of historical usage in impacting levels of 3GC resistant E. coli, we 
hypothesize such historical dairy features play a role in expanding 3GC populations in the 
environment. This helps sustain a higher proportion of 3GC resistant E. coli in the gut of 
untreated animals, and leads to an increased time for resistant bacterial populations to return to 
pre-treatment levels following a two-dose CCFA treatment for metritis. However, due to our 
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small environmental sampling size, limited number of farms, and historical usage data consisting 
of only the year prior to the start of the study, further work is required to properly evaluate the 
role of historical usage.  
It is also important to note the variation of systemic ceftiofur usage. A quarter of the 
historical usage on Dairy Farm 2 was intramammary, which would be less likely to affect levels 
of 3GC resistance among fecal E. coli. On the other hand, Dairy Farm 1 did not use any 
intramammary ceftiofur and a smaller portion of ceftiofur use on Dairy Farm 3 was 
intramammary which helps explain their elevated 3GC resistance among fecal bacteria.  The 
currently observed differences in ceftiofur administration across multiple farms may be a result 
of other variables not considered for the purpose of our study, such as the incidence of foot rot 
and bovine respiratory disease, or the severity or form of metritis at the time of diagnosis. 
Additionally, since rates of treatment were collected from farm records and therefore were farm-
level reported, actual treatment rates may differ from calculated values. Unfortunately, we were 
unable to aggregate historical usage data for additional antibiotics used on the farms in the 
previous year. 
One might imagine farms using ceftiofur at elevated rates may be using greater amounts 
of other antibiotics, but this is far from certain and an important area to consider in future 
research. Across all dairy farms, the proportion of total and 3GC resistant populations returned to 
pre-treatment levels by days 28 and 56.  It has been hypothesized that bacteria with 3GC 
resistance are less able to compete with general E. coli populations after the removal of the 
antibiotic selection pressure due to the fitness cost of harboring a functional AmpC blaCMY-2 or 
another ESBL gene (Lowrance et al., 2007; Singer, Patterson, & Wallace, 2008), thereby 
explaining their decline post-treatment.   
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These results suggest a 13-day withholding period following CCFA treatment does not 
universally provide adequate time to allow for 3GC resistant populations of enteric E. coli to 
return to baseline levels. While these changes in 3GC resistant E. coli populations may seem 
inconsequential when evaluating a single gram of feces, they are not when considering the many 
kg of fecal matter produced by the animal. There are well-documented instances of beef being 
contaminated with AMR Enterobacteriaceae, based on meat samples taken in butcher shops 
(Singer, Patterson, & Wallace, 2008) and grocery stores (Schroeder et al., 2003; Johnson et al., 
2005; Vogt & Dippold, 2005) and with potential transmission from such sources to the human 
population (Angulo, Nargund, & Chiller, 2004). We hypothesize, based upon our findings, there 
may be an increased risk posed to public health should an animal be culled at the current 13-day 
withholding period due to elevated levels of 3GC resistant fecal E. coli. Studies determining 
slaughter withholding periods tend to be performed in healthy animals (Witte et al., 2011); 
however, the pharmacokinetics and pharmacodynamics are likely to vary between healthy and 
clinically ill populations (Kissell et al., 2015) due to pathophysiological changes associated with 
illness. Our study provides insight into the fluctuation of bacterial populations in ill animals 
undergoing treatment versus their healthy untreated counterparts. While E. coli were not typed as 
commensal or pathogenic, because E. coli is an indicator species for gram-negative bacteria, 
these findings may model patterns that could be observed in other enteric gram-negative 
pathogens such as Salmonella spp. (Lowrance et al., 2007; Cummings, Aprea, & Altier, 2014).   
Further studies should be performed to evaluate the effects of such treatment on 3GC 
resistance and shedding of Salmonella, along with quantitative polymerase chain reactions 
(qPCR) or shotgun metagenomics to evaluate the absolute and relative change in resistance 
genes found within samples across time. Based on these data, an additional withholding period 
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prior to slaughter would be advisable on farms with a long-standing history of cephalosporin use, 
or with known moderate to high levels of 3GC resistance, in order to reduce the risk to public 
health and improve antimicrobial stewardship. While a decade ago when ESBLs had not yet 
been reported in the U.S., Daniels et al. reported the frequency with which ceftiofur is 
administered does not impact levels of commensal E. coli containing the blaCMY-2 gene at the 
herd-level (2009); however, discrepancies likely exist regarding genotypic and phenotypic AMR 
indicators based upon the level of antibiotic usage on dairy farm (Davis et al., 2011). Bacteria 
from dairy farms with low levels of antibiotic usage may still harbor bacteria with genetic 
elements encoding for resistance, but not at levels high enough to detect phenotypic resistance; 
meanwhile, the opposite may be observed on farms with high levels of antibiotic usage (Davis et 
al., 2011). 
 
5.2 AmpC AND ESBL E. coli DIFFERENTIATION 
 The purpose of plating selected samples grown on MACCEF and CHROM-ESBL agar to 
the 5 different agar types (plain and agar containing ceftriaxone, cefoxitin, cefepime, or 
ceftriaxone with clavulanic acid at CLSI breakpoints) was to determine the proportion of isolates 
displaying phenotypic resistance to ceftriaxone had AmpC or ESBL phenotypic forms of 
resistance. Cefoxitin resistance has been shown to be highly correlated with the blaCMY-2 AmpC 
gene while cefepime resistance highly correlated with the blaCTX-M ESBL gene (Davis et al., 
2015). Unfortunately, even with a subset of samples that displayed growth on both MACCEF 
and CHROM-ESBL agars, we were unable to determine the proportion of 3GC resistance 
attributed to AmpC or ESBL resistance profiles via this method, regardless of enrichment.  
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 Samples processed without incubation produced countable quantities of growth among all 
plates displaying growth at detectable limits; however, MACFEP plates did not yield detectable 
amounts of growth (Figure 12). When samples were enriched in MAC broth with 1 µg/mL of 
ceftriaxone for 18 hrs, 6 MACFEP plates yielded quantifiable amounts of E. coli growth, but a 
majority of growth on all other agar types yielded a growth of colonies that were too numerous 
to count (Figure 13). In parallel with the children’s story “Goldie Locks and the Three Bears”, if 
no enrichment is not enough and an extended period of enrichment is too much, some 
enrichment should be just right. This was not the case, as a 3 hour incubation in MAC broth with 
2 µg/mL of ceftriaxone yielded MACFEP agar plates without detectable levels of E. coli growth, 
while other agar types yielded a majority of plates with countable levels of growth, as with the 
non-enriched samples.  
 The idea of increasing the concentration of ceftriaxone in the broth was brought about to 
remove bacteria with an MIC below 2 µg/mL. This was to reduce the competition for broth 
resources from undesired bacteria. The reduced enrichment time was to provide the bacteria in 
lower quantities ample time to divide without providing enough time for more populous bacteria 
to grow to levels beyond quantification, thereby reducing the chance of plates with colonies too 
numerous to count. Multivariate regression modeling determined there were no differences in the 
level or lack of growth among each of the agar plates without enrichment or with 3 hrs of 
enrichment (P = 0.270) (Figure 15). The extended enrichment period with 1 µg/mL of 
ceftriaxone displayed elevated levels of growth among each of the 5 agar plates (P < 0.0001). 
  We believe we are the first to attempt to determine the phenotypic proportion of AmpC 
and ESBL resistance mechanisms among a population with phenotypic 3GC resistance. Previous 
work by Mollenkopf et al. (2012) used MacConkey agar with cefepime and cefoxitin to estimate 
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the prevalence of ESBL and AmpC E. coli shedding with PCR to detect blaCTX-M or blaCMY-2 
genes. Davis et al. (2015) used plain MacConkey agar and MacConkey agar with ceftiofur, 
cefoxitin, or cefepime to screen for AmpC and ESBL E. coli in order to select isolates and use 
PCR to screen for blaCTX-M and blaCMY-2 genes. However, neither of these studies sought to 
determine the phenotypic proportion of AmpC or ESBL E. coli through colony counting 
methodologies. This may be a result of E. coli housing the blaCTX-M gene for the ESBL resistance 
profile not being discovered in American agriculture until 2010 (Wittum et al., 2010). Another 
possible reason, as our results indicate, is ESBL E. coli are found in low levels requiring 
enrichment to coax to detectable levels. Each way in which ESBL E. coli were detected in our 
study involved an 18 hour enrichment period in MAC broth containing ceftriaxone. While 
proportions have not been determined based upon colony count data, microbroth dilution data 
from plates determining the phenotypic MIC of gram-negative bacteria can be utilized to 
determine the proportion of AmpC and ESBL E. coli within the selected isolates. This would be 
based upon the MIC of isolates to a second-generation cephalosporin (cefoxitin) and the addition 
of a beta-lactam inhibitor (clavulanic acid). Due to resistance to these compounds, it can be 
inferred the E. coli isolate has an AmpC resistance profile. Resistance to a third-generation 
cephalosporin without resistance to a second-generation cephalosporin or a pairing with a beta-
lactamase inhibitor would indicate an ESBL. Unfortunately, a fourth-generation cephalosporin is 
not included on such gram-negative plates to further support the presence of an isolate containing 
an ESBL resistance profile. Additionally, whole genome sequencing could provide further 





5.3 AmpC/ESBL FECAL E. coli SHEDDING  
5.3.1 Descriptive Statistics 
Through the CROM-ESBL agar selection process, nearly 26% of samples tested positive 
for E. coli that should have had an ESBL resistance profile; however, only 74.52% of those 
isolates showed a phenotypic ESBL E. coli resistance profile (resistance to ampicillin and 
ceftriaxone but susceptible to cefoxitin and amoxicillin/clavulanic acid) with the others showing 
an AmpC phenotypic resistance profile (resistance to ampicillin, ceftriaxone, cefoxitin, and 
amoxicillin/clavulanic acid combination). Resistance to cefoxitin is highly correlated with an 
AmpC resistance genotype (Davis et al., 2015). While nearly 2/3 of phenotypic ESBL E. coli 
isolates were from treated cows, ESBL versus AmpC E. coli was not dependent on the animal 
being treated. This is most likely a result of our enriching the samples to make sure we identified 
as many ESBL E. coli positive samples as possible and not counting the CHROM-ESBL agar 
plates. While we previously tried to perform this with selective MacConkey agar, but were 
unable to do so due to low populations of ESBL E. coli, and were further unable to accomplish 
this due to CHROM-ESBL agar not exclusively identifying the ESBL resistance profile. 
 
5.3.2 E. coli Antibiotic Class Resistance 
Co-selection of antimicrobial resistance can happen due to resistance genes being 
contained on the same mobile genetic elements. These genes are then spread via the horizontal 
transfer of plasmids, transposons, and integrons between bacteria (Bennett, 2008; Tacão et al., 
2014). Therefore, selection for resistance to an antibiotic can occur without the use of that 
antibiotic. Mechanisms for the ESBL resistance profile are not an exception, as the blaCTX-M gene 
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is commonly plasmid-mediated (Livermore et al., 2007). It is important to remember 
characterized isolates in our study were selected through a selective process using CHROM-
ESBL agar, are not representative of the total population, and samples with plates displaying no 
growth were specified as negative.  
The isolates characterized to generate microbroth dilution data were not those of the 
general population, but of a subpopulation of E. coli representing a resistance profile found in 
smaller numbers within the overall population. The number of antibiotic classes to which an 
isolate was resistant in the presented model was first dependent upon a sample producing an 
isolate on the selective agar, which automatically classified the isolate to have resistance to 2 or 
more antibiotic classes. Selecting isolates from the general E. coli population may yield different 
results.  
In addition to the typical ESBL resistance profile, co-resistance has been observed to 
aminoglycosides, tetracycline, quinolones, and sulfamethoxazole/trimethoprim in E. coli isolates 
(Cantón and Coque, 2006) from medical centers (Winokur et al., 2001[b]; Morosini et al., 2006), 
aquatic systems (Tacão et al., 2014; Bajaj et al., 2015), companion animals (Moreno et al., 
2008), and dairy cows (Schwaber et al., 2005; Mann et al., 2011). While our study found co-
resistance among aminoglycosides and tetracycline, co-selection was also observed among 
phenicols and sulfonamides, but not quinolones or sulfamethoxazole/trimethoprim. However, 
there was a connection regarding reduced susceptibility to quinolones. It has been shown ESBL 
E. coli isolates from beef farms were less likely to have resistance to aminoglycosides, 
quinolones, and trimethoprim/sulfamethoxazole in comparison to those on farms with dairy and 
beef cattle (Schmid et al., 2013). Alternatively, while there were differences among co-resistance 
of ESBL E. coli from dairy and beef cattle, isolates with AmpC resistance profiles were co-
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resistant to streptomycin, sulfamethoxazole, and tetracycline from both groups, although isolates 
from beef sources were resistant to ampicillin and chloramphenicol (Tragesser et al., 2006; 
Lowrance et al., 2007).  
Our results based upon Kaplan-Meier curves and Mantel-Haenszel rate ratios, gave 
insight into how the variables of treatment, farm, and day impact the MIC values of isolates 
selected from CHROM-ESBL agar, regardless of AmpC and ESBL resistance phenotype, and 
the concentration at which isolates from those groups reach their MIC. The MIC of isolates was 
significantly higher as for Dairy Farm 1 in comparison to Dairy Farm 2, which was lower than 
Dairy Farm 3 for amoxicillin/clavulanic acid (Figures 17-20), cefoxitin (Figures 25-28), ceftiofur 
(Figures 29-32), chloramphenicol (Figures 37-40), ciprofloxacin (Figures 41-44), gentamicin 
(Figures 45-48), streptomycin (Figures 53-56), and trimethoprim/sulfamethoxazole (Figures 65-
68) while moving upward for all other tested antibiotics (Figures 21-24, 33-36, 49-52, 57-60), 
but tetracycline Figures (61-64). Tetracycline was significant in the opposite direction. This may 
be due to Dairy Farm 1 using lower order antibiotics, like tetracycline, more frequently than the 
other 2. The MIC of isolates increased each time day increased for amoxicillin/clavulanic acid, 
cefoxitin, and trimethoprim/sulfamethoxazole (Figures 20, 28, and 68), but rates decreased as 
day increased for naladixic acid (Figure 52). The only statistical difference among the antibiotics 
with regards to treatment group was the control group had a greater proportion of isolates with 
smaller MICs to gentamicin than the treated group (Figure 46).   
Concerning trends were observed regarding MICs of the fluoroquinolone, ciprofloxacin, 
with multiple isolates (n = 36) testing as resistant. Isolates from later sampling days tended to 
have higher MICs (Figure 44), while isolates from Dairy Farm 2 had a top MIC of 0.5 µg/mL, 
Dairy Farms 1 and 3 had isolates with MICs greater than 4 µg/mL. Particularly interesting, 
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reduced susceptibility to quinolones as conferred by the qnr genes typically allows the bacteria 
greater opportunity to develop the gyrase mutation under reduced antibiotic concentration. This 
was observed on Dairy Farms 1 and 3 where there were several isolates with resistance and 
reduced susceptibility. However, Dairy Farm 3 did not have any isolates with an MIC about 0.5 
µg/mL (of the isolates tested); meaning they likely had fewer bacteria with qnr genes. Seeing 
quinolone resistance in isolates from this setting is concerning due to the fluoroquinolones not 
being used in dairy cows past 20 months of age. If this resistance form were to persist within 
animals and the environment and be co-selected for with ESBL isolates, as previous studies have 
shown, this could create a dangerous resistance combination of 2 already serious forms of 
resistance. Both third (and higher) generation cephalosporins and fluoroquinolones are deemed 
critically important of highest priority to human medicine (WHO, 2019).  Furthermore, the 
finding of macrolide resistance/reduced susceptibility via the mphA gene is concerning, 
especially when found in conjunction with quinolone reduced susceptibility and 3GC resistance 
genes. Macrolides are commonly used in feedlot production settings, but not in dairy production. 
Bacteria with such resistance may be coming from nearby feedlot settings in the region. 
Unfortunately, if now found in dairy farm settings in the region and associated with a 3GC 
resistance gene, macrolide resistance may become inadvertently selected for through 3GC use.  
One should resist drawing too much from the results of treatment and day because of the 
inability to interact variables in these latter analyses. The interaction of treatment and day is 
biologically significant due to the rate at which the antibiotic is absorbed, metabolized, and 
excreted by the animal. However, the results relating to dairy farm further provide insight into 1 
of the themes spanning this project. Isolates tested for their phenotypic MIC to all antibiotics, 
with exception to tetracycline, saw greater proportions of isolates with higher MICs on Dairy 
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Farm 3 followed by Dairy Farm 2 and Dairy Farm 1. This means Dairy Farm 3 tended to have a 
higher proportion of isolates with elevated MICs followed by Dairy Farm 2 and Dairy Farm 1. 
The exception of tetracycline could mean it is a preferred drug of use on Dairy Farm 1 whereas 
other dairy farms may use higher order antibiotics more frequently. This may simply be due to 
the selection bias of the CHROM-ESBL agar selection protocol. Using isolates from the general 
E. coli population may show Dairy Farm 2 is still the best performer and our results are a 
characteristic of the isolates specific to the CHROM-ESBL isolation process. Nonetheless, this 
highlights the continued importance of the dairy farm environment and farm management in the 
mitigation of antimicrobial resistance and stewardship of antimicrobial usage. 
 
5.4 E. coli WHOLE GENOME SEQUENCING 
The variant of the ESBL blaCTX-M gene differs in dominance depending on geographical 
location. Studies in both the Netherlands (Gonggrijp et al., 2016) and the Nile Delta region of 
Egypt (Braun et al., 2016) identified blaCTX-M-1 and blaCTX-M-15 as the dominant ESBL genes, while 
a study in the Republic of Korea (Tamang et al, 2013) identified blaCTX-M-14 and blaCTX-M-32 as the 
dominant ESBL genes. While blaCTX-M-1 and blaCTX-M-32 made up 60% of the blaCTX-M genes found 
in our study, we also found 5 other types of blaCTX-M genes. However, we cannot say these are the 
dominant blaCTX-M genes in our study due to only sequencing 20 E. coli isolates. The blaCTX-M-32 
gene was the first blaCTX-M gene found in the panhandle of Texas (Cottell et al., 2013). Our study 
identified 7 different blaCTX-M genes in the region with each location testing positive for multiple 
types. However, not long after ESBL E. coli harboring a blaCTX-M gene was discovered in Ohio, 
each of 5 farms testing positive for blaCTX-M genes tested positive for only 1 form of the gene 
suggesting a herd homogeneity (Mollenkopf et al., 2012). This team also noted blaCTX-M-1, -14, and 
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-15 were the most common (Mollenkopf et al., 2012), all of which were found on our sequenced 
samples. Similar results were recently observed in Pennsylvania with clonal E. coli with 3GC 
resistance being indistinguishable within the region (Salaheen et al., 2019). However, our results 
indicate the broader dissemination of blaCTX-M genes since first discovered in American 
agriculture in 2010 (Wittum et al., 2010). Additionally, with a small number of E. coli 
sequenced, the high diversity among sequence types, along with resistance genes, does not 
suggest 1 or 2 clonal genes within the region or on a farm. This may also be a result of animal 
movement on and between large farms in this region allowing for easier spread of blaCTX-M genes 
throughout the region. 
Consistent with elevated levels of 3GC resistant E. coli counts and increased prevalence 
of phenotypic ESBL and MDR E. coli, Dairy Farm 3 had the greatest variety of blaCTX-M genes in 
the study. Furthermore, a large proportion of isolates containing the blaCTX-M-1 gene also 
contained a blaTEM-1A gene, which has been previously observed (Mollenkopf et al., 2012). Other 
blaCTX-M genes also possessed a blaTEM-1B gene. These genes encode for resistance to penicillins 
and earlier generation cephalosporins (Salverda, de Visser, & Barlow, 2010), which is also coded 
for by blaCTX-M genes. 
Fluoroquinolone resistance can be selected for through a selection pressure of third-
generation cephalosporin usage, as referenced throughout the document. Fluoroquinolone 
resistance can be facilitated via genes, such as qnrA or qnrB, and topoisomerase mutations 
(Robicsek et al., 2006). Whether the qnrA or qnrB gene is selected for depends on the blaCTX-M 
gene with which it is associated (Nordmann & Poirel, 2005; Jacoby et al., 2006). Our selection of 
isolates with phenotypic MICs below a level of resistance was supported by the work of Bajaj et 
al. (2016) suggesting molecular characterization of only those isolates with phenotypic resistance 
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could inhibit further understanding of co-resistance or multi-drug resistance. All 3 isolates 
containing qnrS1 had a ciprofloxacin MIC of 0.5 µg/mL, which is consistent with previous work 
highlighting isolates with this gene do not show high levels of fluoroquinolone resistance (Bajaj 
et al. 2016). 
A Swedish study found 60% of calf, 44% of environmental, and 28% of cow samples 
tested positive for quinolone-resistant E. coli (Duse et al., 2016). Areas associated with calves 
tended to be more highly associated with quinolone-resistant E. coli, suggesting intervention in 
these areas may result in a decreased prevalence of quinolone-resistant E. coli on the farm (Duse 
et al., 2016). This area of intervention makes sense given fluoroquinolones are used to treat 
disease in calves. Along with co-selection from cephalosporin usage entering adulthood, these 
resistance genes may persist in low levels in the calf gut through maturation until the application 
of 3GC selection pressures leading to the resistance observed in the animals in our study given a 
majority of cows enrolled were first-lactation. Another generated hypothesis is that 
fluoroquinolone resistance is introduced through factors outside of the farm’s control (Duse et 
al., 2015). Only 2 types of plasmid-mediated fluoroquinolone genes were found in our study with 
1 dairy farm only having 1 type of gene, supporting a previous hypothesis that clonal 
fluoroquinolone strains tend to move about the farm (Duse et al., 2016). Overall, fluoroquinolone 
resistance mechanisms were found in E. coli isolates with ESBL resistance mechanisms. While 
there are many hypotheses surrounding why this may be so, more research into fluoroquinolone 
resistance and the factors leading to such resistance on dairy farms is needed to better understand 
and design interventions for this problem. Similarly, further research is needed into the 
introduction and selection of E. coli with an mph(A) in dairy cows, as macrolides are not used in 
dairy production. Unfortunately, with E. coli containing this gene associated with plasmids 
218 
 
containing a blaCTX-M gene in dairy cows in the region, the use of 3GC may also select for co-
resistance to macrolides. 
 
5.5 SALMONELLA SHEDDING 
 A 1996 study representing 83% of dairy cows in the United States found the prevalence 
of Salmonella shedding among dairy cows was 27.5% (Wells et al., 2001). The southern market 
(consisting of Texas and New Mexico) had the highest shedding among farms with milking cows 
at 45.0% (Wells et al., 2001). Studies during the 2000s found Salmonella prevalence rates among 
dairy farms between 44% and 56% (Warnick et al., 2003; Callaway et al., 2005; & Heider et al., 
2009). While our study only contained 3 dairy farms, all farms had cows testing positive for 
Salmonella, although the number of Salmonella positive animals varied by farm. Similarly, 
Loneragan et al. (2012) found at least 1 culled cow from each of 9 study dairy farms in the 
northern Panhandle of Texas tested positive for shedding Salmonella. 
 Fecal sample-level prevalence among milking cows was 5.4% in 1996 (Wells et al., 
2001), but had increased to 9.96% in 2002 (Callaway et al., 2005) and has been maintained at 
9.9% through the decade (Heider et al., 2009) before increasing to 30.0% in 2012 (Loneragan et 
al., 2012). The prevalence of Salmonella shedding among the samples from our study was 
16.85% (Table 12); however, 37.5% of study animals tested positive for Salmonella shedding at 
some point during the 3 sampling days we analyzed (days 0, 6, and 16). This may be elevated 
based upon sample collection taking place in the morning (Fitzgerald et al., 2003).  
 Interestingly, while the team of Edrington et al. (2004) found a lower prevalence of 
Salmonella shedding in the winter sampling period, our study showed an approximate 6 percent 
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increase in Salmonella shedding prevalence in the trial extending from the fall into the winter 
seasons. Sample-level prevalence of Salmonella shedding varied based upon dairy farm. Dairy 
Farm 1 had a prevalence of 21.8%, the prevalence on Dairy Farm 2 was 22.3%, and Dairy Farm 
3 samples had a prevalence of 6.3% (Table 12). These results are consistent with those of 
Callaway et al. (2005) in which the prevalence within herd varied from 0 to 37%. However, the 
prevalence of Salmonella shedding animals at any time of the study was elevated above that 37% 
mark on 2 of the 3 locations. 
 Regression analysis showed there were no differences among treated and untreated 
groups regarding Salmonella shedding; however, shedding varied by sampling day (Figure 70). 
The prevalence on day 0 was 30.9% and decreased to 9.5% and 9.7% on study days 6 and 16 
(Table 12). This was earlier observed in Muñoz-Vargas et al. (2018) where cows were more 
likely to shed Salmonella in the week after calving than in the time leading to calving. Similar 
trends were observed in a study by Fitzgerald et al. (2003) in which cows less than 60 days in 
milk had a higher percentage testing positive for Salmonella shedding. Further study by Hume et 
al. (2004) found no effect regarding genotypic Salmonella shedding among lactating and non-
lactating dairy cows, but days in milk at enrollment was not mentioned. The level of Salmonella 
shedding decreased in our treatment group and remained at decreased levels on study days 6 and 
16. Meanwhile, Ohta et al. (2017) found the prevalence of Salmonella in feedlot cattle decreased 
after CCFA treatment, but rebounded over time when measured out to 26 days post treatment 





5.6 SALMONELLA WHOLE GENOME SEQUENCING 
 The highest number of serotypes found on dairy farms enrolled in our study was eleven 
with an additional four isolates not having a determinable serotype. However, there have been as 
many as 30 Salmonella serotypes associated with on-farm dairy cows (Wells et al., 2001), but 
this diversity tends to remain between 15 – 17 serotypes spread among the cattle population 
(Fitzgerald et al., 2003; Callaway et al., 2005; & Loneragan et al., 2012). Even with such 
diversity of serotypes, dairy farms tend to have dominant serotypes across the animal population 
with those serotypes changing based upon farm location (Callaway et al., 2005), sample type 
(Loneragan et al., 2012), and on-farm versus at-market sampling (Wells et al., 2001). This was 
true of our study too, as 3 or fewer serotypes made up greater than 65% of the serotypes found at 
each location. Much like the findings of Callaway et al., (2005), each of our 3 dairy farms had 
animals shedding multiple Salmonella serotypes. 
 Results from four Southwestern dairy farms in 2001 – 2002 found, while Montevideo, 
Senftenberg, Mbandaka, and Kentucky were the dominant serovars among their study locations, 
the dominant serovar varied based upon the season in which samples were collected (Edrington 
et al., 2004). The dominant Salmonella serotypes among Southwestern dairy farms in 2003 were 
Senftenberg, Newport, and Anatum (Fitzgerald et al., 2003). In 2012, dairy farms in the north 
Panhandle of Texas had higher percentages of Salmonella serotypes Anatum, Kentucky, and 
Cerro overall, but serotypes Cerro and Muenster were the overwhelmingly dominant serotypes in 
fecal samples (Loneragan et al., 2012).   
 Interestingly, the dominant serovars among our dairy farms were Montevideo, 
Meleagridis, and Cerro, which are the dominant serotypes of an older study (Wells et al., 2001). 
Wells et al., (2001) found serotypes Montevideo, Melegridis, and Cerro were the dominant 
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serotypes among on-farm fecal Salmonella from a wide geographic range consisting of the 
Northwestern, Midwestern, Northeastern, and Southern (including Texas and New Mexico) dairy 
farms. Samples from milking cows consisted of serotypes Montevideo, Kentucky, and Menhaden 
representing the dominant Salmonella serotypes (Wells et al., 2001). Another multi-state study 
found the dominant serovar varied based upon the dairy region (Callaway et al., 2005). 
Levels of antimicrobial resistance among Salmonella isolates from agricultural settings 
remain consistently low, particularly regarding resistance to ceftriaxone. Antimicrobial 
resistance among Salmonella isolates collected from a broad range of dairy farms in 1996 
remained low with no isolates having resistance to ceftriaxone (Wells et al., 2001). The same 
was true of a study in the southwestern United States a decade later (Fitzgerald et al., 2005). 
Additionally, a study evaluating antimicrobial susceptibility to thousands of Salmonella isolates 
collected from diagnostics, farms (regardless of species), slaughter facilities, and others from 
1999 to 2003 found resistance to ceftriaxone was consistent at 0.3% throughout the study period 
(Frye & Fedorka-Cray, 2007). However, ceftiofur resistance rose from 4.0% to 18.8% over the 
four-year period (Frye & Fedorka-Cray, 2007).  
Similarly, 1,320 Salmonella isolates from dairy farms in Wisconsin, Michigan, and 
Minnesota did not possess resistance to ceftriaxone, even as 76% of dairy farms possessed at 
least 1 isolate with resistance to 5 antimicrobials and 9.4% of farms with at least 1 isolate with 
resistance to 9 antimicrobials (Ray et al., 2007). Furthermore, an Australian study determined 
none of the Salmonella isolates from the 75 positive dairy cows had resistance to any of the 
tested antimicrobials (Barlow et al., 2015). Additional studies in feedlot cattle identified no 
ceftiofur resistance within the general population (Khaitsa et al., 2007) and low levels of multi-
drug resistant Salmonella among animals treated with CCFA (Ohta et al., 2017). Our results are 
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consistent with those of the aforementioned studies, as only Salmonella isolates from four 
samples from 3 animals tested as phenotypically ceftriaxone-resistant. An additional sample 
from another animal tested as genotypically positive for beta-lactam resistance. 
Previous work has identified Salmonella serotypes Give (Fitzgerald et al., 2005), 
Typhimurium, Dublin (Wells et al., 2001), and Anatum, Kentucky, and Newport (Loneragan et 
al., 2012) as serotypes from fecal dairy cow sample isolates exhibiting multi-drug resistance. Of 
the Salmonella isolates from each of those studies, only Salmonella enterica serovar Newport 
contained an AmpC resistance profile (Loneragan et al., 2012). In our study, 3 serotypes 
(Anatum, Meleagridis, & Newport) were found to contain the blaCMY-2 gene conferring an AmpC 
resistance profile. Based on NARMS and Foodborne Diseases Active Surveillance Network data 
from 1996 to 2013, serotype Newport is the most likely Salmonella serotype to carry ceftriaxone 
resistance in humans with ground beef accounting for 13.5% of ceftriaxone resistant Salmonella 
from 2002 to 2013 (Iwamoto et al., 2017). Meleagridis most frequently contained the gene, but 
also accounted for nearly a quarter of the serotyped isolates. In our study, Meleagridis was the 
only serotype found to harbor genotypic multi-drug resistance. The isolate contained genes for 
resistance to aminoglycosides, beta-lactams, sulfonamides, streptomycin, and trimethoprim.  
 
5.7 LIMITATIONS 
Limitations of this study include its small geographic region. Our study included only 3 
dairy farms from western Texas and eastern New Mexico, which tend to have warmer, drier 
climates, versus other dairy production regions, such as Wisconsin and New York. Differences in 
climate may impact bacterial survival outside the host, affecting the oral-fecal transmission 
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dynamics within the farm, bacterial fitness in the environment, and the ability of such bacteria to 
further distribute resistance genes in the environment. In addition to climate, environment and 
resource availability could impact 3GC resistant bacterial populations or else herd management 
techniques resulting from those factors (Berge et al., 2010). Studies across diverse regions of the 
U.S. with high levels of dairy production would aid in providing additional insight into the 
generalizability of our findings. It is beneficial to sample animals from a dairy farm multiple 
times to evaluate temporal dynamics; however, due to the resources required for repeated 
intensive temporal sampling only 3 dairy farms could be enrolled in the study. As a result, the 
generalizability of our data is restricted. Our use of multiple imputations to complete the 
truncated left tail of the empirical distribution and assist in meeting model assumptions may have 
introduced bias into the models. 
Furthermore, phenotypically evaluating antimicrobial resistance susceptibility to the 
general E. coli population could provide better insight into the levels and forms of antimicrobial 
resistance within this population. We were unable to obtain phenotypic count data differentiating 
the AmpC and ESBL resistance profiles. Developing a method to do so would provide an 
opportunity to understand the changes and interactions of bacteria with such resistance profiles 
across time and treatment. We sequenced a small number of E. coli isolates. Expanding the 
number of sequenced isolates based upon their 3GC and fluoroquinolone resistance profiles 
would strengthen any hypotheses regarding the mechanisms bringing bacteria with reduced 





CHAPTER VI  
CONCLUSION  
 The findings of this study suggest that the currently labeled 13-day slaughter-withholding 
period following a second dose of CCFA is generally inadequate to allow levels of 3GC resistant 
bacteria to return to baseline levels in treated dairy cows housed on dairy farms with elevated 
levels of resistance to third-generation cephalosporins. Existing slaughter withholding times 
designed to avoid pharmaceutical residues in meat products provide no microbial safety 
assurances once bacterial resistance establishes in agricultural environments. A longer 
stakeholder-initiated voluntary slaughter-withholding period could be deployed to reduce the risk 
of fecal contamination at slaughter harboring antimicrobial resistant enteric bacteria. Dairy-
specific stewardship approaches targeting practices with higher risk of selecting for antimicrobial 
resistance would be beneficial in mitigating resistance. Further research into the genetic diversity 
of resistance will provide more information into the mechanisms at play and the added potential 
for 3GC resistance co-selection via alternative antimicrobial classes that may be employed 
instead of cephalosporins. 
While there were no statistically significant differences between our treatment and 
control groups, general patterns were observed based on the prevalence of phenotypic ESBL E. 
coli and MDR E. coli and by sampling day. With increases observed in each prevalence type, it 
is hypothesized there are environmental factors at play as the animals move throughout the dairy 
system. This is further supported by differences in baseline prevalence among both phenotypic 
ESBL E. coli and MDR E. coli prevalence by individual dairy farm showing an animal’s initial 
risk is associated with the environment of its farm as a whole and changes through each stage of 
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production. The role of the dairy farm is further shown via the Mantel-Haenzel rate ratios and 
Kaplan-Meier survival plots. While similar patterns were observed within each location, the 
initial risk varied by farm. This shows stewardship tools tailored to each dairy farm’s individual 
needs could have positive impacts in mitigating the spread of enteric bacteria with 3GC and 
multi-drug resistance. 
Our results indicate Salmonella shedding is not impacted by metritis or a two-dose CCFA 
treatment for metritis, as there were no differences between either the treated or untreated group 
on any of the sampling days evaluated. There was a higher prevalence of Salmonella shedding on 
day 0 than the other days suggesting the stress of calving may disrupt the gastrointestinal flora 
resulting in increased Salmonella shedding. As with many other studies, each study location was 
positive for multiple Salmonella serotypes with a few serotypes dominating each farm. On a 
positive note, few samples were found to possess Salmonella with 3GC resistance mechanisms 
and, although all positive samples were from treated cows, significance was not determined 
between resistance and treatment.  
In final conclusion, the current slaughter withholding period after a two-dose CCFA 
treatment is not adequate time to allow for 3GC resistance to decrease back to baseline and 
voluntary slaughter withholding periods should extend up to 28 days after the first treatment. 
Furthermore, stewardship tools should be tailored toward individual dairy farms, as different 
locations tend to have different baseline risks of 3GC, phenotypic ESBL, and MDR E. coli. By 
addressing antimicrobial stewardship on dairy farms, improvements can be made in controlling 
AMR development and spread in the farm environment and extending the volunteer slaughter 




      CHAPTER VII 
FUTURE WORK 
 A common theme throughout our study was the difference among the farms regarding 
baseline levels of 3GC resistant E. coli, levels of 3GC resistant E. coli in the environment of those 
locations, and baseline Salmonella shedding. Unfortunately, due to a small number of 
environmental samples from a small number of dairy farms, we were unable to properly evaluate 
the role of the dairy farm environment in our models. Furthermore, we only evaluated the 
historical usage of CCFA on the farm since that was the selection pressure we were evaluating. 
Future work needs to involve enrolling a larger number of dairy farms with frequent 
environmental sampling and the evaluation of the historic usage of multiple antibiotics at both 
cow and herd levels, along with other management factors to better evaluate the factors behind 
differing baseline levels of AMR on farms.  
Additionally, our study had low levels of Salmonella shedding and phenotypic ESBL E. 
coli. This provided resulted in large confidence intervals among our data for each animal group on 
each sampling day, so only patterns could be observed. Future work should focus on generating 
counts for Salmonella and a more specific test for doing the same for phenotypic ESBL E. coli as 
another way of evaluating these pathogens and resistance profile beyond prevalence.  
While we explored phenotypic MICs of E. coli with an expected ESBL resistance profile 
to evaluate co-resistance, future work should evaluate the phenotypic MICs of E. coli from the 
general (non-selective) population to evaluate how the treatment impacts the resistance profile of 
the broader population. Further research should be done into the drivers of fluoroquinolone and 
macrolide resistance in dairy cattle. Our results show MICs from sampling days later in the trial 
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were higher than those from earlier days and a difference in MIC by location. However, this class 
of antibiotic should not be used in dairy cattle above 20 months of age. Understanding the 
mechanisms and drivers of this resistance, along with why it is seen more in isolates from 
sampling days farthest from CCFA treatment, is important in curbing its spread.  
Lastly, future work should include metagenomics to evaluate the changes of bacterial 
populations within the ecosystem of the intestine and inferred from the fecal environment. Little is 
known about how the administration of an antibiotic affects the microbiome of the gut 
environment sequentially over time in the post-partum dairy cow. The changes in the fecal 
microbiome from baseline, to shortly after the treatment administration, and during population 
recovery should be evaluated. The selection of these days will allow for the observation of how 
other bacterial populations are affected by a two-dose CCFA treatment, what bacterial populations 
expand (or contract) after treatment, and if those populations remain in such states as time moves 
forward. Through this additional work, we can continue to build upon the impacts of the CCFA 
selection pressure, the role of dairy farm environment and management in baseline levels of AMR, 
and the selection pressures for bacterial resistance to fluoroquinolones in multi-parity cattle when 
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